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Cells are constantly responding to signals from the surrounding tissues and the
environment. To dispose of infected and potentially dangerous cells, to ensure the optimal
execution of developmental processes and to maintain tissue homeostasis, a multicellular
organism needs to tightly control both the number and the quality of its cells. Apoptosis is a
form of active cellular self-destruction that enables an organism to regulate its cell number
by deleting damaged or potentially dangerous cells. Apoptosis can be induced by death
ligands, which bind to death receptors on the cell surface. Ligation of the receptors leads to
the formation of an intracellular death inducing signaling complex (DISC). One of the DISC
components is caspase-8, a protease that triggers the caspase cascade and is thereby a
key initiator of programmed cell death. The activation of caspase-8 is controlled by the
cellular FLICE-inhibitory proteins (c-FLIPs). Consequently, sensitivity towards receptor-
mediated apoptosis is determined by the amount of c-FLIP, and the c-FLIP levels are
actively regulated for example during erythroid differentiation of K562 erythroleukemia cells
and by hyperthermia in Jurkat leukemia cells. The aim of my thesis was to investigate how
c-FLIP is regulated during these processes. We found that c-FLIP isoforms are short-lived
proteins, although c-FLIPS had an even shorter half-life than c-FLIPL. In both experimental
models, increased death receptor sensitivity correlated with induced ubiquitylation and
consequent proteasomal degradation of c-FLIP. Furthermore, we elucidated how
phosphorylation regulates the biological functions and the turnover of c-FLIP, thereby
contributing to death receptor sensitivity. We mapped the first phosphorylation sites on c-
FLIP and dissected how their phosphorylation affects c-FLIP. Moreover, we demonstrated
that phosphorylation of serine 193, a phosphorylated residue common to all c-FLIPs, is
primarily mediated by the classical PKC. Furthermore, we discovered a novel connection
between the phosphorylation and ubiquitylation of c-FLIP: phosphorylation of S193 protects
c-FLIP from ubiquitylation. Surprisingly, although all c-FLIP isoforms are phosphorylated on
this conserved residue, the biological outcome is different for the long and short isoforms,
since S193 specifically prolongs the half-lives of the short c-FLIP isoforms, but not c-FLIPL.
To summarize, we show that c-FLIP proteins are modified by ubiquitylation and






The life of a human being begins from a single cell, which through regulated growth and
proliferation gives rise to the estimated 1014 cells that comprise the body of an adult. Yet
already during embryonic development some cells die and give way to new ones. In an
adult organism, approximately 60 billion cells are generated daily, and an equal number die
in order to maintain homeostasis. In addition, an organism has to defend itself against
harmful agents by activating the immune system, which aims at eliminating the danger and
the infected cells, after which the excess immune cells have to be cleared from the body.
Therefore, the life of an organism depends on its ability to detect and specifically remove
damaged or excess cells. Insufficient or excess killing of cells may lead to cancer or
autoimmune diseases.
All cells share the ability to die through programmed cell death, or apoptosis. When the
death signal comes from outside the cell, apoptosis is usually initiated by death ligands that
bind to death receptors on the cell surface. However, the death signal is not perceived as
an absolute, and the cellular response to a given death signals is determined by a delicate
balance between the activities of pro- and anti-apoptotic proteins. These activities, as well
as protein levels and localization, are governed by post-translational modifications, such as
phosphorylation and ubiquitylation. If a cell is sensitive to death-inducing stimuli, receptor
ligation is followed by intracellular signaling cascades that activate the caspase family of
proteases. Caspases subsequently cleave several substrates in an orderly manner, leading
to the destruction of proteins, DNA, and organelles and to the cleavage of the cell into
smaller particles or apoptotic bodies, which are finally engulfed by neighboring cells.
It is hardly surprising that the cellular life-or-death decision needs to be regulated at multiple
levels. For example, a cell may express varying amounts of different death receptors,
thereby determining its degree of sensitivity against specific death ligands. Moreover, the
activation of caspases is controlled by a plethora of pro- and anti-apoptotic proteins. An
additional mode of regulation is achieved through post-translational modification of proteins,
resulting in swift and precise changes in protein activity, localization, or stability. Among the
various post-translational mechanisms, phosphorylation is perhaps the best known, and it is
involved in practically all cellular processes, including programmed cell death. Attaching of
a small protein called ubiquitin is known to target proteins for proteasomal degradation,
enabling the cell to specifically and dynamically adjust the levels of pivotal regulatory
proteins. Furthermore, there is cross-talk between post-translational modifications.
Therefore, even subtle changes in protein modification can have profound implications on
death receptor sensitivity.
Regulation of the apoptotic machinery is complex, and elaborate mechanisms and signaling
pathways are constantly being discovered. The importance of both apoptosis and
ubiquitylation is emphasized by the fact that the fundamental discoveries made in these
research areas have been awarded with the Nobel Prize. In this thesis, I first introduce how
proteins and biological processes are post-translationally regulated by phosphorylation and
ubiquitylation. Thereafter I describe the central events and players of cell death,
accompanied with examples of how they are affected by post-translational modifications. In
the experimental part, I have studied how the stability and biological functions of c-FLIP are
regulated by ubiquitylation and phosphorylation in an isoform-specific fashion in two
experimental models. Furthermore, I have investigated the functions and biological
implications of novel phosphorylation sites.
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REVIEW OF THE LITERATURE
1 Post-translational regulation of proteins
The astonishing varieties of biological processes of all organisms are carried out and
regulated by proteins. The blueprint of all proteins of prokaryotic and eukaryotic organisms
is contained within the genes, the basic functional units of DNA, which are written in a
universal genetic code. To extract the protein-coding information, the cell first copies the
nucleotide sequence of a gene onto an messenger RNA molecule. This process, called
transcription, is regulated by a plethora of general and gene-specific transcription factors,
which interact with regulatory DNA sequences and stimulate the transcription of the gene.
In the next step, the information contained within messenger RNA copy is used as a
template to guide the production of a chain of amino acids. Much like a necklace is built up
from sequential pearls, all proteins are built up by amino acids, where the number, order
and chemical properties of the amino acids determine the features of the protein.
The genetic code produces one amino acid for each three-letter codon of the messenger
RNA, and the resulting polypeptides contain diverse combinations of the twenty amino
acids encompassed by the genetic code. Next, the nascent polypeptide chain is folded into
secondary and tertiary structures on the basis of the amino acid side chains adopting a
specific three-dimensional shape demanding the least energy. The simple secondary
structures include -helices, -sheets, and random coils, and they are further folded into
tertiary structures which usually have a hydrophobic core, while the polar and charged
amino acids tend to reside on the outer surface of the protein to mediate interactions. The
tertiary structures are further stabilized by weak interactions.
While the three-dimensional structure of the protein largely governs its chemical properties
and biological functions, drastic changes in protein function must be rapidly achieved when
the cell has to react to environmental cues. The organization, localization, enzymatic activity
and interactions of proteins can all be quickly transformed by post-translational
modifications. Post-translational modifications include an astounding range of covalent and
non-covalent modifications that regulate biological processes in complex ways. Proteins
can be covalently modified by adding or removing chemical groups (e.g. phosphorylation,
methylation, deamination), fatty acids (e.g. myristoylation, palmitoylation) or sugars
(glycosylation), as well as chemical processes such as nitrosylation or oxidation-reduction
reactions. In addition, a high degree of versatility is provided by covalent and non-covalent
modifications by small proteins, such as ubiquitylation and neddylation. Finally, enzymatic
processing of proteins, as well as prolyl isomerization, represents a mode of post-
translational regulation. Most post-translational modifications are reversible, allowing more
alternatives for protein regulation.
2 Protein phosphorylation enables versatile protein modification
The first observations of protein modification by phosphorylation were made over 100 years
ago when Phoebus Levene noted that the vitellin protein contained phosphoserine (Levene
and Alsberg 1906). Decades later, Eugene Kennedy described a phenomenon he called
“enzymatic phosphorylation of proteins” (Burnett and Kennedy 1954). From this started an
era of vigorous endeavor to understand the biochemistry of phosphorylation and its
biological significance.
11
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Phosphorylation denotes the covalent attachment of a small, negatively charged phosphate
group to the substrate and is probably the most widespread and the best characterized
mechanism for post-translational modification of protein function. Phosphorylation targets
an estimated one third of all cellular proteins, and is used for signal transduction in all
cellular processes, including differentiation, trafficking, metabolism and growth (reviewed by
Ubersax and Ferrell 2007). Like most types of post-translational modifications, the outcome
of phosphorylation is highly substrate specific, and is known to regulate protein function
negatively or positively, provide novel interaction interfaces, or affect protein stability or
localization. Most phosphorylation events occur on serine, threonine or tyrosine residues, of
which serine phosphorylation is by far the most common. The dynamics of phosphorylation
is regulated by the counteracting forces of kinases, which catalyze the addition of the
phosphate group to the substrate, and phosphatases, which remove phosphate groups. In
eukaryotes, kinase genes make up 1.5-2.5% of the genome and are highly conserved
between species. Nevertheless, different kinases display a remarkable diversity in terms of
activation mechanisms. For example, whereas some kinases are activated by cellular
stresses such as DNA damage or proteotoxic stress, others function as sensors of the
nutritional status of the cell. Moreover, the tissue-specific expression of kinases, their
subcellular localization and preference for particular substrate sequences allow for the
precise targeting of phosphorylation events. Compared to kinases, the number of
phosphatases is smaller. Consequently, phosphatases tend to display a greater promiscuity
in substrate recognition. Certain phosphatases prefer phosphorylated serine/threonine
residues, while some catalyze tyrosine dephosphorylation, and the dual specificity
phosphatases are able to strip all of the above from the covalently linked phosphate group.
2.1 The classification and regulation of the protein kinase C
The protein kinase C (PKC) family comprises several serine/threonine kinases that play
pivotal roles in cell proliferation, apoptosis, growth and malignant transformation (reviewed
by Griner and Kazanietz 2007). For this reason, PKC has been suggested to be a potential
target for cancer therapy (reviewed by Mackay and Twelves 2007). Most PKC isoforms are
ubiquitously expressed in different types of tissues. The ATP and substrate-binding
properties of the PKC family members are mediated by a highly conserved catalytic
domain. PKC proteins are regulated by their N-terminal regulatory domains, which target
the PKC to the plasma membrane, as well as by their pseudosubstrate domains which are
required for autoinhibition. Kinases of the PKC family phosphorylate serine or threonine
residues that usually conform to the consensus sequence, R/K1-3-X2-0-S/T-X2-0-R/K1-3
(reviewed by Steinberg 2008).
The members of the protein kinase C family are divided into three groups according to their
structure and activating stimuli (Figure 1). The classical PKCs include isoforms , I, II and
. Their regulatory domains contain a C1 region that binds diacylglycerol (DAG) or 12-O-
tetradecanoylphorbol-13-acetate (TPA)/phorbol 12-myristate 13-acetate (PMA), and a C2
region that binds to anionic phospholipids in a calcium-dependent manner (Castagna et al.
1982, Kikkawa et al. 1983, Sharkey et al. 1984). Hence, the activation of the cPKCs
depends on lipids and calcium. The novel PKCs, in turn, contain two C1 domains and a
non-functional C2 domain. Because the C2 domain is unable to bind calcium, nPKCs are
activated in a calcium-independent manner by DAG or TPA alone. Finally, the atypical
PKCs lack the C2 domain, but contain an atypical C1 domain that binds ceramide and PIP3,
thereby mediating their activation.
12
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Figure 1. The PKC isozymes are classified on the basis of their structure and method of
activation. The classical PKCs include , I, II, and , and they bind calcium via their C2
domains. This increases the affinity of the C1 domain for diacylglycerol and phorbol
esters. Novel PKC respond to DAG, but not calcium. Because the atypical PKCs lack a
C2 domain, as well as a functional C1 domain, they do not respond to calcium or DAG.
The catalytic domains (C3 and C4) are highly conserved. The PKC isozymes also
contain pseudosubstrate domains which keep them in an inactive conformation in the
absence of activating stimuli. Adapted from Churchill et al. (2008).
The PKCs are activated in a multi-step manner including sequential phosphorylations,
changes in localization and structural reorganizations (Cazaubon et al. 1994, Orr and
Newton 1994, Srinivasan et al. 1996, Hansra et al. 1999, Parekh et al. 1999, Ziegler et al.
1999). First, the PKC undergo maturation by phosphoinositide-dependent kinase 1 (PDK1)-
mediated phosphorylation of the activation loop. This reveals the critical domains in the C
terminus of the PKC, leading to autophosphorylation and stabilization of the kinase. The
mature PKC is then capable of being activated by DAG and calcium. A mature PKC usually
resides in the cytosol, where it is kept inactive state by interactions between the kinase
domain and the pseudosubstrate domain.
Mature PKCs are recruited to the membrane upon a rise in intracellular DAG or calcium in
response to phorbol esters or receptor stimulation. When the intracellular calcium and DAG
levels rise, the classical and the novel PKCs respond differently (reviewed by Parekh et al.
2000, Newton 2003). The classical PKC are recruited to the membrane by their calcium-
binding C2 domain. When the C1 domain binds DAG, the conformation of the enzyme is
massively re-organized, releasing the pseudosubstrate domain and allowing substrate
binding. The novel PKCs, in turn, are not recruited to the membrane as quickly as the
cPKC, because the nPKCs do not bind calcium. Strong affinity to DAG, however,
compensates for this over time (Giorgione et al. 2006). Although binding to DAG is a key
step in the activation of the cPKC and nPKC, it does not explain the diversity of PKC
subcellular localization. PKC isozymes are distributed around cellular organelles such as
the nuclear membrane, mitochondria, and the Golgi, upon phorbol ester treatment or growth
factor stimulation. These alterations in localization are likely to explain the differences in
substrate specificity, making the underlying mechanisms attracting targets of research. The
binding of PKC to DAG results in conformational change that reveals the pseudosubstrate
domain of the PKC, thereby enabling substrate binding.
Inactivation of the PKCs occurs by a negative feed-back loop, although the mechanisms
seem to differ according to the isoform. The mechanism of PKC downregulation is not yet
very well known, but it is partly explained by the short half-life of DAG. Upon prolonged
phorbol ester treatment, at least PKC  is known to become dephosphorylated and
13
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subsequently internalized by a caveolae-dependent mechanism into an endosomal
compartment (Bornancin and Parker 1996, Hansra et al. 1999, Prevostel et al. 2000).
PKC , on the other hand, is thought to become prone to degradation by its activating
phosphorylation events (Srivastava et al. 2002). Other PKC isoforms have also been shown
to be regulated by the ubiquitin-proteasome pathway by a mechanism that depends on their
kinase activity (Lee et al. 1996, Lu et al 1998, Leontieva et al. 2004).
The degree of substrate specificity and the level of functional overlap between the PKC
isoforms are still incompletely understood. As the PKC isozymes are distributed around
cellular organelles, such as nuclear membrane, mitochondria, and the Golgi upon phorbol
ester treatment or growth factor stimulation, some features in PKC substrate selection are
likely to be explained by changes in PKC localization (reviewed by Jaken and Parker 2000,
Schechtman and Mochly-Rosen 2001). In addition, the activity and substrate selection of
the PKC are regulated by specific interaction partners. The proteins that recognize
particular sequences on active PKCs are collectively referred to as receptors of activated
protein kinase C (RACKs). The RACKs are membrane-associated proteins, which anchor
and scaffold PKCs to domains in the membrane to co-localize with their activators and
substrates. Specific RACKs, RACK1 and RACK2/ -COP, have been characterized for
PKC  and PKC , respectively (Csukai et al. 1997, reviewed in Mackay and Mochly-Rosen
2001, Schechtman and Mochly-Rosen 2001). In addition, p32/gCIqBP has been found to
act as a RACK for PKC , but as it also binds inactive PKC , its role is still somewhat
unclear (Robles-Flores et al. 2002). The original hypothesis of Mochly-Rosen and
colleagues was that each PKC isoform has its own, specific RACK, and that this accounts
for isoform-specific PKC responses. A convincing body of evidence suggests, however, that
localization of the PKC is regulated also independently of RACKs, and that interactions with
cytoskeletal proteins such as actin and tubulin, as well as other, non-RACK scaffolding
proteins, are important in many situations (Jaken and Parker 2000, Schechtman and
Mochly-Rosen 2001).
2.2 PKCs as targets for cancer therapy
Since the PKC family plays such multi-faceted roles in various central biological processes,
its members have been considered as tempting targets for cancer treatment. However,
functional characterization of the PKC isozymes has suffered from the poor specificity of the
current PKC inhibitors as well as the frequent use of overexpression studies. Recently, the
function of the PKC isozymes has been successfully disrupted by short peptides which
target regions of the C2 domain required for RACK binding (reviewed by Churchill et al.
2008). Discrimination between PKC isozymes can also be achieved by targeting the C1
domains for their small structural dissimilarities (Pu et al. 2005). In addition to inhibitors of
PKC activity, isozyme-specific activators would also be desirable.
Several pharmacological agents targeting PKC are currently in clinical trials. Two
indolocarbazoles, enzastaurin and midostaurin, are in phase I-II trials for various cancer
types. Enzastaurin is a macrocyclic bisindolylmaleimide that competes with ATP in binding
to PKC, thereby preventing activation. While PKC  is the primary target of enzastaurin,
many other PKC isoforms are inhibited, and in addition, also the phosphatidylinositol 3-
kinase (PI3K)/Akt and glycogen synthase kinase 3 (GSK3) pathways are affected (Graff et
al. 2005). Enzastaurin is being trialed alone or in combination with conventional therapies
for example for breast, ovarian, and peritoneal cavity cancer, as well as for metastasized
malignancies of colorectal and pancreatic cancer (reviewed by Podar et al. 2007).
Midostaurin is a staurosporine derivative that targets the classical and the novel PKCs. In
addition, midostaurin blocks several growth factor receptor tyrosine kinases (Weisberg and
Griffin 2001, Growney et al. 2005). Midostaurin has proved promising for example in the
14
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preclinical models for acute myeloid leukemia, mast cell leukemia, peripheral T-cell
lymphoma and solid tumors (reviewed by Podar et al. 2007). Current clinical trials focus on
the effects of midostaurin in aggressive systemic mastocytosis, mast cell leukemia and
acute myeloid leukemia. In addition to these indolocarbazoles, other PKC-targeting drugs
like tamoxifen, bryostatin and curcumin are currently in phase I-III trials for treating a wide
array of tumors. While these developments demonstrate that PKCs are attractive targets
especially for cancer therapy, further information is needed on the specific tasks of
individual PKC isozymes. A deeper understanding of their isozyme-specific features and
biological roles will help delineate future therapies targeting PKC proteins.
3 Post-translational modification of proteins by ubiquitin
Until recently, ubiquitylation was thought to function primarily as a mediator of proteasomal
degradation. However, the biological versatility of ubiquitin signaling has begun to emerge,
and today ubiquitylation is considered as one of the most common post-translational
regulatory mechanisms. Ubiquitin moieties can be attached onto substrates as single
proteins or in chains of variable length. Further complexity is provided by different linkage
types, as ubiquitin moieties can be conjugated to different lysine residues of ubiquitin, as
well as by non-covalent ubiquitin binding through specialized ubiquitin-binding domains.
Ubiquitin contains seven lysines, all of which serve as platforms for chain branching. Recent
studies have revealed that the number of genes encoding proteins involved in the
enzymatic reactions of ubiquitin and ubiquitin-like proteins is similar to the genes whose
products are associated with phosphorylation (reviewed by Herrmann et al. 2007). In the
following section, I review the biochemical basis of ubiquitin signaling and discuss its
biological implications, with a particular emphasis on proteasomal degradation.
3.1 Ubiquitin and ubiquitin-like proteins
Ubiquitin is a small, 76-amino-acid protein that was originally cloned from bovine thymus
and named after its ubiquitous expression (Figure 2, Goldstein et al. 1975). Ubiquitin is one
of the most conserved of proteins, and although it is absent in prokaryotes, it is expressed
in all eukaryote tissues and cell types. Remarkably, the amino acid sequences of ubiquitin
in yeast and humans differ by only three amino acids. The mammalian genome contains
multiple ubiquitin genes. Ubiquitin is translated as fusions, and it is processed into mature
proteins by ubiquitin C-terminal hydrolases. Ubiquitin is a globular protein that contains a
conserved ubiquitin fold ( ), shared by other members of ubiquitin-like molecules.
The conjugation of ubiquitin to its substrate is mediated by two glycine residues in the C-
terminal end of ubiquitin. Although ubiquitin is usually attached to lysine residues of the
substrate, also proteins or protein fragments without lysines have been found to be
ubiquitylated. In these occasions, the ubiquitylation has been proposed to occur on serine
and threonine residues (Cadwell and Coscoy 2005, Wang et al. 2007). In addition, the
ubiquitylation of certain substrates is controlled by destabilizing N-terminal amino acids,
which attract ubiquitin ligases and mediate the ubiquitylation of internal lysines (reviewed by
Varshavsky 1997).
Ubiquitin is not the only small molecule used for signal transfer. To date, more than 10
different ubiquitin-like modifiers have been identified in mammals, including small ubiquitin-
related modifier (SUMO), human leukocyte antigen F-associated transcript 10 (FAT10) and
neural-precursor-cell-expressed developmentally down-regulated 8 (Nedd8) (Hochstrasser
2009). The ubiquitin-like proteins are classified on the basis of common tertiary structures
15
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and certain pivotal features, such as the ubiquitin fold and the C-terminal glycine residue
(reviewed by Herrmann et al. 2007). In addition, several proteins contain ubiquitin-binding
motifs or domains that mediate non-covalent ubiquitin binding. The ubiquitin-domain
proteins are also capable of modifying ubiquitylation-related processes by acting as
cofactors and adaptors, one example being the proteasomal subunit Rpn10 that recognizes
polyubiquitylated substrates.
3.2 Non-covalent ubiquitin binding
Ubiquitin signaling is mediated by specific domains that bind different forms of ubiquitin in a
non-covalent manner. To date, close to 20 ubiquitin-binding domains (UBD) have been
identified (reviewed by Hurley et al. 2006). Remarkably, these domains share little similarity
with each other, and they also interact with several surfaces of ubiquitin. In addition, some
ubiquitin-binding domains specifically bind interfaces of two ubiquitin molecules bound to
each other, while some recognize differing ubiquitin chain topologies. The ubiquitin-binding
domains are diverse also in size, ranging from 20 to 150 amino acids (Hurley et al. 2006).
Many ubiquitin-binding domains are -helical. These include the ubiquitin-associated
domain (UBA), ubiquitin-interacting motif (UIM), double-sided UIM (DUIM), motif interacting
with ubiquitin (MIU), coupling of ubiquitin conjugation to endoplasmic reticulum degradation
(CUE), Golgi-localized, gamma-ear-containing ADP-ribosylation-factor binding protein
(GAT), and target of Myb (TOM) (Hurley et al. 2006). All -helical interaction domains
interact with ubiquitin I44 residing in a hydrophobic patch (for example Swanson et al. 2003,
Bilodeau et al. 2004, Varadan et al. 2005, Wang et al. 2005). The UIMs are characterized
by short stretches of hydrophobic amino acids, and they are common in proteins involved in
intracellular trafficking. Ubiquitin serves as a signaling tag that is recognized by proteins
containing UIMs, many of which regulate the transport of ubiquitylated cargo. In addition,
the proteasomal subunit S5a contains UIMs. Non-covalent interaction via UIM often
promotes covalent ubiquitylation of the target protein. As suggested by the name, MIU and
DUIM are UIM variants (Hirano et al. 2006).
The UBA domains constitute an important group of ubiquitin-binding domains, which differs
from others in recognizing polyubiquitin chains displaying certain types of linkages (Raasi et
al. 2005). It is currently unclear how the UBAs distinguish between differently linked
ubiquitin chains, but K48-linked di- and tetraubiquitin has been shown to adapt a closed
conformation, whereas K63 di- and tetraubiquitin harbors an extended conformation,
providing a putative basis for differential recognition (Varadan et al. 2002, Varadan et al.
Figure 2. Structure of ubiquitin. The C-
terminus of the protein, through which
ubiquitin is attached to its substrates, is
seen to the right. The image was made
using DeepView/Swiss-pdbViewer v. 3.7
and is based on the crystal structure of
human ubiquitin (protein data bank code
1UBQ). Structure of ubiquitin refined at
1.8 A resolution (Vijay-Kumar et al.
1987).
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2004). The interactions mediated by ubiquitin-binding domains are typically weak, although
they are essential for many physiological processes. An interesting example of how
ubiquitin-binding domains can affect covalent ubiquitylation events is the E3-independent
monoubiquitylation (Hoeller et al. 2007). Proteins containing any of a number of ubiquitin-
binding domains are able to directly interact with E2 ubiquitin-conjugating enzymes, thereby
enabling direct monoubiquitylation without E3 enzymes.
3.3 Three enzymatic steps of ubiquitin conjugation
The covalent conjugation of ubiquitin to its substrate is executed by a three-step enzymatic
pathway, composed of an E1 ubiquitin-activating enzyme, an E2 ubiquitin-conjugating
enzyme, and an E3 ubiquitin ligase (Figure 3, reviewed by Glickman and Ciechanover
2002). At every step, the number of enzymes involved in ubiquitin conjugation increases, as
does the specificity of the reactions they catalyze. The ubiquitin-activating enzyme E1
initiates a cascade of enzymatic events that leads to covalent conjugation of ubiquitin to the
substrate. From E1 the activated ubiquitin is transferred to the E2 ubiquitin conjugating
enzymes. Covalent attachment of ubiquitin to the substrate is either directly executed or
indirectly facilitated by the E3 ubiquitin ligases, which fall into two categories, the HECT and
RING ligases. Of these, the HECT ligases bind the ubiquitin before transferring it to the
substrate, whereas the RING E3 ligases act as scaffolds that mediate direct transfer of the
ubiquitin to the substrate.
Most organisms, including humans and the baker’s yeast Saccharomyces cerevisiae,
contain a single ubiquitin E1 enzyme. In mammals, however, the UBA1 gene gives rise to
two transcripts by alternative splicing (Busch and Goldknopf 1981). The initial findings on
the physiological importance of ubiquitylation arose from the observation that cells, in which
the expression of E1 is temperature-sensitive, undergo cell-cycle arrest (Finley et al. 1984,
McGrath et al. 1991). Not surprisingly, the deletion of the single ubiquitin gene is lethal
(McGrath et al. 1991).
In the first step of ubiquitin conjugation, ubiquitin is loaded to the E1 ubiquitin-activating
enzyme, which activates the ubiquitin moiety in an ATP-dependent reaction. This gives rise
to an adenylate ubiquitin intermediate, donating the ubiquitin to the E1 active site cysteine.
The binding of ubiquitin to the active cysteine by a thioester bond enables the E1 to bind
two ubiquitins simultaneously, one in adenylate and one in thioester form. The high-energy
E1-ubiquitin thioester intermediate is the activated ubiquitin, which can be further
transferred to the ubiquitin-conjugating enzyme E2.
The ubiquitin-conjugating enzymes share a conserved core domain of ~150 amino acids,
consisting of four standard helices, a short helix and a four-stranded antiparallel -sheet
(reviewed by Pickart 2001). The active cysteine is located in a long loop, and the conserved
residues surrounding it are likely to mediate interactions with E1, ubiquitin or both. Some
E2s have N- or C-terminal extensions, which probably facilitate interactions with the E3
enzymes and provide specificity. The size of individual E2s varies greatly, ranging from the
approximately 30 kDa S. cerevisiae E2 enzymes to the mammalian 528-kDa ubiquitin-
conjugating enzyme (BRUCE; Hauser et al. 1998). In addition to E2-like activity, BRUCE
contains baculovirus repeats which provide it with IAP-like properties.
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Figure 3. Covalent conjugation of ubiquitin to the substrate requires a three-step enzymatic
process. In the first step, ubiquitin is activated in an ATP-dependent manner by the ubiquitin
activating enzyme, E1. Thereafter, activated ubiquitin is transferred to the E2 enzyme, which
either conjugates the ubiquitin either to a homologous to the E6-AP COOH terminus (HECT)
domain ubiquitin ligase E3 or directly to the substrate, if catalyzed by a really interesting new
gene (RING) finger E3. E3 ubiquitin ligases are responsible for recognizing and binding the
substrate. Adapted from Weissman (2001).
The yeast genome encodes 13 E2 enzymes, Ubc1-13, and at least 25 E2s are encoded by
the mammalian genomes. Some of the 25 mammalian enzymes are, however, not
dedicated to ubiquitin, but to other ubiquitin-like proteins. Despite the structural similarity
among the E2 enzymes, they play diverse biological roles. This is mainly due to the
specificity of the E2-E3 interactions. In addition, some E2 enzymes have specialized in
mediating conjugation of certain types of ubiquitin chains, for instance chains linked via K63
are often catalyzed by Ubc13. A yeast strain deficient in Ubc13 is viable but sensitive to
ultraviolet radiation, indicating a role for K63-linked ubiquitin chains in DNA repair and
illustrating the specialization of E2s (Hofmann and Pickart 1999).
The E2-ubiquitin thioester intermediate is labile. However, as the E2-ubiquitin interface
includes the C terminus of ubiquitin and some residues surrounding the active cysteine, the
ubiquitin C terminus is probably extended and partly surrounds the E2, but does not overlap
with its E3 binding regions. The crystal structures of the E2-E3 complexes have revealed
that most E2 enzymes contact E3 by the side chains of their C terminus (for example
Huang et al. 1999, Zheng et al. 2000).
The third class of enzymes involved in ubiquitin conjugation is the E3 ubiquitin ligases,
which constitute the largest and the most diverse group of enzymes in the ubiquitylation
pathway. The lack of homology and the greatest variety in structure underlie specific
recognition of individual substrates. Despite their variety, all E3 enzymes fall into two major
categories, the homologous to the E6-AP COOH terminus (HECT) domain and the really
interesting new gene (RING)-finger domain E3s. An estimated >30 HECT ligases exist in
mammals, while the number of RING ligases is much larger, over 200 (reviewed by Pickart
2001, Petroski and Deshaies 2005, Bernassola et al. 2008). Many of these ligases are yet
to be characterized.
The first identified HECT ligase was E6-AP that targets p53 in the presence of the human
papilloma virus (HPV) oncoprotein (Huibregtse et al. 1991). The HECT E3 ligases are
called the “true” ubiquitin ligases, because during the conjugation process, they accept the
ubiquitin via their active cysteine generating a covalent thioester intermediate with ubiquitin
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(Scheffner et al. 1995). The active cysteine is located in the C-terminal HECT domain
encompassing about 350 amino acids. The amino terminus of the HECT domain is variable
and likely to mediate substrate recognition. In addition to the C-terminal HECT domain, the
N termini of E3 ligases often contain conserved domains, such as WW domains, which bind
proline-rich sequences and phosphorylated serine and threonine residues, as well as PKC-
like C2 domains, which bind lipids in response to calcium influx (Springael et al. 1999,
reviewed by Bernassola et al. 2008).
In contrast to HECT-type E3 ligases, members of the RING-finger ligase family do not form
thioester intermediates with ubiquitin, but rather serve as scaffolds that bring substrates and
the ubiquitin-loaded E2 enzyme together (for example Joazeiro et al. 1999, Lorick et al.
1999, Fang et al. 2000). The RING-finger consists of a conserved pattern of cysteine and
histidine residues that cross-brace each other coordinating the binding of two zinc cations.
Depending on whether the fifth coordination site is occupied by cysteine or histidine, the
RING-finger domains are divided into RING-HC and RING-H2 subgroups, respectively. The
RING-finger E3 family is further divided to single and multi-subunit ligases. Well-known
examples of the single subunit ligases include Parkin (Shimura et al. 2000) and murine
double minute 2 (Mdm2), the E3 for p53 (Fang et al. 2000). These ligases are mono- or
homodimeric proteins with a RING finger domain and substrate-recognition regions within
one polypeptide.
The multi-subunit RING E3 complexes are classified into three types, the Skp1-cullin-F-box
protein (SCF), anaphase promoting complex (APC) and the von Hippel-Lindau-Cul2/elongin
B-elongin C (VCB-CBC) type ligases. Some multisubunit RING finger ligases consist of a
significant number of subunits. For example, the yeast APC/cyclosome contains 11
subunits and the mammalian as many as 12. Of these components, Apc11 contains a RING
finger and performs some of the substrate binding functions (Leverson et al. 2000). The
Apc2 subunit contains a Cullin homology domain, resembling the Cdc53/Cullin1 subunits of
the SCF complexes. APC/cyclosome is a well characterized cell cycle regulator, whose
functions are determined by numerous regulatory subunits and their post-translational
modifications (reviewed by Pesin and Orr-Weaver 2008). The SCF complexes, in turn, act
in concert with the E2 Cdc34/Ubc3 and the members of the UBCH5 family. The
Hrt1/Rbx1/Roc1, Skp1 and members of the Cdc53/Cullin-1 family are thought to be the
common components of all SCF ligase complexes (reviewed by Glickman and Ciechanover
2002), which are further organized and complemented by additional subunits (Kamura et al.
1999, Skowyra et al. 1999). The SCF complexes are named after the F-box subunit, which
is responsible for substrate recognition. The VCB-Cul2-Rbx1 complex, an archetypal
example of the VCB-CBC E3 complex, resembles the SCF complexes. Similarly to SCF, a
VCB complex contains a Hrt1/Rbx1/Roc1 RING finger protein, as well as elongins B and C,
Cullin 2, and the substrate recognition subunit pVHL (Kamura et al. 1999, Hon et al. 2002).
An elongin B/C interaction motif called the Socs box provides additional substrate specificity
to the VCB E3 ligases (reviewed in Stebbins et al. 1999). The best-known substrate of the
VHL E3 ligase may be the hypoxia-induced factor (HIF) 1  (Ivan et al. 2001, Jaakkola et al.
2001).
In addition to the E1, E2 and E3 enzymes, some proteins involved in ubiquitin conjugation
cannot be unambiguously categorized to the above-mentioned groups. The E4 elongation
factors help build polyubiquitin chains by binding to substrates modified with short ubiquitin
chains and catalyzing chain elongation with the help of the E1-E3 machinery. E4 proteins
contain a motif called homologous to ubiquitin fusion degradation 2 or U-box, which
resembles the RING finger (Aravind and Koonin 2000, Hatakeyama et al. 2001).
Intriguingly, certain U-box proteins have been shown to elongate ubiquitin chains
independently of RING or HECT E3s. An interesting example of a U-box protein is the
carboxyl terminus of Hsc70-interacting protein (CHIP), which binds substrates with the help
of heat shock cognate protein 70 (Hsc70) and heat shock protein 90 (Hsp90), thereby
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promoting the ubiquitylation of unfolded or aggregated proteins (Murata et al. 2001). In
addition, the ubiquitin E2 variant (UEV) family resembles ubiquitin-conjugating enzymes,
but lacks the active cysteine residues required for enzymatic activity (Sancho et al. 1998).
The known UEV proteins act in heterodimeric complexes with Ubc13 to assemble K63
ubiquitin chains in an E3-dependent manner. Therefore, the UEV-E2 complexes can be
seen as a subgroup of E2 enzymes dedicated to K63-chain assembly. Both U-box and UEV
proteins illustrate that ubiquitin chains may be subjected to significant remodeling also after
they have been appended to the substrate.
3.4 The deubiquitylating enzymes
The work of the E1-3 enzymes is balanced, counteracted and refined by the
deubiquitylating enzymes (DUBs). In addition to removing ubiquitin moieties from
substrates, the DUBs are important regulators of ubiquitin maturation and ubiquitin chain
remodeling (reviewed by Reyes-Turcu et al. 2009). Of the 100 putative DUBs encoded by
the human genome (Nijman et al. 2005), the ubiquitin-specific DUBs are divided into five
families on the basis of their structure and conserved domains. Four of them, including
ubiquitin C-terminal hydrolases (UCH), ubiquitin-specific proteases (USP), ovarian tumor-
type proteases (OTU), and the Machado-Joseph disease proteases (MJD), display papain-
like cysteine protease activity. How the activity of DUBs is regulated has remained largely
enigmatic, but at least transcriptional regulation, post-translational modifications and
scaffold binding contribute to adjusting DUB-like activity (Reyes-Turcu et al. 2009).
Intriguingly, some DUBs have been found to operate in a complex with E3 ubiquitin ligases
(Ventii and Wilkinson 2008).
The DUBs have an essential role in maturation of ubiquitin from proproteins that are
produced as linear polyubiquitin or as fusions of ubiquitin and a ribosomal protein (Wiborg
et al. 1985, Baker and Board 1987, Ozkaynak et al. 1987). DUBs process these proproteins
into mature ubiquitin monomers. The DUBs are also responsible for recycling ubiquitin from
the substrates that are targeted to the proteasome, or from ubiquitin that has remained as a
thioester intermediate (Pickart and Rose 1985). There is evidence that DUBs, such as
Usp14, Uch37, and POH1/Rpn11, associate and cooperate with the regulatory particle of
the proteasome and edit ubiquitin chains (Eytan et al. 1993, Lam et al. 1997, Chernova et
al. 2003, Crosas et al. 2006, Hanna et al. 2006, Yao et al. 2006). A20 and cylindromatosis
tumor-suppressor (CYLD), on the other hand, have been found to modulate nuclear factor 
enhancer binding protein (NF- B) signaling by deubiquitylating several proteins of the
pathway (Wertz et al. 2004, Wang et al. 2008).
3.5 The diverse outcomes of ubiquitylation
Ubiquitin signaling is extremely diverse. A protein can be ubiquitylated on several lysine
residues by single ubiquitins or ubiquitin chains of variable lengths (reviewed by Ikeda and
Dikic 2008). In addition, heterologous ubiquitin chains contain ubiquitin together with other
ubiquitin-like proteins. Ubiquitin chains can be assembled on all seven lysine residues of
ubiquitin, and different linkage types generate distinct chain topologies. Recent reports
show the chains may also branch via several different lysines within one chain (Ikeda and
Dikic 2008). Yet another level of complexity to the ubiquitin network is provided by the
numerous motifs and domains that mediate non-covalent ubiquitin binding. The astonishing
variety of biological outcomes of ubiquitin signaling is discussed below using different
ubiquitin chain linkage types as examples.
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3.5.1 Monoubiquitylation
Formation of a ubiquitin chain is not a prerequisite for ubiquitin signaling. The attachment of
single ubiquitin moieties to substrates (monoubiquitylation) takes part in diverse biological
processes. For example, monoubiquitylation of histones modulates transcription and DNA
repair (reviewed by Weake and Workman 2008), and the mutation of a single histone H2B
ubiquitylation site in S. cerevisiae ceases the sporulation of the yeast cells, indicating that
H2B ubiquitylation is also required for meiosis (Robzyk et al. 2000)
Monoubiquitylation has been ascribed important roles in regulating multiple aspects of
membrane trafficking. In addition, several endocytic and biosynthetic transmembrane
proteins are known to require ubiquitylation for vesicular transport into lysosome/vacuole
compartments in vesicles (reviewed by Katzmann et al. 2002, Hicke and Dunn 2004). The
biological significance of monoubiquitylation was originally demonstrated with membrane
proteins such as permeases and transporters, which depend on ubiquitylation for rapid
internalization. Conclusive evidence for the role of monoubiquitylation in endosomal
trafficking was later obtained by extensive yeast studies (Nakatsu et al. 2000, Roth and
Davis 2000, Shih et al. 2000, Katzmann et al. 2002, Haglund et al. 2003).
Monoubiquitylation also serves as a sorting signal during later stages of endosomal
trafficking and regulates the formation of multivesicular bodies. In addition,
monoubiquitylation is involved in protein sorting by the trans-Golgi network (Beck et al.
1999, Helliwell et al. 2001, Soetens et al. 2001). Finally, monoubiquitylation of the gag
polyprotein has been found fundamental for viral budding (Patnaik et al. 2000, Schubert et
al. 2000, Strack et al. 2000).
3.5.2 Polyubiquitylation
K63-linked ubiquitin chains regulate a variety of processes, most of which are unrelated to
proteasomal degradation, including endocytosis of cell surface receptors (reviewed by
Hicke 1999, Strous and Govers 1999), DNA repair (Spence et al. 1995), stress responses
(Arnason and Ellison 1994), ribosome function (Spence et al. 2000), as well as signaling
pathways (Deng et al. 2000, Wang et al. 2001). In contrast to K63 ubiquitin chains,
biological functions mediated by K29 chains are not well understood. Nonetheless, K29
polyubiquitylation by the E3 ligase Itch has been shown to mediate lysosomal degradation
of Deltex transcription factor (Chastagner et al. 2006). In addition, the K6- and K11-linked
ubiquitin chains have not yet been studied in a great detail, but the proteasome subunit
Rpn10/S5a is known to bind both K6- and K11-linked ubiquitin chains (Baboshina and Haas
1996). K11 polyubiquitin chains also signal endoplasmic reticulum-associated degradation
(ERAD; Xu et al. 2009). It is not currently known if K6 and K11 chains can serve other
signaling purposes.
K48-linked polyubiquitylation efficiently targets proteins for proteasomal degradation. For
efficient degradation, a K48 chain of at least four ubiquitin moieties is required (Thrower et
al. 2000). The Rpn10 and Rpn13 subunits of the proteasome recognize both the K48-linked
diubiquitin and the ubiquitin-like domains (UBLs) of ubiquitin-associated proteins (Husnjak
et al. 2008). However, it was recently reported that in yeast all polyubiquitin chains, apart
from K63, mediate proteosomal degradation, and they can be disassembled by the
proteasome (Xu et al. 2009).
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3.6 Proteasomal degradation of ubiquitylated proteins
By far, the best-known consequence of protein polyubiquitylation is proteasomal
degradation. Carefully regulated degradation of proteins allows the cell to adapt to differing
stimuli by modulating the half-lives of key regulatory proteins. Since the life span of a
protein may vary from less than a minute to several days, a cell must be capable of
dynamic degradation of pivotal proteins, as well as steady bulk degradation of the less
seminal components. The former is operated by the ubiquitin-proteasome pathway, in which
proteins are tagged by ubiquitin chains, recognized by the proteasome, cleaved, and finally
released as short peptides. Although this machinery is crucial for regulating the stability of
important signaling molecules, it is also responsible for protecting the cells from proteotoxic
stress by eliminating damaged and misfolded proteins in close collaboration with the
chaperone proteins (reviewed by Goldberg 2003). Remarkably, the proteasome has been
found to degrade also non-ubiquitylated proteins, such as p21, indicating that multiple
signals are capable of targeting proteins to the proteasome (Sheaff et al. 2000).
3.6.1 Structure of the 26S proteasome
The 26S proteasome is a ~2.5 MDa holoenzyme that consists of more than 30 subunits
(Figure 4). The proteasome subunits are highly conserved among eukaryotes: most
proteasome subunits exhibit >40% similarity between yeast and humans, while certain
crucial components, such as the proteasomal ATPases, display similarity as high as 70-
80%. The subunits are also functionally conserved, and several yeast proteasome knockout
phenotypes can be rescued by expressing their human counterparts (Glickman and Coux
2001). Functional proteasomal degradation is essential to virtually all cellular processes,
and the ubiquitin-proteasome pathway may therefore be one of the most conserved
regulatory pathway in eukaryotes.
The 26S proteasome consists of two major subcomplexes, the 20S core particle and the
19S regulatory particle. The 20S core is barrel-shaped, containing four rings of seven
subunits each. The -rings in the middle form a proteolytic chamber in which the
chymotrypsin, trypsin, and peptidoglutamyl transferase active sites are directed inwards
(Groll et al. 1997, reviewed by Glickman and Ciechanover 2002). The -rings at the outer
ends of the -rings, in turn, form narrow chambers by their N-terminal tails and control the
Figure 4. The 26S
proteasome is a ~2.5 MDa
holoenzyme consisting of the
20S core particle and one or
two 19S regulatory particles.
The 20S core includes two -
rings surrounded by two -
rings, forming a proteolytic
cylinder. The 19S regulatory
particle, in turn, consists of




lid and the base are held
together by another subunit
called Rpn10. Adapted from
Murata et al. (2009).
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passage of substrates into the proteasome core and the release of peptides from the other
end (Groll et al. 2000). One or both ends of the 20S core are capped with 19S regulatory
particles. The 19S subunit contains at least 19 subunits and it can be further divided into
two subcomplexes, the base and the lid (Glickman et al. 1998). The interaction between the
lid and the base is stabilized by the Rpn10 subunit (reviewed by Soboleva and Baker 2004).
The selectivity of proteasomal degradation is established by the sequestration of the 20S
core particle, as well as the limited access of the substrates, which is governed by the -
rings and the 19S regulatory particle.
The base consists of nine subunits, the Rpt1-6 ATPases and the Rpn1, -2, and -10 non-
ATPases, all of which directly interact with the -subunits of the core particle (Davy et al.
2001, Fu et al. 2001). The ATPases are responsible for unfolding the substrates, thereby
enabling the transportation of the peptides to the core. The lid is located on top of the base,
consisting of eight non-ATPase subunits, Rpn3, 5-9 and 10-12. The lid subunits are capable
of detaching and rebinding to the proteasome, indicating that the lid is a flexible structure
that allows the proteasome to react to changing conditions. The lid is necessary for efficient
degradation of polyubiquitylated proteins, and it is thought to be involved in recognizing and
processing ubiquitin chains (Glickman et al. 1998).
3.6.2 Mechanisms of proteasomal degradation
The mechanism by which the proteasome identifies its ubiquitylated substrates is not yet
fully understood. Efficient proteasomal degradation is mediated by K48-linked
polyubiquitylation, and some E3 ligases, such as Parkin and Hul5, directly bind and
cooperate with the proteasome (Leggett et al. 2002, Sakata et al. 2003). Rpn10 recognizes
the hydrophobic patches of ubiquitin molecules via its UIM (Young et al. 1998, Fu et al.
2001). However, where substrate preparation for degradation ends and processing by the
proteasome begins is still somewhat obscure. Although Rpn10 efficiently binds K48-linked
tetraubiquitin chains, K6- or K11- linked multiubiquitin chains have been reported to bind
Rpn10 with similar affinity (Baboshina and Haas 1996). This indicates that recognition by
the proteasome does not guarantee the degradation of the substrate. It has been
suggested that the UBD-containing proteins Rad23 and Dsk2 assist the proteasome in the
recognition of ubiquitylated substrates (reviewed in Hartmann-Petersen and Gordon 2004).
After the substrate has reached the proteasome, the regulatory particle unfolds the
substrate and positions it for the entry into the proteolytic core of the proteasome. The
proteasome lid keeps the ubiquitin chain from blocking the channel while the base efficiently
recognizes non-ubiquitylated, unfolded proteins and aids their refolding (Braun et al. 1999,
Strickland et al. 2000). Proteolysis within the proteasome depends on ATP, and the
conformational changes of the proteasome are accompanied by cycles of ATP hydrolysis
(Hershko et al. 1984, DeMartino et al. 1994). The ATPase cycle is coupled to gating of the
core by the N termini of the -rings, unfolding of the substrate, and threading the unfolded
polypeptide through the channel into the cylinder of the core particle. These cycles cause
the regulatory particle to sequentially bind and release the substrate.
Proteasomal ATPases of the regulatory subunit prepare the substrates for degradation
(Glickman et al. 1998). The regulatory particle forms interactions that compete with the
amino-terminal tails of the -subunits, enabling the proteolytic core to control the channel
opening (Groll et al. 2000). Once the substrate has entered the core particle, the
proteasome is able to cleave all peptide bonds in the substrate, albeit the active site-
containing -subunits prefer cleaving after certain amino acids. 1 prefers cutting after
acidic or small hydrophobic amino acids and 2 after basic or small hydrophobic amino
acids, whereas 5 prefers hydrophobic residues regardless of their size (Dick et al. 1998).
The proteasome only processes one substrate at a time. Proteolysis in the core channel
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produces small peptides of 3-23 amino acids, the average length being seven to nine amino
acids (Nussbaum et al. 1998, Kisselev et al. 1999). Once released from the proteasome,
the small peptides are hydrolyzed by downstream proteases and aminopeptidases.
4 Multiform regulation of programmed cell death
As tens of millions of cells die daily in the human body, efficient and safe mechanisms are
called for to execute cell death and to dispose of the cell remnants (Reed 1999).
Multicellular organisms utilize programmed cell death to eliminate excess, damaged, or
potentially dangerous cells. The term “programmed cell death” is used to distinguish
between expedient, regulated forms of cellular destruction and accidental, violent cell death.
By programmed cell death, an organism is able to avoid inflammation caused by leakage of
the cell contents to the surrounding tissue. Apoptosis, the classical form of programmed cell
death, was first described in the 18th century and identified as a dynamic process in the
1970s in a founding work by John Kerr, Andrew Wylie and Sir Alastair Currie (Kerr et al.
1972). This study introduced the term apoptosis and described the morphology of an
apoptotic cell. A typical apoptotic cell rounds up and retracts its pseudopodes. In addition,
the cellular volume is reduced, the chromatin condensates, the nucleus becomes
fragmented, and the plasma membrane blebs. Finally, the apoptotic cell is decomposed into
apoptotic bodies, which are then engulfed by phagocytes (Kerr et al. 1972).
In addition to apoptosis, other modes of cell death have been described, displaying a
variable degree of regulation. Necrosis has traditionally been defined as accidental cell
death characterized by plasma membrane rupture and subsequent loss of intracellular
contents, but necrosis has recently been found to be more regulated than originally thought
(Fiers et al. 1999). However, many of the causative elements and bystander effects of
necrosis are still unclear. Autophagy, in turn, is primarily a mechanism for keeping the cell
operative during nutrient deprivation. However, autophagic cell death characterized by
massive autophagic cytoplasmic vacuolization occurs in response to prolonged lack of
nutrients (reviewed by Baehrecke 2005, Kroemer and Jäättelä 2005). Different types of cell
death form a continuum rather than represent totally separate physiological processes
(reviewed by Kroemer et al. 2009). Although apoptosis relies on caspases in the execution
of the death program, it is possible to re-route death signals towards necrosis or other
modes of cell death, if the caspases are inhibited. In concert, the presence of limited
caspase activity does not usually constitute apoptosis, as caspases perform specific tasks
during diverse physiological processes, including differentiation and proliferation. The
following section is dedicated solely to apoptosis.
4.1 Execution of apoptosis through the intrinsic and extrinsic pathways
The apoptotic program can be carried out by two main biochemical routes (Figure 5). The
extrinsic apoptotic pathway operates during development, in the immune system and in
immunosurveillance for tumor removal, whereas the intrinsic pathway eliminates cells in
response to ionizing radiation, chemotherapeutic drugs, and mitochondrial damage. Both
pathways mediate the activation of caspases, a family of cysteine proteases that execute
the organized destruction during apoptosis in a stepwise fashion. Without apoptotic stimuli,
caspases reside in the cytosol as inert proforms. While the extrinsic pathway is triggered by
death receptor ligation, the intrinsic pathway activates caspases in response to
mitochondrial membrane permeabilization, which leads to the release of apoptotic
molecules into the cytosol. Both pathways transmit the death signal through a series of
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proteolytic events called the caspase cascade. Initiator caspases are first activated in
multiprotein complexes, called the death inducing signaling complex (DISC) in the extrinsic
pathway and the apoptosome in the intrinsic pathway. Downstream caspases are then
activated by mature initiator caspases, and the proteolytic signal is thereby extended.
Executioner caspases are responsible for cleaving hundreds of cellular substrates, evoking
the morphological features characteristic to apoptosis.
Figure 5. Schematic presentation of the major apoptotic pathways. In the intrinsic apoptotic
pathway, the apoptotic program is initiated in response to severe stress stimuli, for example
genotoxic damage. As a result, the mitochondrial membrane potential is lost, cytochrome c gets
released from the intermembrane space, and the apoptosome is formed in the cytosol, enabling
caspase-9 activation. Active caspase-9 initiates the caspase cascade leading to cleavage of
several cytoplasmic and nuclear substrates. The extrinsic pathway is initiated by death receptor
ligation, which leads to the formation of the death-inducing signaling complex (DISC). DISC
brings together caspase-8 molecules, which then dimerize and activate each other, resulting in
downstream caspase activation. The extrinsic pathway can be amplified through the
mitochondrial loop by caspase-8-mediated cleavage of Bid.
4.2 Bcl-2 proteins regulate the intrinsic pathway and mitochondrial apoptotic
signaling
The initiation and progression of the mitochondrial apoptosis is controlled at multiple levels
by the B-cell lymphoma (Bcl) proteins, named after the human Bcl-2 oncogene (Tsujimoto
et al. 1984). The Bcl-2 family includes both pro- and anti-apoptotic members, which activate
or neutralize each other by homo- and heterodimerization. The pro-apoptotic Bcl-2 proteins
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sense the apoptotic stimuli and transmit it to the mitochondria, while the anti-apoptotic Bcl-2
proteins act as to prevent them. Therefore, the Bcl-2 proteins are considered the
gatekeepers of the mitochondrial membrane integrity.
The BH3 domain only-proteins sense the signals that initiate mitochondrial apoptosis. There
are currently 11 known BH3 domain-only proteins, including BH3-interacting domain death
agonist (Bid), BH3-interacting mediator of cell death (Bim), Bcl-2-associated death protein
Figure 6. The anti-apoptotic Bcl-2 proteins protect the cell from apoptosis by
inhibiting the pro-apoptotic Bcl-2 proteins. The pro-apoptotic multidomain proteins
induce mitochondrial outer membrane permeabilization. The BH3 domain-only
proteins act as sensors of variable apoptotic signals and transfer them further to
the multidomain pro-apoptotic Bcl-2 proteins. Bcl-2 homology (BH) domains and
putative transmembrane (TM) domains are indicated. Adapted from Adams and
Cory (2007). The figure is not drawn to scale.
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Based on their structure, the Bcl-2 proteins can be divided into three groups, the anti-
apoptotic, the pro-apoptotic multidomain and the pro-apoptotic BH3-only Bcl-2 proteins
(Figure 6; reviewed by Adams and Cory 2007). All Bcl-2 proteins are characterized by one
or more Bcl-2 homology domains (BH), and the number and location of the BH domains
dictates the attributes of an individual Bcl-2 protein. The pro-apoptotic Bcl-2 proteins are
guarded by the pro-survival Bcl-2 proteins, which include Bcl-2, Mcl-1, and the Bcl-XL
isoform of the Bcl-X gene. The anti-apoptotic Bcl-2 proteins have been shown to bind to the
BH3-only proteins in order to keep them from activating Bax and Bak, but it has also been
suggested that the Bcl-2 proteins directly bind and inhibit Bax and Bak. Nevertheless,
correct execution of the anti-apoptotic function necessitates that Bcl-2 and Bcl-XL are
correctly targeted to the outer mitochondrial membrane. Since the anti-apoptotic Bcl-2
proteins set the balance for apoptotic sensitivity, their levels and activity are carefully
regulated. Bcl-2, for instance, is marked for ubiquitylation and degradation by
phosphorylation (Breitschopf et al. 2000). The levels of anti-apoptotic Bcl-2 proteins are
often found to be upregulated in malignant cells, partly accounting for their abnormal
resistance towards apoptosis (Adams and Cory 2007). In addition to ubiquitylation, other
post-translational mechanisms also regulate the pro-survival Bcl-2 proteins. Upon DNA
damage, Bcl-XL becomes deaminated and is thereby inhibited from binding to BH3-only
proteins (Deverman et al. 2002). The activity of Bcl-2, in turn, is positively modulated by
multiple phosphorylations (Ruvolo 1999, Ruvolo et al. 2001).
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(Bad), Noxa, and p53-upregulated modulator of apoptosis (Puma). During normal
circumstances, the BH3 only-proteins are present in an inactive form, but they are post-
translationally activated in response to stress. It seems that different types of stress stimuli
are sensed by distinct BH3 only-proteins. For example, Bid is cleaved by active caspase-8
into its active truncated conformation (tBid; Li et al. 1998, Luo et al. 1998), although other
proteases, such as caspase-3, are also capable of cleaving Bid in vitro (Desagher et al.
2001, Degli Esposti et al. 2003). Full tBid activation requires further cleavage, ubiquitylation
and degradation of the N-terminal fragment (Tait et al. 2007). Bad, in turn, is normally kept
inactive by Akt-mediated phosphorylation, but is released from the 14-3-3 scaffold by
dephosphorylation (Zha et al. 1996, Wang et al. 1999). Bim is activated and freed from the
filament network in response to increased levels of calcium or cytokine deprivation
(Puthalakath et al. 1999), but targeted to ubiquitylation and proteasomal degradation by
phosphorylation (Ley et al. 2003, Ley et al. 2004). Finally, Puma and Noxa are targets of
p53, and their transcription is upregulated upon DNA damage (Nakano and Vousden 2001,
Yu et al. 2001, reviewed by Puthalakath and Strasser 2002). The BH3 only-proteins harbor
some specificity towards the anti-apoptotic Bcl-2 proteins. Bim, Puma and tBid bind the anti-
apoptotic Bcl-2 proteins with limited selectivity, whereas Noxa is selective towards Mcl-1
and A1, and Bad towards Bcl-2, Bcl-XL, and Bcl-w (Chen et al. 2005, Kuwana et al. 2005).
Although the anti-apoptotic proteins need to be neutralized in order for apoptosis to
proceed, it is currently not known to which extent the neutralization needs to progress to
allow apoptosis.
After activation, the BH3-only proteins transmit the signal by activating the pro-apoptotic
multidomain proteins, such as Bcl-2-associated X (Bax) protein and Bcl-2 homologous
antagonist/killer (Bak). Bax and Bak are essential executioners of mitochondrial apoptosis,
since the BH3-only proteins are not capable of initiating apoptosis in cells lacking both Bax
and Bak (Cheng et al. 2001, Zong et al. 2001). However, Bax and Bak seem to be
redundant, as either one alone is sufficient to transmit the death signal from the BH3 only-
proteins. Bax and Bak are constitutively expressed and sequestered to the cytosol and to
the mitochondria, respectively. Upon activation, Bax is translocated from the cytoplasm to
the mitochondrial outer membrane, where Bak already resides. Both Bax and Bak have to
undergo conformational changes and oligomerize to be able to penetrate the outer
mitochondrial membrane.
There are currently two models for Bax and Bak activation by the BH3-only proteins. In the
direct activation model (reviewed by Willis and Adams 2005), Bim and tBid directly bind Bax
and Bak, thereby promoting their activation (Letai et al. 2002, Kuwana et al. 2005, Certo et
al. 2006, Oh et al. 2006, Walensky et al. 2006), while the remaining BH3-only proteins bind
the anti-apoptotic Bcl-2 proteins. According to this model, Bim and tBid are released from
the anti-apoptotic Bcl-2 proteins because they are displaced by the other BH3-only proteins,
allowing Bim and tBid to bind Bax and Bak. In the indirect activation model, in turn, the
BH3-only proteins do not directly interact with Bax or Bak, but with the anti-apoptotic Bcl-2
proteins (Chen et al. 2005, Willis et al. 2005, Willis et al. 2007). Here, the efficiency of tBid
and Bim as apoptosis inducers is measured by their ability to bind the anti-apoptotic Bcl-2
family members. Later studies have questioned the direct activation model, but it has also
been stated that Bax and Bak need an additional activating signal in order to promote
apoptosis (reviewed by Green 2005, Adams and Cory 2007). Therefore, the indirect model
at its simplest may also be insufficient.
The depletion of Bax and Bak results in the lack of mitochondrial outer membrane
permeabilization (MOMP), as well as resistance to a wide range of apoptotic stimuli in the
double knock-out mice (Wei et al. 2001). It is not known, however, how Bax and Bak are
able to induce the release of cytochrome c. It has been suggested that Bax and Bak form
channels on their own (Wei et al. 2000), interact with other channel-forming proteins to
create permeability transition pores (Tsujimoto and Shimizu 2000, Zamzami and Kroemer
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2001), or form supramolecular openings to the membrane (Kuwana et al. 2002).
Interestingly, a recent report proposes that the mitochondrial fission induced by Bax and
Bak may in fact be separate from the cytochrome c release, as the anti-apoptotic Bcl-2
family members were capable of rescuing the cell from cytochrome c release, but not from
the fragmentation of the mitochondrial network (Sheridan et al. 2008).
MOMP is considered the point of no return for the intrinsic apoptotic pathway. MOMP is
induced by numerous pro-apoptotic and pathological stimuli which converge in the
mitochondria, and it is required for caspase activation in the intrinsic apoptotic pathway.
Biochemical mechanisms for MOMP induction have remained controversial, although
several proteins have been assigned MOMP-inhibiting or -promoting functions (Letai et al.
2002, Chen et al. 2005, Kuwana et al. 2005, Willis et al. 2005). MOMP results in the release
of apoptotic factors such as cytochrome c, SMAC/DIABLO, and OMI/HtrA2 to the
cytoplasm. In addition, the loss of mitochondrial membrane potential leads to mitochondrial
metabolic failure.
Two basic models for MOMP have been proposed (reviewed by Green and Kroemer 2004).
According to the first model, small permeability transition pores are formed on the inner
mitochondrial membrane, allowing water and molecules of 1.5 kDa to pass through. The
opening of these pores results in loss of the mitochondrial membrane potential and swelling
of the matrix, which disrupts the outer mitochondrial membrane and releases the contents,
including the caspase-9 activation co-factor cytochrome c. In the second, permeability
transition pore-independent model, the MOMP does not depend on permeability transition
pores, but instead the pro- and anti-apoptotic Bcl-2 proteins that reside on the outer
mitochondrial membrane (Green and Kroemer 2004). The apoptotic Bcl-2 proteins are
perhaps accompanied by other proteins, and together they permeabilize the outer
mitochondrial membrane.
The mitochondrial pathway is sometimes involved in amplifying the signal that stems from
death receptor ligation. According to this type 1 - type 2 hypothesis (Scaffidi et al. 1999),
death receptor activation in type 1 cells results in caspase-8 activation that is strong enough
to initiate the caspase cascade and apoptosis on its own. In contrast, caspase-8 activation
in type 2 cells is too weak to sufficiently activate the downstream caspases, and the cell
requires a mitochondrial amplification loop to intensify the signal. This is achieved through
caspase-8-mediated proteolysis of Bid, producing an active truncated Bid (tBid). tBid then
translocates to the mitochondria, where it triggers the release of cytochrome c from the
intermembrane space to the cytosol, thereby enabling the activation of caspase-9.
However, although it is widely accepted that caspase-8 mediates Bid cleavage in type 2
cells during extrinsic apoptotic cell death, some aspects of the type 1 - type 2 model have
remained controversial. Caspase-8 is not the only protease that is capable of cleaving Bid,
but also caspase-2 and caspase-3 have been reported to process Bid (Guo et al. 2002,
Bonzon et al. 2006, Bossy-Wetzel and Green, 1999, Slee et al. 2000). In addition,
cathepsins and calpains have been found to activate Bid (Stoka et al. 2001, Mandic et al.
2002, Werner et al. 2004, Droga-Mazovec et al. 2008). Therefore, Bid cleavage is not
always a corollary of caspase-8 activity, although active caspase-8 would simultaneously be
present.
4.3 Apoptotic initiator and effector caspases
According to the current view, a cell is considered dead when its plasma membrane
integrity is lost, it has been fragmented into apoptotic bodies, and these fragments are
eventually engulfed by adjacent cells (Kroemer et al. 2009). The majority of the apoptotic
morphology is due to substrate cleavage by the caspases. Caspases are cysteine aspartate
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proteases that are responsible for organized destruction of proteins and DNA during
apoptosis. The pivotal role of caspases was originally discovered in Caenorhabditis elegans
studies. The product of the C. elegans CED-3 (cell death abnormality) gene was similar to
the human caspase-1 or interleukin-1 -converting enzyme, the first human caspase to be
identified (Yuan et al. 1993). A total of four caspases have since been discovered in C.
elegans, while CED-3 remains its only apoptotic caspase.
4.3.1 The classification and structure of caspases
Caspase enzymes have been classified into two subfamilies based on phylogenetic
analyses. The first subclass is the interleukin-1  converting enzyme (ICE)-like caspases,
whereas the second subclass resembles the C. elegans apoptotic caspase, CED-3. To
date, 13 caspases have been cloned from mammals. Caspases fall into two major
functional groups, the apoptotic and the inflammatory caspases. Of these, the apoptotic
caspases (-2, -8, -9, -10, -3, -6 and -7) are involved in initiating and executing cell death in
an orderly manner (Figure 7), whereas the inflammatory caspases (-1, -4, -5, -11, -12 and -
13) function in response to a variety of immunogenic stimuli by forming and regulating a
signaling complex called the inflammasome (reviewed by Martinon et al. 2009).
Figure 7. Structure, classification and conservation of the mammalian apoptotic caspases.
Caspases -8 and -10 are the initiator caspases of the extrinsic pathway, both of them
containing two N-terminal death effector domains (DED) and a C-terminal caspase domain.
In contrast, the remaining initiator caspases -2 and -9 oligomerize via their caspase
recruitment domains (CARD). During autoprocessing, all initiator caspases are cleaved
twice to produce the large p20 and small p10 subunits. The effector caspases include
caspase-3, -6 and -7, and they do not contain large prodomains. Instead, they are
proteolytically activated by initiator caspases to produce the active conformation and a
mature caspase. Adapted from Riedl and Shi 2004. The figure is not drawn to scale.
Caspases are produced as inactive zymogens that need targeted proteolysis for activation.
Since inappropriate caspase activation would be detrimental to the cell, caspase zymogen
processing is carefully regulated. The broad-scale activation of caspases is guarded by
activation of the initiator caspases. Initiator caspases -8, -9, -2 and -10 mediate the
cleavage of effector caspases -6, -7 and -3, which amplify the signal and cleave a large
number of substrates. In addition to homology, caspases are categorized based on their
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favored substrate motifs: while effector caspases prefer to cleave substrates after DEVD or
VEVD, caspase-8 favors LETD and caspase-9 LEHD (Thornberry et al. 1997).
Unlike effector caspases, initiator caspases include conserved interaction domains (Figure
7). Hydrophilic interactions between the N-terminal death effector domains (DEDs) of
caspases and the adaptor Fas-associated death domain protein (FADD) mediate the
binding of caspase-8 and -10 to activated death receptors. In addition, the homophilic
dimerization, which is crucial to caspase activation, relies on their second DED. Caspase-2
and -9, in turn, have single N-terminal caspase-associated recruitment domains (CARDs),
which mediate homophilic, electrostatic interactions. Both DED and CARD are members of
the death-fold domain family (reviewed by Liang and Fesik 1997), the two other members
being the death domain (DD) and the pyrin domain (reviewed by Lahm et al. 2003).
4.3.2 Caspase-9 is activated in the apoptosome holoenzyme
The initiator caspases are activated in protein complexes. While caspase-8 and caspase-10
dimerize at the plasma membrane in a death receptor-based complex, caspase-9 is
activated in the apoptosome holoenzyme following MOMP. MOMP releases proteins from
the mitochondrial intermembrane space, some of which contribute to the formation of the
apoptosome. The apoptosome signaling complex forms in the cytoplasm after some of its
crucial subunits have been released from the mitochondria. One of these pivotal factors is
cytochrome c, a water-soluble 13 kDa heme-containing protein, which under normal
conditions is sequestered by cristae junctions in the spaces between cristae in the inner
mitochondrial membrane and participates in the mitochondrial electron-transport chain
(reviewed by Pellegrini and Scorrano 2007, Ow et al. 2008). After being released from the
mitochondria, cytochrome c binds to the conserved WD40 domains of the adaptor molecule
Apaf-1, which mediates the oligomerization of seven Apaf-1 molecules. Apaf-1-cytochrome
c binding also allows ATP-binding by the CED-4-like domain of Apaf-1, leading to an
elongated conformation. In addition, upon cytochrome c binding, the CARD domain of Apaf-
1 is exposed, enabling the homotypic interaction between Apaf-1 and caspase-9 (Hao et al.
2005, Riedl et al. 2005). Together these molecules form the apoptosome, a complex with a
wheel-like structure (Yu et al. 2005). The apoptosome provides a platform for caspase-9
dimerization, which is required for its activation. It has been suggested that the apoptosome
operates like a molecular timer: the concentration of unprocessed procaspase-9 determines
the duration of the complex, while the autoprocessing of procaspase-9 activates the timer,
and the dissociation rate of mature caspase-9 from the apoptosome determines how long it
is capable of activating procaspase-3 (Malladi et al. 2009).
Preceding MOMP and cytochrome c release, caspase-9 is an inactive monomer. In the
cytosol, cytochrome c forms the apoptosome complex around the adaptor protein apoptotic
protease activating factor 1 (Apaf-1; Zou et al. 1999). The interaction between Apaf-1 and
cytochrome c alters the conformation of Apaf-1 into an ATP-binding, elongated state,
enabling the assembly of the 1.4 MDa apoptosome complex structured like a seven-spoked
wheel. The N-terminal CARD domains of Apaf-1 recruit caspase-9 molecules to the central
hub of the apoptosome, where the induced proximity of these caspases promotes their
dimerization and activation. Similarly to caspase-8, further cleavage is unnecessary for the
enzymatic activity of caspase-9. A fully active caspase-9 dimer harbors only one active
domain, and it is formed by small rearrangements of the surface loops defining the
substrate cleft and catalytic residues (Hao et al. 2005, Riedl et al. 2005). The apoptosome
has been considered the only activation platform for caspase-9, but lately this view has
challenged. Caspase-9 was found to be in a complex with downregulated in
rhabdomyosarcoma LIM-domain protein (DRAL), when the dependence receptor Patched is
not occupied by its ligand, Sonic hedgehog (Mille et al. 2009). In addition, caspase-9 has
been reported to be cleaved and activated by caspase-8 during TNF-mediated lysosomal
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cell death (Gyrd-Hansen et al. 2006), illustrating the overlap between both different cell
death programs and the extrinsic and intrinsic pathways.
4.3.3 Activation of the effector caspases
Following apoptotic stimuli, initiator caspases cleave and activate the effector caspases.
The mechanism for activation of effecetor caspases -3, -6 and -7 differs markedly from that
of initiator caspases. In contrast to initiator caspases, effector caspases are present in the
cytosol as inactive dimers. Effector caspases contain a short prodomain spanning 20-30
amino acids, active-site loops L1-4, and C-terminal caspase domains. Caspases -3, -6 and
-7 are activated by limited proteolysis within the interdomain linker at L2 loops, and
following cleavage, the active cysteine residues in the N-terminal segment of loop L2 and
the C-terminal L2' loop translocate to opposite directions to stabilize the active conformation
(Figure 8). After the first cleavage by the initiators, effector caspases cleave the remaining
loops in autoproteolytic fashion. The model of effector caspase activation is largely based
on the crystal structure data obtained from the inactive and active conformations of
caspase-7 (Chai et al. 2001, Riedl et al. 2001).
4.3.4 Regulation of caspase activity
The activity of caspases is regulated on multiple levels to ensure safe and precise
execution of apoptosis and to maintain appropriate caspase activity during development,
differentiation and proliferation. The activation of caspase-8 is inhibited by cellular FLICE-
inhibitory proteins (c-FLIPs). Active caspases, on the other hand, are specifically regulated
by the members of the IAP (inhibitor of apoptosis) protein family (reviewed by Srinivasula
and Ashwell 2008). After the viral IAPs were originally cloned from baculovirus-infected
insect cells, their cellular orthologs have been found in organisms including yeast,
nematodes, flies, mammals and even plants (Higashi et al. 2005). To date, 8 mammalian
IAPs have been identified (Figure 9), among which cellular inhibitor of apoptosis proteins 1
(c-IAP1 or MIHB, hiap2, BIRC2) and 2 (c-IAP2 or MIHC, hiap2, BIRC3), as well as X-linked
IAP (XIAP, hILP, MIHA, BIC4) are the most thoroughly characterized. The remaining five,
BRUCE, ILP2, ML-IAP, NAIP and survivin, regulate variable physiologial processes,
including innate immunity (Srinivasula and Ashwell 2008). Surprisingly, IAP gene deletion
studies show that BRUCE, a 528 kDa IAP with an N-terminal BIR and a C-terminal UBC
domain, is absolutely required for development, as BRUCE deficiency causes embryonic or
neonatal lethality (Hao et al. 2004). In contrast, XIAP or c-IAPs are not required for survival
Figure 8. Model for effector
caspase activation based on the
crystal structure of caspase-7. The
procaspase-7 dimer (left) and its
active site loops are shown (L1 and
L1’ excluded). Proteolytic
processing of the L2 loop from its
interdomain linker (dotted line)
between the small and large
subunits produces a mature,
stabilized structure, where the active
cysteine is differentially located
compared to the unprocessed
procaspase-7 zymogen. Adapted
from Riedl and Shi (2004).
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or normal development in mice, perhaps due to functional redundancy between the RING-
containing IAPs (Harlin et al. 2001, Conze et al. 2005, Conte et al. 2006).
Figure 9. Schematic presentation of the mammalian IAPs. IAPs contain several conserved
domains, of which the baculoviral IAP repeat (BIR) domain is common to all IAPs. In
addition, c-IAPs contain CARDs, which enable them to interact with caspases, and IAPs
containing RING domains can act as E3 ubiquitin ligases. The c-IAPs and XIAP also contain
ubiquitin-associated domains that enable them to bind K63-linked ubiquitin in a non-covalent
manner (Gyrd-Hansen et al. 2009). In addition, BRUCE is a large ubiquitin conjugating
enzyme. The IAPs are known to inhibit different caspases: c-IAPs, XIAP and NAIP are
capable of inhibiting caspase-3 and caspase-7 by the linker region N-terminal to BIR2, while
XIAP also inhibits caspase-9 by its BIR3 domain. Adapted from Riedl and Shi (2004). The
figure is not drawn to scale.
The IAPs are characterized by a variable number of the baculovirus IAP repeat (BIR)
domains, which mediate direct binding and inhibition of proteolytically active caspases
(reviewed by Eckelman et al. 2006). The BIR domains encompass about 70 amino acids,
including a signature sequence C-X2-CX16-H-X6-C (where X denotes any amino acid), which
forms a hydrophobic core with a zinc atom in the center. In addition to the BIR domains, a
subset of IAPs contains RING domains, thereby equipping these proteins with ubiquitin
ligase E3 activity. c-IAPs also contain CARD domains, although their biological function has
remained obscure.
An acidic surface groove of the BIR domain operates as an anchoring motif for caspases.
Different BIR domains, however, display some specificity for caspase binding. For example,
the surface groove of BIR2 strongly binds caspase-3 and -7, but not caspase-9. The same
motif, when surrounded by different residues in BIR3, only binds caspase-9, but not
caspase-3 or -7 (Eckelman et al. 2006). Binding alone, however, does not effectively inhibit
caspase activity, and XIAP seems to be a more potent inhibitor of caspases than the c-IAPs
(Eckelman and Salvesen 2006). Instead, XIAP blocks the substrate binding site of caspase-
3 and -7 by its flexible linker region (Chai et al. 2001, Huang et al. 2001, Riedl et al 2001).
Caspase-9, in turn, is inhibited by XIAP by a distinct mechanism: after caspase-9 has been
processed in the apoptosome holoenzyme, the XIAP BIR3 domain binds to the exposed
linker peptide of the small caspase-9 subunit (Srinivasula et al. 2001).
The IAPs are regulated by several pro-apoptotic proteins, including second mitochondrial-
derived activator of caspases/direct inhibitor of apoptosis-binding protein with low pI
32
Review of the Literature
33
(SMAC/DIABLO; Du et al. 2000, Verhagen et al. 2000) and Omi/high temperature-
requirement protein A2 (HtrA2; Suzuki et al. 2001, Hegde et al. 2002). The IAP inhibitors do
not share any obvious sequence homology, apart from the IAP-binding motif (IBM)
characterized by an N-terminal tetrapeptide (AVPI/AVSI) that is revealed by cleavage of the
mitochondrial targeting sequence. During apoptosis, the IAP inhibitors move from the
mitochondrial intermembrane space to the cytosol and bind to BIR2 and BIR3, thereby
preventing IAPs from binding to caspases (Srinivasula and Ashwell 2008). In addition,
SMAC triggers the autoubiquitylation and proteasomal degradation of c-IAPs. The recent
development of SMAC mimetics has provided important tools for dissecting the role of IAPs
in diverse physiological contexts. As described by several independent studies, SMAC
mimetics induce the autoubiquitylation and degradation of c-IAP1 and c-IAP2 (Petersen et
al. 2007, Varfolomeev et al. 2007, Vince et al. 2007). Intriguingly, SMAC mimetics seem
capable of inducing both NF- B and subsequent apoptosis. Following c-IAP depletion, RIP
becomes deubiquitylated by CYLD, which leads to the release of RIP form the membrane-
associated complex I into the cytosol. There RIP interacts with FADD and caspase-8 to
form a death-inducing complex (Wang et al. 2008). How caspase-8 activation is regulated in
this context is not entirely known.
Some IAPs possess a RING domain providing them with ubiquitin ligase activity, which
partly explains the versatile roles of IAPs in death and survival signaling. The RING-
containing IAPs include XIAP, ILP2, ML-IAP, c-IAP1 and c-IAP2 (Figure 9). At least XIAP
and c-IAPs have been shown to be able to ubiquitylate themselves to mediate their own
degradation. In addition, controversing reports exist on the effect of SMAC to the ligase
activity of the IAPs (Creagh et al. 2004, Yang et al. 2004).
4.3.5 Processing of caspase substrates
The name 'caspase' derives from cysteine-dependent aspartate specific protease. As many
other proteases, caspases use the cysteine side chain as a nucleophile during peptide
bond hydrolysis. However, unlike most other proteases, caspases have strict specificity for
cleavage after D residues (Sleath et al. 1990, Thornberry et al. 1992). The caspase
consensus sequences are often used to indicate specificity, although the preferred caspase
cleavage sites are far from exclusive. In general, caspases recognize a tetrapeptide (P4-
P3-P2-P1) in which P1 is D. Charged or bulky residues are poorly tolerated at the P1'
position after the scissile bond - G, A, T, S and N are suitable for caspase processing,
whereas E, D, K, R and W do not favor catalysis. Several caspases prefer Q at P3,
whereas the nature of the P2 seems to be less important, and the preferences for P4 vary
among the caspases (Sleath et al. 1990, Talanian et al. 1997, Thornberry et al. 1997).
Usually, the cleavage site of caspase substrates adapts a disordered and flexible
conformation (Hubbard et al. 1991, reviewed by Timmer and Salvesen 2007). Although
caspases favor slightly differing substrate sequences, the degree of overlap is still largely
unknown. According to recent findings, caspase-3 and caspase-7 exhibit some differences
in protease activities: caspase-3 appears more promiscuous than caspase-7, and therefore
caspase-3 is likely to be the major executioner of apoptosis (Walsh et al. 2008).
Caspases were previously considered solely responsible for all the biochemical and
morphological changes that occur during apoptosis. Yet it is difficult to distinguish the
specific effects of active caspases from indirect secondary effects. Although hundreds of
proteins have been identified as potential caspase substrates, only a subset has been
confirmed to be in vivo substrates with a designated physiological role. Established caspase
substrates include the executioner caspases, the pro-apoptotic Bcl-2 protein Bid, the tumor
suppressor Rb, the nuclease regulator inhibitor of caspase-activated DNase (ICAD), and
the poly(ADP-ribose) polymerase (PARP).  Caspase cleavage typically results either in
gain-of-function or in loss-of-function of the substrate. For example, the activation of
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executioner caspases -3 and -7 is a gain-of-function event. The cleavage of ICAD, in turn,
results in loss of enzyme inhibition, and as a result, the CAD is free to cleave double-
stranded DNA (Liu et al. 1997, Enari et al. 1998). The degradation of DNA is a classical
biochemical feature of apoptosis, along with the caspase-mediated cleavage and
subsequent inhibition of the PARP enzyme, which routinely repairs breaks in double-
stranded DNA (D'Amours et al. 2001). The ATP-dependent enzymes and processes are
generally inhibited by apoptosis, because programmed cell death requires energy.
4.4 The death receptor systems and the extrinsic apoptotic pathway
4.4.1 The TNF superfamily of death ligands and receptors
Whereas the intrinsic pathway is induced from within the cell, the death signals initiating the
extrinsic pathway may be expressed by the cell itself or by the neighboring cells. The
extrinsic apoptotic pathway is initiated by binding of a death ligand to its cognate death
receptor on the plasma membrane. The key mediators of receptor-mediated apoptosis are
the ligands and receptors of the tumor necrosis factor (TNF) superfamily. The finding and
characterization of the TNF cytokines and their respective receptors was a result of
vigorous scientific work, the first discoveries dating back to the 19th century. Initial
observations of TNF addressed tumor regression after bacterial infection (Bruns 1868), a
phenomenon which has since been demonstrated in several models from guinea pigs to
humans. TNF  and TNF  were purified, sequenced and cloned in the 1980s, and TNF
receptors (TNFR) 1 and 2 followed shortly thereafter (Aggarwal et al. 1984, Gray et al.
1984, Pennica et al. 1984, Aggarwal et al. 1985a, Aggarwal et al. 1985b). The 19 ligands
and 32 receptors of the TNF superfamily are involved in a wide array of biological
processes, including the regulation of cell death and survival, innate and adaptive immunity,
and differentiation (reviewed by Aggarwal 2003). During the last decade, also non-apoptotic
roles have begun to emerge for several death receptors.
TNF receptors and ligands are expressed in varying degrees in a wide range of tissues.
Nearly all TNF ligands are expressed in immune cells, with the exception of the secreted
vascular endothelial cell-growth inhibitor (VEGI), which is mainly expressed by the
endothelial cells (Zhai et al. 1999). In contrast to TNF ligands, almost all cell types express
some death and decoy receptors, thereby equipping them with the capacity to undergo
receptor-mediated apoptosis. Receptors of the TNF superfamily are type 1 transmembrane
proteins with an extracellular N terminus and an intracellular C terminus, and they reside on
the membrane as preassembled homotrimers. The TNF receptors are characterized by one
to six conserved cysteine-rich extracellular domains that mediate the receptor-ligand-
interactions (reviewed by Ashkenazi and Dixit 1999, Chan 2007). In addition, some of the
TNF receptors share a common cytoplasmic death domain (DD). These receptors are bona
fide death receptors, as opposed to the decoy receptors which lack the cytoplasmic death
domains and are therefore unable to transmit the death signals. However, decoy receptors
are still potent modulators of death receptor signaling, because they bind death ligands.
Many vertebrate death receptors contain DDs, but, surprisingly, the Drosophila TNFR
homologue Wengen is able to transmit apoptotic signals although it lacks a functional death
domain (Kanda et al. 2002, Kauppila et al. 2003). However, as other Drosophila proteins
contain functional DDs, this is probably not an indication of the evolutionary development of
the DD. In addition to the DDs, another homologous structure has been addressed to
TNFR-1, CD95 and TRAILR-1, called the pre-ligand-binding assembly domain (PLAD). The
PLADs mediate receptor homotrimerization, which is essential for ligand binding (Chan et
al. 2000).
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The TNF ligands are type 2 transmembrane proteins with an intracellular N terminus and an
extracellular C terminus. The ligands reside at the plasma membrane as homotrimers
(Chan et al. 2000). Similarly to the death receptors, death ligands contain two to four
cysteine-rich repeats, some of which are required for binding to the receptor. In addition, the
cysteine-rich repeats mediate the trimerization of CD95L (Orlinick et al. 1997a, Orlinick et
al. 1997b). While some death ligands require solubilization to become activated, others are
reportedly inhibited by shedding from the plasma membrane. For example, the membrane-
bound CD95 ligand has been found to induce apoptosis, whereas the soluble CD95L
antagonizes the membrane-bound form and suppresses apoptosis in human peripheral T
lymphocytes (Suda et al. 1997). However, the mechanism for ligand activation or
inactivation by shedding has remained elusive. A soluble ligand is produced from a
membrane-bound ligand by matrix metalloproteinases (MMPs; Mitsiades et al. 2001, Ethell
et al. 2002). To transmit apoptotic signals, the ligand must at least be in a hexameric state
to bind multimerized death receptors (Holler et al. 2003). In addition, sensitivity to
programmed cell death can also be adjusted through the shedding of death receptors from
the cell surface (Tanaka et al. 1998, Ahonen et al. 2003, Strand et al. 2004). Interestingly,
many of the TNF superfamily ligands have more than one cognate receptor, and this
phenomenon has fundamental consequences: for example, the diverse functions of TNF
and the toxicity of its pharmacological derivatives are due to ubiquitous expression of the
TNF receptors.
4.4.2 The TNF receptor system in cell death and survival signaling
The TNF cytokines TNF  and TNF  (also called lymphotoxin ) transmit signals via TNFR-
1 and TNFR-2. Since TNFR-2 lacks the intracellular death domain, TNF signaling is
primarily mediated via TNFR-1 (Tartaglia et al. 1993). The TNF receptors are single
transmembrane glycoproteins, which contain four extracellular cysteine-rich domains. It is
interesting to note that these domains can be proteolytically shed, and the soluble receptor
has neutralizing potential (Wallach et al. 1991). The TNF ligand is a type 2 transmembrane
protein existing as stable trimers in a 26-kDa membrane-bound proform and a 17-kDa
soluble form cleaved by matrix metalloproteinases, such as TACE (Smith and Baglioni
1987, Tang et al. 1996, Black et al. 1997). TNF signaling is extremely versatile and may
promote either death or survival, depending on the context.
Ligation of TNF  to the TNFR-1 may initiate a number of signaling pathways through
different TNFR complexes. The TNFR complexes located at the plasma membrane form
around the adaptor protein TRADD (TNFR-associated death domain) in a fashion
analogous to the CD95 or TRAIL DISCs. The death domains of TRADD mediate
interactions between the intracellular parts of TNFR-1. TRADD recruits another adaptor
protein, TNF receptor-associated factor 2 (TRAF2), and a serine/threonine kinase, receptor-
interacting protein (RIP) to TNFR complex 1 at the plasma membrane (Figure 10). Complex
1 activates the canonical NF- B pathway by activating the I B kinase (IKK) complex, which
then phosphorylates I B, the inhibitor of NF- B. Phosphorylation primes I B for
ubiquitylation and proteasomal degradation by recruiting the E3 ligase SCFβ-TrCP (Yaron et
al. 1998, reviewed by Karin and Ben-Neriah 2000). Degradation of I B leads to the
exposure of the nuclear localization signal of NF- B, allowing it to translocate to the nucleus
and act as a transcription factor.
While the formation of TNFR complex 1 relies on TRADD and RIP, TRADD can also
mediate the formation of a FADD-dependent complex 2, which is cytosolic and signals cell
death instead of survival. FADD is recruited to TNFR complex 2 by TRADD or ubiquitylated
RIP1, after which FADD binds caspase-8 molecules to initiate apoptosis (Micheau and
Tschopp 2003, Wang et al. 2008, reviewed by Wilson et al. 2009). Caspase activity in
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complex 2 is regulated by c-FLIPs, c-IAPs, and the deubiquitylating enzyme CYLD (Figure
10; Micheau and Tschopp 2003, Wang et al. 2008).
Ubiquitin-mediated modifications have important regulatory roles in death receptor
signaling, in particular in defining the outcomes of TNF receptor stimulation. TRAF2 is an
adaptor protein that is recruited to the TNF complex 1 at the plasma membrane. TRAF2 is
also a RING-finger ubiquitin E3 ligase, and it attracts yet more ligases, c-IAPs, to the same
complex. The interaction between c-IAPs and TRAF2 is primarily mediated through the c-
IAP BIR domain (Samuel et al. 2006), and it conveys c-IAP-mediated modification of RIP
with K63-linked ubiquitin chains. The K63-linked ubiquitin chains of RIP serve as a binding
platform for the IKK and TAK kinase complexes (Ea et al. 2006), and thereafter TAK
phosphorylates and activates IKK  of the IKK complex (Figure 10). After IKK-
phosphorylated IkB is recognized and tagged with K48-linked ubiquitin chains by SCFβ-TrCP,
NF- B is free to translocate to the nucleus to drive the transcription of its target genes.
After forming at the plasma membrane, complex 1 is released to the cytosol, where the
assembly of complex 2 begins. In the absence of the c-IAPs, RIP remains unubiquitylated
and is free to recruit procaspase-8 molecules. The induced proximity of procaspase-8
proteins promotes their dimerization and activation, initiating apoptosis. Apoptosis is further
promoted by A20, an enzyme harboring both ubiquitin ligase and deubiquitylating enzyme-
like activities. A20 has been reported to deubiquitylate RIP, thereby contributing to
apoptosis (Wertz et al. 2004). Another deubiquitylating enzyme, CYLD, has been
demonstrated to regulate TNF responses by a similar mechanism (Wang et al. 2008). In the
non-canonical NF- B pathway, the c-IAPs have an unexpected negative role in
ubiquitylating the NF- B-inducing kinase (NIK), facilitating its proteasomal degradation.
The IKK complex has been shown to be regulated by ubiquitylation in numerous ways
(Figure 10). In addition to phosphorylation, IKK is activated by TRAF6-mediated
polyubiquitylation (Sun et al. 2004). Furthermore, the polyubiquitylation of NEMO has been
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was recently found to be catalyzed by linear ubiquitin chain assembly complex (LUBAC;
Tokunaga et al. 2009). However, it has also been reported that NEMO contains an ubiquitin
binding in ABIN and NEMO (UBAN) motif, an interaction surface that mediates non-
covalent ubiquitin binding, and that NEMO specifically recognizes linear diubiquitin (Rahighi
et al. 2009). Previous reports, however, demonstrated that NEMO binds K63-linked
ubiquitin chains (Wu et al. 2006).
In addition to ubiquitin signaling, phosphorylation has been shown to regulate TNF
responses. However, no clear physiological function has been demonstrated. For instance,
TNFR-1 is phosphorylated by MAPK on several residues, and the phosphorylation alters its
subcellular localization, yet there are no documented effects on receptor function by
phosphorylation during apoptosis (Cottin et al. 1999). The TNFR-1 receptor itself is
phosphorylated primarily on T236 and S244, and secondarily to S240 and S244, by
mitogen-activated protein kinase/extracellular-signal-regulated kinase 2 (MAPK/Erk2; Van
Linden et al. 2000). Phosphorylation induces the relocalization of TNFR-1 from the Golgi to
tubular ER structures to recruit Bcl-2 (Cottin et al. 1999, Cottin et al. 2001). TRADD, the
adaptor protein of the TNFR-based signaling complexes, becomes phosphorylated upon
the dissociation of the TNFR complex 1 from the receptor (Jiang et al. 1999). However, the
exact functions of this modification are also currently unknown. Finally, recent studies
suggest that programmed necrosis induced by TNFα depends on RIP3-mediated
phosphorylation of RIP, and that this pathway is operates during viral inflammation and
exposure to reactive oxygen species (Cho et al. 2009, He et al. 2009, Zhang et al. 2009). In
summary, post-translational modifications are essential regulators of the known TNF
pathways.
4.4.3 The CD95 and TRAIL receptor systems
CD95 is perhaps the best characterized of the TNF death receptor systems. The CD95
receptor (also known as Fas or APO-1) was originally discovered as the target of two
mouse antibodies capable of inducing apoptosis in tumor cell lines and in xenotransplants
planted in immunodeficient mice (Itoh et al. 1991, Oehm et al. 1992). Later, CD95L was
cloned and identified based on its sequence homology to TNF (Suda et al. 1993). CD95 is
expressed on the surface of a wide range of cell types, but it is especially pronounced in
thymocytes and activated T cells, as well as in the heart, kidney and liver. However, the
expression of CD95L is restricted to cells in immune privileged sites, and to cytotoxic T cells
and natural killer cells which utilize CD95L to efficiently kill target cells (Suda et al. 1993).
The CD95 machinery is a central regulator of the immune system. The physiological roles
of CD95 and CD95L were discovered in spontaneous mutant mouse strains, lpr and gld,
which developed systemic lupus erythematosus (SLE) and lymphoadenopathy due to
mutations in CD95 or CD95L, respectively (Watanabe-Fukunaga et al. 1992, Takahashi et
al. 1994). In addition, mice completely deficient in CD95 or CD95L exhibit lymphocyte
hyperproliferation, and substantial liver hyperplasia (Adachi et al. 1995). Moreover,
lymphoadenopathy and splenomegaly are more pronounced and develop faster in CD95-/-
mice compared to lpr mice, demonstrating the severity of the knock-out phenotype (Adachi
et al. 1996). Correspondingly, complete loss of CD95L results in early death of the animal,
alongside with a more severe phenotype of general lymphoproliferative disease than in the
gld mice (Karray et al. 2004). The role of CD95 in maintaining homeostasis in the immune
system was further demonstrated by the discovery of hereditary heterozygous mutations in
the CD95 gene in a portion of autoimmune lympho-proliferative syndrome (ALPS) patients
(Fisher et al. 1995, reviewed by Rieux-Laucat et al. 1995). Moreover, the CD95 and CD95L-
deficient mice and ALPS patients have an increased risk for developing lymphoma,
whereas excessive CD95 activity may lead to serious immunopathological conditions, such
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as hepatitis (Ogasawara et al. 1993, Straus et al. 2001). Together, these reports highlight
the importance of CD95 in preserving homeostasis in the immune system.
TNF-related apoptosis inducing ligand (TRAIL), the physiological ligand for the TRAIL
receptors, was identified through its homology to other TNF family members (Wiley et al.
1995, Marsters et al. 1996). TRAIL is a type 2 transmembrane protein that can be
proteolytically shed from the membrane to produce a soluble ligand. There are five TRAIL
receptors, TRAILR-1-5, of which TRAILR-1 and TRAILR-2 (also called DR4 and DR5) are
bona fide death receptors, whereas TRAIL receptors 3-5 are antagonistic decoy receptors.
The expression of TRAIL receptor genes is regulated by p53 (reviewed by Kontny and
Kovar 2005) and NF- B (for example Ravi et al. 2001). The biological relevance of the
TRAIL system has been studied by genetic depletion of genes encoding TRAIL receptors or
ligand. In contrast to humans, mice only express one TRAIL receptor, which closely
resembles human TRAILR-1 and -2 (Wu et al. 1999). The generation of TRAILR knockout
mice showed that TRAIL receptor is not essential for embryonic development, but instead
plays a role in innate immunity. Although the TRAILR-/- mice develop normal lymphocyte
populations, they exhibit elevated levels of several cytokines and enhanced responses to
the murine cytomegalovirus (Diehl et al. 2004). Late phase Toll-like receptor (TLR) signaling
is also abnormal in the TRAILR-/- mice. In addition, the DNA damage response of the
TRAILR-deficient mice appears to be compromised, as their spleen, thymus and brain
tissues fail to undergo normal apoptosis after radiation (Finnberg et al. 2005).
Although the knockout phenotypes of CD95 and TRAIL ligands and receptors are dissimilar,
it is interesting to speculate that they result form distinct expression patterns rather than
distinct downstream signaling mechanisms. The differences in the way the CD95 and
TRAIL systems operate, however, has had profound implications on therapeutic
approaches. When the tumor toxicity of CD95 was discovered, anti-CD95 antibodies were
seen as future drugs for cancer. However, early studies demonstrated that systemic
administration of anti-CD95 antibodies in vivo was severely hepatotoxic (Ogasawara et al.
1993). In contrast to CD95, TRAIL has turned out to be non-toxic to normal tissues in
animal models (Ashkenazi 2008, Ashkenazi and Herbst 2008), and it is also effective in
inducing apoptosis in solid tumor cell lines (Ashkenazi et al. 1999, Walczak et al. 1999).
Monoclonal antibodies against TRAIL and TRAIL receptors are in clinical trials for treating
different types of cancer either alone or in combinations with traditional cancer therapies
(reviewed by Melnikova and Golden 2004).
The TRAIL and CD95 receptor systems also transmit similar signals downstream from the
receptor. The ligation of the CD95 or TRAIL receptor initiates the formation of the DISC. For
the CD95 DISC assembly, a minimum of six oligomerized receptors is required (Holler et al.
2003). In addition, the preassociation of the receptors is essential for efficient signaling
(Siegel et al. 2000a). The crystal structure of TRAIL bound to TRAILR-2 illustrated that the
principle mechanisms of ligand and receptor binding are similar to the CD95 systems
(Hymowitz et al. 1999). The cytoplasmic parts of individual CD95 receptors adapt a stable,
closed conformation, which does not reveal the DDs or favor interaction (Scott et al. 2009).
However, when ligands bind to the receptors, causing their oligomerization at the plasma
membrane, the cytoplasmic parts of the receptors are reorganized into an extended
conformation which is stabilized by interactions between the DDs. The extension of the
cytoplasmic stem helices enables FADD to bind to the receptors. Both CD95 and TRAIL
DISCs are formed around the adaptor protein FADD. FADD contains a death domain and a
death effector domain, enabling homophilic interactions with the death receptor and the
recruiting of additional DED-containing proteins to the DISC. These proteins include
caspase-8 and caspase-10, as well as the caspase inhibitor c-FLIP. Depending on the
strength of the death signal and the vicinity of DED-containing proteins, DISC formation
results in substantial or little caspase-8 activity, leading either to apoptosis or alternative
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signaling pathways (Figure 11). For instance, c-FLIP isoforms differentially transmit signals
that preferably activate either the Erk or the NF- B pathway (Kataoka et al. 2000).
Post-translational modifications affect death receptor signaling on several levels. Membrane
trafficking can be adjusted to augment the activation of DISC. When the intracellular domain
of CD95 is palmitoylated, it is translocated to the plasma membrane lipid rafts to favor
receptor clustering and activation thereafter (Feig et al. 2007). O-glycosylation of TRAILR-1
and TRAILR-2 extracellular domains has been found to promote ligand binding-induced
receptor clustering (Wagner et al. 2007). In contrast, proteolytic processing has profound
implications on death receptors. For instance, the cleavage of CD95L between S126 and
L127 by matrix metalloproteinases results in loss of cytotoxicity and pro-apoptotic potential
(Schneider et al. 1998). The adaptor protein FADD, in turn, has been found to be
phosphorylated on S194 by casein kinase 1  (CKI ; Scaffidi et al. 2000, Appalat et al.
2005). However, this modification seems to be irrelevant to apoptotic signaling, because
S194 phosphorylation affects the subcellular localization of FADD and apparently regulates
its non-apoptotic functions of FADD during mitosis (Appalat et al. 2005).
Figure 11. Examples of how the composition of the DISC dictates the outcome of
death receptor stimulation. After CD95L binds to the CD95, the recruitment of FADD
and procaspases-8 molecules results in caspase cascade and apoptosis. Some
reports suggest that also caspase-2 can be recruited to the DISC via RAIDD to
initiate apoptosis. In addition, death receptor stimulation may lead to stress or
survival signaling. The short and long c-FLIP isoforms are differential regulators of
DISC signaling. Adapted from Curtin and Cotter (2003).
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4.4.4 Activation and biological roles of caspase-8 and caspase-10
Initiator caspases -8 and -10 are structurally similar, both containing two death effector
domains and a caspase domain. Caspase-8 and -10 have evolved by genetic duplication,
located at 2q33-q34, and they are both expressed in various products of alternative splicing
(Rasper et al. 1998, Hadano et al. 2001). Caspase-8a/b of 55 and 53 kDa are widely
expressed and well characterized. Another caspase-8 isoform, caspase-8L, has been
cloned and proposed to have an anti-apoptotic function (Himeji et al. 2002). Caspase-10 is
known to act similarly to caspase-8 during receptor-mediated apoptosis, but it is yet unclear
whether caspase-8 and caspase-10 are functionally redundant. For example, caspase-10
appears not to be expressed in mice or lower organisms (Reed et al. 2003). Caspase-10a/d
splice variants are the large isoforms of 55 and 59 kDa, respectively. Interestingly, the short
caspase-10 isoform, caspase-10g, was found to inhibit receptor-mediated apoptosis and
activate NF- B, thereby operating in a dominant negative manner against the long caspase-
10 isoforms (Wang et al. 2007).
The unprocessed initiator procaspases possess little, if any, catalytic activity. However,
when a large number of initiator procaspases is brought together, the high concentration
promotes homophilic interactions between inactive precursors, producing active caspase
dimers. Initiator caspase activation is a result of limited proteolysis. During this process, the
N-terminal activation domains are removed, and the proteolytic domain is cleaved to
produce a fully mature caspase. This proximity-induced dimerization model for caspase
activation was recently refined from the preceding induced proximity model (Boatright et al.
2003, reviewed by Riedl and Shi 2004). According to current understanding, the enhanced
proximity of procaspases alone is enough to induce dimerization, which in turn suffices for
enzymatic activity, contradicting the previous model according to which proteolytic cleavage
precedes full initiator caspase activation.
To facilitate close proximity, dimerization and activation, initiator caspases are recruited to
protein complexes whose formation depends on specific stimuli. Caspases -8 and -10 of the
extrinsic apoptotic pathway are activated following death receptor activation in the DISC. An
inactive initiator caspase-8 is a monomer, but upon death ligand ligation several caspase-8
monomers bind to the DISC via FADD and gather many low-activity enzymes to a close
proximity to enable dimerization. The N-terminal DEDs allow for homophilic interactions
among the procaspase-8 molecules, which is enough to produce an active enzyme
(Boatright et al. 2003). Dimerization is followed by two-step proteolytic processing. The first
cleavage of caspase-8 at D374 produces the p43/41 and p12 fragments, whereas the p18
and p10 subunits of the mature caspase-8 are formed upon the second cleavage at D216
and D384 (Chen et al. 2002). These proteolytic events have been thought to stabilize the
active conformation of the enzyme (Boatright et al. 2003), but new structural studies have
shown that complete processing is needed for caspase-8 to be fully active (Keller et al.
2009). After the proteolytic shedding of the N-terminal DEDs, a mature caspase-8 enzyme
is released from the membrane into the cytosol. Recently, caspase-8 was appointed a new
cleavage site at D210, which produces a cleavage fragment p30, an intermediate that is
thought to amplify procaspase-8 activation (Hoffmann et al. 2009).
The functional differences between caspase-8 and -10 are still poorly understood. Despite
high degree of homology, they do not seem to interact to generate caspase activity (Chen
et al. 2002). However, caspase-8 and -10 coimmunoprecipitate with each other and seem
to have some redundant functions due to partly overlapping substrate specificities (Fischer
et al. 2006). However, caspase-10 has proven unable to entirely substitute for caspase-8
(Sprick et al. 2002).
Although the studies on caspase-8 have focused on death receptor signaling, it is becoming
increasingly clear that caspase-8 is involved in a variety of non-apoptotic processes.
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Targeted caspase-8 gene deletion has shed light on its role in development, differentiation
and migration. Whereas mice deficient in death receptors are viable, deficiency in caspase-
8, FADD or c-FLIP results in embryonic lethality (Varfolomeev et al. 1998, Yeh et al. 1998a,
Yeh et al. 2000). Interestingly, the caspase-8 knock-out phenotype is strikingly similar to c-
FLIP and FADD knock-out animals. Major developmental defects occur by day E11.5 of
gestation, and the fetus displays impaired heart and neural tube development, hyperemia
and liver erythrocytosis (Varfolomeev et al. 1998). These effects are probably due to
abnormalities in the yolk sack of the caspase-8 null mouse (Varfolomeev et al. 1998,
Sakamaki et al. 2002, Kang et al. 2004).
Caspase-8 also plays a major role in the immune system, and in humans caspase-8
deficiency leads to immune system defects. A homozygous R248W mutation in the
caspase-8 gene, as well as mutations in CD95, CD95L and caspase-10 genes, have been
linked to autoimmune lymphoproliferative syndrome-like symptoms, such as
lymphoadenopathy, splenomegaly and autoimmunity (reviewed by Rieux-Laucat 2006).
These symptoms are a consequence of defective apoptosis during negative selection of
autoreactive CD4+/CD8+ T cells. Cleavage of caspase-8 has been reported to occur rapidly
upon CD3/CD28-induced proliferation of T cells, although no apoptosis takes place (Alam et
al. 1999, Kennedy et al. 1999), and caspase-8 deficient cells even fail to proliferate upon T
cell receptor stimulation (Salmena et al. 2003). These data indicate that caspase-8 has a
pivotal role in the proliferation of human T cells. Caspase-8 is also involved in modulating
innate immunity, as it is found to bind to receptor signaling complexes initiated by the
recognition of specific microbial components by the Toll-like receptors (TLRs; Su et al.
2005). In addition, caspase-8 deficiency has been shown to abolish NF- B signaling in
response to antigen receptor and Fc receptor activation in T, B and natural killer cells,
supporting a major role for caspase-8 in immune regulation (Su et al. 2005). Some reports
show a role for caspase-8 in NF- B signaling in B cells, but conclude that caspase-8 is
dispensible for B cell proliferation (Imtiyaz et al. 2006, Lemmers et al. 2007).
Substantial body of evidence suggests that the activity of caspases is modified by post-
translational modifications, especially ubiquitylation. In Drosophila, both the initiator
caspase Dronc and the effector caspase drICE are ubiquitylated by DIAP1 (Wilson et al.
2002, Ditzel et al. 2008). As drICE is sterically inhibited by DIAP1-mediated
polyubiquitylation by K63-linked chains (Ditzel et al. 2008), and polyubiquitylation of Dronc
by DIAP1 suppresses Dronc-mediated cell death, it seems evident that ubiquitylation of
caspases generally inhibits their functions. However, the aggregation and subsequent
activation of the mammalian caspase-8 was recently reported to be regulated in a positive
manner by Cullin3-catalyzed polyubiquitylation upon TRAIL receptor stimulation (Jin et al.
2009). According to Jin and coworkers, polyubiquitylation on K461 enhances caspase-8
aggregation by enabling the sequestration of ubiquitylated caspase-8 on specific regions on
the plasma membrane by the ubiquitin-binding protein p62/sequestosome-1. It is
conceivable that ubiquitylation that occurs in different cellular compartments, under
dissimilar physiological conditions, or is catalyzed by various E3 ligases on different target
lysines, may have different implications on the function of the caspase. Future studies will
show whether the current reports can be reconciled.
4.5 Regulation of death receptor signaling by c-FLIP
The FLICE-inhibitory proteins (FLIPs) are homologues of caspase-8 and -10 that
fundamentally influence the outcome of DISC signaling. The FLIPs were originally cloned
from viruses amidst a quest for new DED-containing proteins. The first discovered FLIP was
bovine herpesvirus v-FLIP (Thome et al. 1997), and more viral FLIPs exist in the family of
the  herpes viruses (equine herpesvirus-2 v-FLIP E8, herpesvirus saimiri v-FLIP ORF71,
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human herpesvirus-8 v-FLIP K13), as well as the human molluscipox viruses (v-FLIPS
MC159 and MC160). The viral FLIPs are quite variable in their amino acid sequence, but
also v-FLIPs inhibit caspase-8 activation in order to promote the transformation and survival
of virally infected cells (Thome et al. 1997).
Shortly after the identification of the viral FLIP proteins, several groups independently
cloned cellular FLIPs. For this reason, the cellular FLICE-inhibitory protein (c-FLIP; Irmler et
al. 1997), is also called caspase homolog (CASH; Goltsev et al 1997), inhibitor of FLICE (I-
FLICE; Hu et al. 1997), FADD-like anti-apoptotic molecule (FLAME-I; Srinivasula et al.
1997), caspase-like apoptosis-regulatory protein (CLARP; Inohara et al. 1997), MACH-
related inducer of toxicity (MRIT; Han et al. 1997), caspase-eight-related protein (Casper;
Shu et al. 1997) and usurpin (Rasper et al. 1998). The c-FLIP gene is located at 2q33-34
close to the caspase-8 and -10 genes, indicating that these homologues have arisen by
gene duplication (Rasper et al. 1998, Hadano et al. 2001). Although 14 c-FLIP splice
variants have been detected at the mRNA level, only two were originally identified at the
protein level.  c-FLIP short (c-FLIPS) is a small, 26 kDa protein, whereas c-FLIP long (c-
FLIPL) is large, 55 kDa (Irmler et al. 1997, Shu et al. 1997). Another short isoform was later
identified from Raji cells and hence named c-FLIPR (Djerbi et al. 2001, Golks et al. 2005). A
recent study indicates that c-FLIPR is, in fact, of more ancient evolutionary origin than c-
FLIPS, as it is present in a wider array of organisms. However, c-FLIP proteins appear not
to be present in non-mammalian eukaryotes. The production of the short isoforms is
determined by a single nucleotide polymorphism in a 3’ splicing site in the CFLAR gene
(Ueffing et al. 2009).
All c-FLIP isoforms are identical in their 202 N-terminal amino acids (Figure 12). These
residues include two death effector domains that mediate binding to the DISC and
dimerization with caspase-8 (Irmler et al. 1997). In contrast, the remaining C termini are
entirely different in all isoforms. The short isoforms have unique splicing tails of 11 and 19
amino acids. c-FLIPL, in turn, contains a C-terminal caspase-like domain which lacks the
active cysteine residue and hence the caspase-like catalytic activity. These structural
differences provide basis for differential regulation and function of the c-FLIP isoforms.
Upon the cloning of c-FLIP, its biological functions were somewhat controversial. Some
initial findings described c-FLIP as an inhibitor of apoptosis, whereas others stated it had a
pro-apoptotic role. It was then noted that high levels of overexpressed c-FLIPL, as well as
Figure 12. The FLIP proteins and caspase-8
share similar structural features. First, all FLIPs
contain two conserved death effector domains. In
addition, c-FLIPL contains a non-functional
caspase-like domain (* denotes the active
cysteine of caspase-8). The short c-FLIP proteins,
c-FLIPS and c-FLIPR, only have short splicing tails
or 19 and 11 amino acids, respectively. C-
terminal structures of the viral FLIP proteins differ
in length and sequence.
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any other DED-containing protein, form toxic aggregates that activate caspase-8. The anti-
apoptotic role of c-FLIP was established by the observation that the embryonic fibroblasts
derived from c-FLIP deficient mice are highly sensitive to TNF - and CD95-mediated
apoptosis (Yeh et al. 2000). The generation of a knock-out animal also provided data on the
physiological roles of c-FLIP. The phenotype of the knock-out animals was strikingly similar
to those of the CASP8-/- and FADD-/- mice. The c-FLIP-deficient animals died at day E10.5
because of impaired heart development and cardiac failure (Varfolomeev et al. 1998a, Yeh
et al. 2000). Interestingly, recent reports have addressed the role caspase-8 in
development. This raises the possibility that also c-FLIP may regulate these less well
characterized functions of caspase-8, and that some features of the CFLAR-/- phenotype
can be derived from these tasks.
4.5.1 c-FLIP is recruited to diverse signaling complexes
c-FLIP is recruited to a number of death receptor signaling complexes, where it regulates
receptor-mediated apoptosis by restraining caspase-8 (Figure 13). The c-FLIP splice
variants have been extensively studied in the CD95 and TRAIL systems, where c-FLIP
competes with procaspase-8 in DISC binding (reviewed by Krueger et al. 2001). It has been
estimated that c-FLIP binds to the DISC with affinity that is 18 times higher than that of
procaspase-8 (Chang et al. 2002), while the reported number of c-FLIP molecules in one
cell is over 100 times smaller than the number of procaspase-8 molecules (Scaffidi et al.
1999). Moreover, the interaction between c-FLIPL and caspase-8 is stronger than within the
caspase-8 homodimer (Chang et al. 2002), further underlining the capacity of c-FLIP to
modulate death receptor responses. The short and long isoforms, however, affect caspase-
8 differently. The short c-FLIP isoforms, c-FLIPS and c-FLIPR, simply block the recruitment
and the activation of caspase-8 (Krueger et al. 2001, Golks et al. 2005). The binding of
murine c-FLIPR to the DISC depends on five critical residues of the DED2 (Ueffing et al.
2008). In contrast to the short c-FLIP proteins, the outcomes of the caspase-8:c-FLIPL
interaction are more diverse. The dimerization allows the first cleavage of caspase-8 to
p43/41 and p10 fragments, and c-FLIPL itself is also cleaved once. A recent piece of work
by Yu and coworkers (2009) has provided structural insight into for the formation and
processing of the procaspases-8:c-FLIPL heterodimer. Compared to full-length c-FLIPL, p43
markedly promotes caspase-8 activation, explaining why caspase-8 is differently regulated
by c-FLIPL compared to the short c-FLIP isoforms.
When procaspase-8 has processed itself and c-FLIPL once, the larger fragments remain in
the DISC, while no active caspase-8 is formed or released to the cytosol. The remaining
heterodimer binds additional proteins and is able to transmit signals. For example, the
caspase-8:c-FLIPL heterodimer may bind TRAF2, a RING-containing E3 ligase, and
adaptor protein, and the death domain-containing kinase RIP (Kataoka and Tschopp 2004).
These recruitments have been shown to mediate the activation of the NF- B pathway. In
addition, c-FLIPS and c-FLIPL have been suggested to preferably promote NF- B and
MAPK/Erk pathways, respectively (Kataoka et al. 2000). This occurs presumably via the
dissimilar C-terminal domains, but the detailed mechanisms are not currently known. In
addition to DISC composition, the nature of death receptor signaling is governed by the
strength of receptor activation. For example, the stimulation of the CD95R at sub-lethal
levels activates the Erk pathway, but does not induce apoptosis (Lavrik et al. 2007).
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c-FLIP and caspase-8 have been found to contribute to NF- B signaling also within the
TNFR complex 2 and the T-cell receptor complex (reviewed in Budd et al. 2006). Upon the
ligation of the T-cell receptor (TCR), an intracellular CD3 complex is formed in a PKCθ-
dependent manner. Subsequently, a second complex is assembled, containing caspase-
recruitment domain membrane-associated guanylate kinase (MAGUK) protein 1
(CARMA1), B-cell lymphoma 10 (Bcl-10), and the paracaspase mucosa-associated
lymphoid tissue lymphoma-translocating gene 1 (MALT1). This Bcl complex regulates I B
degradation and NF- B localization upstream of the IKK complex. Caspase-8 and c-FLIP
are recruited to the Bcl complex via Bcl-10 and the death domain-containing MALT, and the
enzymatic activity of caspase-8 is required for the Bcl-mediated NF- B activation. In
addition, caspase-8 is also involved in NF- B signaling via the Fc receptor and Toll-like
receptor 4, but not via TNFR complex 1 or CD40 (Su et al. 2005).
Strikingly, c-FLIP has been found to promote NF- B activation in the absence of receptor
stimulation in certain tumor cell types. Golks and colleagues (2006) found that in malignant
non-apoptotic primary T and B cells and mature dendritic cells, the basal caspase-8 activity
is sufficiently high to cleave a portion of c-FLIP at D196 to form an N-terminal fragment
called c-FLIP-p22. c-FLIP-p22 was reported to directly interact with NEMO, the regulator of
the IKK complex, to induce NF- B. A recent report described the structure of KSHV-FLIP
bound to NEMO (Bagneris et al. 2008), demonstrating how c-FLIP-p22 is able to induce
NF- B through conserved interaction surfaces. Nevertheless, the characterization of p22
still warrants further studies, and its biological significance remains to be determined.
In contrast to several reports described above, some studies conclude that c-FLIPL
prevents NF- B activation. In these studies, however, NF- B activity was originated by
stimulation of CD95 and TRAIL receptors (Imamura et al. 2004, Wachter et al. 2004).
Although caspase inhibition has been shown to prevent caspase-8 and/or c-FLIP-mediated
NF- B activation (Chaudhary et al. 2000, Hu et al. 2000, Kataoka et al. 2000, Shikama et al.
Figure 13. The c-FLIP isoforms differentially regulate caspase-8 processing in the
DISC. While caspase-8 alone is autoproteolytically processed into a mature caspase-8
enzyme, no active caspase-8 is formed in a complex with c-FLIPS. Sublethal death
receptor stimulation may instead activate the NF- B pathway. In contrast to c-FLIPS,
the caspase-8-c-FLIPL heterodimer is partially processed, but does not produce mature
caspase-8. However, this heterodimer displays local enzymatic activity, which has
been reported to promote Erk signaling. Adapted from Kataoka et al. (2000).
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2003, Kreuz et al. 2004), others have also reported that caspase-8 and c-FLIP are, in fact,
dispensible for NF- B activation. This was indicated by detection of normal NF- B activity in
c-FLIP deficient T lymphocytes (Zhang and He 2005), as well as in CASP8-/- and CFLAR-/-
mouse embryonic fibroblasts (MEFs; Varfolomeev et al. 1998). These findings indicate that
the roles of caspase-8 and c-FLIP in regulating NF- B vary a lot depending on cell type and
physiological context.
4.5.2 Transcriptional regulation of c-FLIP
c-FLIP is widely expressed in mammalian tissues, especially the heart, lymphoid tissue,
skeletal muscle and kidney (Irmler et al. 1997, Rasper et al. 1998). The expression pattern
includes neurons, endothelial cells, keratinocytes, dendritic cells, macrophages,
hematopoietic cells, spermatocytes and pancreatic  cells. In most cell types, c-FLIPL is
present in higher abundace than the short c-FLIP isoforms (Irmler et al. 1997, Rasper et al.
1998).
The expression of c-FLIP is administered by several pro-survival signaling pathways. The
mitogen-activated Erk pathway positively regulates c-FLIP expression in stimulated T cells
(Yeh et al. 1998), and inhibition of Erk downregulates c-FLIP in certain cancer cell lines
(Panka et al. 2001). The growth-factor-induced PI3K/Akt pathway has been shown to
promote c-FLIP expression in several tumor cell lines, including breast, prostate and
melanoma cancer, emphasizing PI3K/Akt as a key regulator of c-FLIP transcription (Panka
et al. 2001). In addition to tumor cells, the PI3K pathway regulates death receptor sensitivity
in B cells by inducing the rapid up-regulation of c-FLIP expression in response to antigen
stimulation (Moriyama and Yonehara 2007). Moreover, endothelial cells become sensitized
to CD95-mediated apoptosis upon PI3K/Akt inhibition due to c-FLIP repression (Suhara et
al. 2001).
Interestingly, isoform-specific regulation of c-FLIP proteins has been reported to occur in
glioblastoma cells via the Akt/ mammalian target of rapamycin (mTOR) pathway (Panner et
al. 2005). In human glioblastoma multiforme cells, the level of c-FLIPS, but not c-FLIPL,
determines the sensitivity towards TRAIL. The overexpression of c-FLIP in these cells is
mediated by mTOR, and rapamycin specifically downregulates the translation of c-FLIPS.
Although c-FLIPS and c-FLIPL originate from the same transcript, they differ in their 3’
untranslated regions (Irmler et al. 1997, Ueffing et al. 2009), which may be occupied by a
range of splicing factors recruited by mTOR in c-FLIPS, but not in c-FLIPL (Panner et al.
2005). To date, little is known about the isoform-specific regulation of the stability of the c-
FLIP messenger RNA.
c-FLIP not only promotes NF- B signaling, but the CFLAR gene is also a transcriptional
target of NF- B. Kreuz and coworkers (2001) reported that several stimuli, including TNF ,
IL-1, and agonistic CD40 antibodies, induce the expression of c-FLIP. The induction of the
CFLAR gene by TNF required NF- B activity and occurred in a variety of cell lines.
Moreover, c-FLIP expression is rapidly induced via NF- B in fibrosarcoma cells and T
lymphocytes, in which c-FLIP determines the sensitivity against CD95L and TNF  (Micheau
et al. 2001). Interestingly, the kinetics of induction vary in a cell type and isoform-specific
manner (Micheau et al. 2001). Therefore, c-FLIP isoforms provide possibilities to fine-tune
cellular responses.
The nuclear factor of activated T cells (NFAT) family of transcription factors has been
shown to promote c-FLIP expression. NFATc2 is recruited directly to the CFLAR promoter
in response to VEGF, providing a mechanism for regulating endothelial apoptosis by
angiogenic factors (Volpert et al. 2002, Zaichuk et al. 2004). p53, in turn, is a tumor
suppressor that mediates apoptosis via the intrinsic pathway upon DNA damage (reviewed
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by Levine 1997). p53 regulates the expression of several key proteins that affect apoptosis,
including c-FLIP (Bartke et al. 2001). Counter-intuitively, however, p53 promotes c-FLIP
expression, shifting the focus of p53-mediated apoptosis from the extrinsic towards the
intrinsic pathway (Bartke et al. 2001). Moreover, expression of c-FLIPL has been shown to
inversely correlate with the accumulation of p53 in several ovarian carcinoma cell lines
(Mezzanzanica et al. 2004).
In addition to positive transcriptional regulators, some transcription factors act as repressors
of CFLAR. One of them, c-Myc, sensitizes a variety of tumor cells to TRAIL-mediated
apoptosis (Ricci et al. 2004). c-Myc binds directly to the promoter of CFLAR and represses
CFLAR messenger RNA levels (Ricci et al. 2004). In addition, transcription factor FOXO3
modulates endothelial cell viability by downregulating c-FLIP expression (Skurk et al. 2004).
In addition to these transcription factors, c-FLIP expression is decreased in response to
histone deacetylase (HDAC) inhibitors. HDAC inhibitor-mediated c-FLIP repression was
sufficient to sensitize CD95-resistant osteosarcoma cell lines to apoptosis (Watanabe et al.
2005). HDAC inhibitors have also been shown to increase the apoptotic sensitivity of
hepatocellular carcinoma cells, which normally are resistant towards chemotherapeutic
drugs and other apoptotic stimuli (Pathil et al. 2006, Schuchmann et al. 2006). Notably, the
mechanism for HDAC-mediated apoptosis in these cells was tumor-specific, raising the
possibility of successful treatment of hepatocellular carcinoma by HDAC inhibitors (Pathil et
al. 2006). In summary, the transcription of c-FLIP is affected by the central, well-established
signaling pathways that regulate cell survival. However, the mechanisms that regulate the
alternative splicing of CFLAR are still incompletely understood and require further efforts.
4.5.3 Post-translational regulation of c-FLIP
The c-FLIP isoforms are short-lived proteins whose activity can be regulated isoform-
specifically by post-translational modifications. The modifications most commonly
connected to c-FLIP are ubiquitylation and phosphorylation. Although c-FLIP is targeted by
several modes of post-translational regulation, the interplay between different post-
translational modifications is poorly characterized.
The proteasomal degradation of c-FLIP is determined by ubiquitylation. Initially, c-FLIP
proteins were found to accumulate in response to proteasome inhibitors such as MG132,
epoxomicin, lactacystin, and bortezomib/Velcade (Fukazawa et al. 2001, Kim et al. 2002a,
Perez and White 2003, Chanvorachote et al. 2005, Zhang et al. 2005, Chang et al. 2006).
Ubiquitylation of c-FLIP has been reported to occur during adenoviral infection (Perez and
White 2003), p53 activation (Fukazawa et al. 2001), PPAR  modulators (Kim et al. 2002)
and inhibition of cyclo-oxygenase-2 (Liu et al. 2006). In contrast, S-nitrosylation on C254
and C259 was demonstrated to protect c-FLIPL from ubiquitylation (Chanvorachote et al.
2005). These data suggests that diverse stimuli can affect c-FLIP ubiquitylation. Although
some interaction partners of c-FLIP have conserved HECT or RING domains providing
them with E3 ubiquitin ligase activity, the enzymes that regulate c-FLIP ubiquitylation are
still largely unknown. The available data, however, supports the notion of isoform-specific
regulation also in this respect. Chang and coworkers (2006) demonstrated that the HECT
E3 ligase Itch specifically targets c-FLIPL for degradation in response to TNF . The stability
of the most recently identified isoform, c-FLIPR, was reported to be similar to c-FLIPS (Golks
et al. 2005). In addition, c-Cbl was recently shown to regulate the stability of the murine
short c-FLIP isoform (Kundu et al. 2009).
In addition to ubiquitylation, c-FLIP proteins are regulated by phosphorylation. Earlier
reports on c-FLIP phosphorylation indicate the involvement of several signaling pathways.
Calcium-calmodulin-dependent protein kinase II (CaMKII) has been demonstrated to
phosphorylate and stabilize c-FLIPL in the DISC, thereby providing protection against CD95
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and TRAIL-mediated apoptosis (Yang et al. 2003, Xiao et al. 2005). In contrast, others have
detected the loss of c-FLIP from the DISC in response to bile acid-induced, PKC-mediated
phosphorylation, resulting in sensitization to TRAIL-mediated apoptosis (Higuchi et al.
2003). Recently, c-FLIPL S273 was identified as a PI3K/Akt-phosphorylation site (Shi et al.
2009). The authors reported that S273 phosphorylation is induced by TNF -mediated
macrophage activation, and that phosphorylation renders c-FLIPL susceptible for
proteosomal degradation. This effect was not, however, carried out by the E3 ligase Itch.
Murine short c-FLIP isoform was recently described to be phosphorylated on S4 and Y211
by p38 and c-Abl, respectively, enabling the recognition by the E3 ligase c-Cbl and
subsequent ubiquitin-mediated proteasomal degradation (Kundu et al. 2009). Together,
these reports show that c-FLIP proteins are likely to be phosphorylated on several residues
by an array of kinases, and the consequences depend on cell type and physiological
context.
4.5.4 Dynamic regulation of c-FLIP levels affects a multitude of physiological
processes
The physiological roles of c-FLIP encompass a variety of biological processes from
development to correct function of the immune system. In addition, c-FLIP is indicated in
autoimmune diseases and cancer. In various cell types, c-FLIP expression directly
correlates with death receptor sensitivity (Irisarri et al. 2000, reviewed by Krueger et al.
2001). Importantly, the CFLAR knock-out MEFs are extremely sensitive to CD95 and TNF -
induced apoptosis (Yeh et al. 2000). In addition, genetic knock-down of c-FLIP has been
shown to increase the death receptor sensitivity of several cancer cell types, such as breast
cancer and T cell lymphoma (Fulda et al. 2000, Siegmund et al. 2002, Ricci et al. 2004,
Krueger et al. 2006, Palacios et al. 2006). The levels of c-FLIP are adjusted during
physiological processes and stresses, such as erythroid differentiation or hyperthermia
(Hietakangas et al. 2003, Tran et al. 2003).
Several studies have convincingly demonstrated the anti-apoptotic role of c-FLIP (Inohara
et al. 1997, Irmler et al 1997, Shu et al. 1997, Fulda et al. 2000, Chang et al. 2002, Kim et
al. 2002b, Davidson et al. 2003). While c-FLIPS is an unequivocal inhibitor of apoptosis (for
example Bin et al. 2002), overexpression of c-FLIPL may lead to a different outcome. For
example, Panner and colleagues were unable to detect any changes in death receptor
sensitivity after overexpressing c-FLIPL (Panner et al. 2005). High overexpression of c-FLIPL
has even led to increased apoptosis, either due to the formation of death effector filaments,
or the spontaneous dimerization of c-FLIPL with caspase-8 (Inohara et al. 1997, Irmler et al.
1997, Shu et al. 1997, Fulda et al. 2000, Chang et al. 2002). However, several tumor cell
types are resistant to death receptor-mediated apoptosis due to elevated c-FLIP
expression, strongly supporting the anti-apoptotic role of c-FLIPL. Therefore, it can be
concluded that although extremely high levels of c-FLIPL are capable of promoting caspase-
8 activation and sometimes even apoptosis, at physiological levels c-FLIPL is also an
inhibitor of apoptosis.
The ability to resist apoptosis is a classical hallmark of cancer (Hanahan and Weinberg
2000). High expression levels of c-FLIP can provide selection benefits for cancer cells. In
fact, it was discovered early on that c-FLIP is overexpressed in human metastatic
melanoma tumors (Irmler et al. 1997). It was later demonstrated that overexpression of c-
FLIP provides selection advantage to tumor cells compared to cells with lower c-FLIP levels
(Medema et al. 1999). Experiments in murine tumor models showed that the
overexpression of c-FLIP provided significant resistance towards cytotoxic T lymphocytes
and CD95-mediated apoptosis. In addition to c-FLIP, v-FLIP proteins have been shown to
promote tumorigenesis and mediate abnormal death receptor resistance (Djerbi et al.
1999). A tumor-promoting role has been described for the KSHV-FLIP, which is expressed
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by HHV-8 and associated to certain lymphomas. In accordance with cellular FLIP, the v-
FLIP protected cells from CD95-mediated apoptosis and permitted the clonal growth in the
presence of death receptor stimulation by the cytotoxic T cells (Djerbi et al. 1999). These
reports indicate that while death receptor triggering by cytotoxic T cells is indeed a crucial
method for evading tumor cells, the expression of c-FLIP provides significant protection to
tumor cells in vivo.
The dynamic regulation of c-FLIP has been described to play multiple roles in immune cells.
The physiological roles of c-FLIP have been extensively studied in T cells. c-FLIPS was
originally found to rescue primary human T cells from activation-induced cell death that
occurs in activated and re-stimulated T cells (AICD; Kirchhoff et al. 2000). Later, c-FLIPR
was reported to possess similar properties in primary human T cells (Golks et al. 2005). It
seems that the isoform-specific roles of c-FLIP are relevant in physiological settings. Since
c-FLIP is a major determinant for T lymphocyte persistence, imbalances in its regulation
lead to harmful consequences. Abnormal c-FLIP levels and functions have also been
indicated in several autoimmune diseases. The initial onset of autoimmune diseases is
incompletely understood, but it is thought to include the failure of activated T lymphocytes to
die via AICD, leading to overt production of autoantibodies by activated B cells. Decreased
sensitivity to apoptosis due to increased c-FLIP levels has been detected in patients
suffering from multiple sclerosis (MS). In healthy cells, c-FLIP levels decline towards the
end of T cell activation, which makes the cells sensitive to AICD by CD95 receptor
stimulation (Semra et al. 2001). In contrast, the T lymphocytes of an MS patient are unable
to downregulate c-FLIP, thereby promoting the survival of the activated T cells and
contributing to the clinical symptoms of MS.
In addition to regulating AICD, c-FLIP contributes to the differentiation of the naïve CD4+ T
lymphocytes to Th1 and Th2 cells. In transgenic mice overexpressing c-FLIPL,  the  Th2
differentiation is favored, and as a result, the mice are hypersensitive to allergens and
produce abnormal quantities of immunoglobulins. In addition, the mice are sensitive to
allergic airway inflammations and their T cells are abnormally resistant towards CD95-
mediated apoptosis (Tseveleki et al. 2004, Wu et al. 2004). This phenotype is probably
provoked by c-FLIPL-mediated activity of caspase-8, leading to increased apoptosis of the
sensitive Th1 cells (Wu et al. 2004). In accordance with these results, it has been shown
that c-FLIPL transgenic mice are protected from experimental autoimmune
encephalomyelitis (EAE), an autoimmune disease driven by overaccentuated Th1
responses (Tseveleki et al. 2004). The results are different, if c-FLIPL is introduced after the
EAE onset: in this case, the overexpression of c-FLIPL prolongs the inflammatory response
in the central nervous system by suppressing the death receptor sensitivity of activated T
cells (Djerbi et al 2003).
Homeostasis in lymphoid cells is governed by fluctuations in c-FLIP levels. While death
receptor sensitivity changes during T cell activation, cells respond differently to death
receptor stimulation. Various reports have described roles for caspase-8, caspase-10 and
c-FLIP in NF- B activation in response to various stimuli (Kataoka et al. 2000, Golks et al.
2005, Su et al. 2005, Wang et al. 2007). As shown by Kataoka and colleagues, activated T
cells expressing high levels of c-FLIP are protected from death signals and respond to
CD95 receptor stimulation by growing and proliferating in an NF- B and Erk/AP-1-
dependent manner (Kataoka et al. 2000). In T cells, the activation of these pathways
contributes to IL-2 production. Consistently, the primary T cells of the conditional c-FLIP
knock-out mice display decreased NF- B and Erk activity upon stimulation (Zhang and He
2005).
c-FLIP serves an important role in TCR-mediated NF- B activation. Whereas the initial
reports concluded that NF- B could be induced by the DEDs of caspase-8, caspase-10 or
c-FLIP (Shikama et al. 1998, Chaudhary et al. 2000, Hu et al. 2000, Kataoka et al. 2000),
48
Review of the Literature
49
later developments have shed some light on how the roles of different players change
according to activating stimuli and experimental set-up. Su and coworkers (2005)
demonstrated that the enzymatic activity of caspase-8 is required for TCR-induced NF- B
activity. The experiments were conducted on patient material from humans and mice with a
disorder called caspase-8 deficiency, in which mutations in the caspase-8 gene cause
defective apoptosis, and imperfect T, B, and natural killer cell activation leads to
immunodeficiency (Chun et al. 2002). Caspase-8 was found essential for NF- B signaling
through the antigen receptor, the Fc receptor and Toll-like receptors 3 and 4 (Su et al.
2005). Although the potential role of c-FLIP was not addressed, the requirement for
caspase-8 activity gives rise to two explanations: either the need for caspase-like activity
implies that c-FLIP is a negative regulator of NF- B, or then caspase-8 contributes to NF- B
by processing c-FLIP. The latter hypothesis is supported by a study conducted in c-FLIPL
transgenic mice, where CD8+ T cell activation was regulated by c-FLIPL through caspase-8-
dependent NF- B activation (Dohrman et al. 2005).
Death receptor sensitivity of the B cells is also affected by c-FLIP levels. In unstimulated B
cells the expression of c-FLIP is low, but upon CD40 or BCR stimulation, both c-FLIP
isoforms are upregulated (Hennino et al. 2000). The upregulation of c-FLIPL seems to be
stronger and more prolonged than that of c-FLIPS, and the upregulation not only protects B
cells from CD95-mediated apoptosis, but also contributes to the selection and maturation of
B cells (Wang et al. 2000). In addition, the homeostasis of macrophages and dendritic cells
are regulated by c-FLIP. During monocyte-macrophage differentiation, the levels of c-FLIP
are increased, resulting in enhanced resistance towards CD95-mediated apoptosis
(Perlman et al. 1999). A parallel phenomenon occurs upon the maturation of the dendritic
cells, which further highlights the importance of c-FLIP as as essential regulator of
homeostasis in the immune system.
4.6 PKC as a regulator of cell death
Many PKCs are known to be involved in regulating the sensitivity to apoptotic signals
(reviewed by Gutcher et al. 2003). The diverse nature of PKC signaling explains why an
individual kinase may act as a pro-apoptotic agent in one cell type, while inhibiting cell
death in another context. Among the PKC family members, the anti-apoptotic PKC  and the
pro-apoptotic PKC  have been the focus of much research, of which a summary is provided
below.
PKC  has been demonstrated to counteract apoptosis in several types of cells. Active PKC
enhances Akt activity and the subsequent, indirect upregulation of survival-related proteins.
In addition, overexpression of PKC  has been shown to account for resistance to
chemotherapeutic drugs (reviewed by Dempsey et al. 2000). PKC  is overexpressed in
gliomas, and the ectopic expression of PKC  protects glioma cell lines from TRAIL-induced
apoptosis. Conversely, silencing of the PKCE gene leads to loss of Akt expression and is
sufficient to induce apoptosis (Okhrimenko et al. 2005). The relationship between PKC  and
Akt is also evident in breast cancer cells, because PKC  cannot protect these cells from
apoptosis in the absence of Akt (Lu et al. 2006). The role of PKC  in chemoresistance has
been reported in several cell types. In non-small-cell lung carcinoma cells, the abnormally
high expression of PKC  provides protection against etoposide and doxorubicin (Ding et al.
2002). In addition, increased PKC  expression is also indicated in cisplatin-resistant ovarian
carcinoma cells (Basu and Weixel 1995). However, in contrast, PKC  has also been found
to regulate Akt in a negative manner in mouse keratinocytes, thereby sensitizing them to
UVC-induced apoptosis (Li et al. 2006).
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PKC , in turn, is considered a pro-apoptotic kinase and a negative regulator of cell growth.
Upon apoptotic stimulus, PKC  is translocated to the mitochondria, where it promotes
cytochrome c release. PKC  is also capable of inducing the autocrine secretion of death
ligands, resulting in the activation of the extrinsic apoptotic pathway (Gonzalez-Guerrico
and Kazanietz 2005). Moreover, PKC  is a substrate for caspase-3 and activated by this
proteolytic processing (Emoto et al. 1995). The cleavage of PKC  by caspase-3 is induced
by UV radiation, etoposide and cisplatin, and if PKC  is inhibited upon these treatments,
apoptosis is notably dampened (Denning et al. 1998, Reyland et al. 1999, Persaud et al.
2005). The pivotal role of PKC  in apoptosis was initially established by the observation that
the PKCD null mice are defective in mitochondria-dependent apoptosis and caspase-3
activation (Humphries et al. 2006). PKC  is most likely to act on many levels in apoptosis
regulation; PKC  is translocated to the mitochondria in response to diverse death stimuli,
and once cytochrome c is released and caspase-3 activated, proteolytic processing of
PKC  serves as a positive feedback signal (Li et al. 1999, Majumder et al. 2000, Denning et
al. 2002). In addition, PKC  decreases the activity of Akt, thereby promoting UVC-induced
apoptosis in mouse keratinocytes. Finally, the autocrine apoptotic loop, in which PKC  is
able to promote the secretion of TNF  and TRAIL, has been described in prostate cancer
cells (Gonzalez-Guerrico and Kazanietz 2005). As far as other novel PKCs are concerned,
the role of PKC  has been mainly studied in the context of T cell apoptosis and AICD. The
PKC -/- T cells are resistant to CD95L-induced apoptosis and AICD, indicating that PKC
has a pro-apoptotic role in these processes (Manicassamy and Sun 2007).
Compared to PKC  and PKC , much less is known about the role of other PKCs in
apoptotic regulation. PKC  predominantly promotes pro-survival pathways, such as Akt and
Erk signaling, by phosphorylating Raf-1 (Ueda et al. 1996, Majewski et al. 1999, Li et al.
2006). Moreover, PKC  has been demonstrated to phosphorylate and stabilize the anti-
apoptotic Bcl-2 protein (Ruvolo et al. 1998). In endometrial cancer cells treated with the
DNA-damaging agent etoposide, inhibition of PKC  results in increased apoptosis, whereas
whereas inhibition of PKC  suppresses apoptosis (Haughian et al. 2006). However,
contrasting reports suggest that PKC  may also play a pro-apoptotic role in some cell
systems, such as prostate cancer (Powell et al. 1996). In addition to PKC , another
classical isoform, PKC , has been appointed anti-apoptotic functions. Similarly to PKC ,
the PKC II splice variant has been suggested to stabilize Bcl-2 (Whitman et al. 1997), and
recent studies also indicated an essential role for PKC  in NF- B survival signaling in B
lymphocytes (Su et al. 2002). Nevertheless, PKC  was also reported to be necessary for
JNK signaling and phorbol ester-induced apoptosis in monocytes (Ito et al. 2001). These
examples depict the diversity of PKC signaling and describe how the PKC isoforms serve
differing roles according to different stimuli.
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OUTLINE OF THE STUDY
The aim of this PhD thesis was to study how death receptor signaling is affected by post-
translational modifications of the anti-apoptotic c-FLIP proteins. In particular, I focused on
phosphorylation and ubiquitylation, both of which have diverse and wide-ranging functions.
Prior to this work, some reports indicated that c-FLIP proteins are subjected to
phosphorylation and ubiquitylation. However, the underlying regulatory mechanisms and
broader biological implications were largely unknown.
When this thesis work was initiated, our laboratory had discovered that while K562
erythroleukemia cells are generally resistant to TRAIL, they become sensitized upon hemin-
induced differentiation due to downregulation of c-FLIP. Alongside with this observation, our
group had shown that heat stress reduces c-FLIP levels, thereby sensitizing cells to CD95-
mediated apoptosis. The goal of my study was to investigate how c-FLIP is regulated during
these processes, as well as to determine whether the c-FLIP isoforms differ in their
response to differentiating stimuli or heat stress. These experiments were conducted
primarily in two cell models, the human erythroleukemia K562 cells and the human
leukemic Jurkat T cells.
Furthermore, I aimed at finding and characterizing c-FLIP phosphorylation sites, as this had
not been done before. We succeeded in finding two in vivo phosphorylation sites, one of
which was present in all c-FLIP proteins and the other being c-FLIPL-specific. A biological
function and a regulatory pathway were assigned for the common phosphorylation site, and
a potential role in survival signaling is suggested for c-FLIPL-specific phosphorylation.
During the course of this work, I discovered that c-FLIP phosphorylation and ubiquitylation
are intertwined regulatory mechanisms that affect the two isoforms in distinct ways. While
both c-FLIP proteins are protected from ubiquitylation by S193 phosphorylation, these
modifications only affect the stability of the short c-FLIP isoforms. Therefore, although the
phosphorylation of c-FLIP proteins is regulated by the PKC and it has similar effects on
ubiquitylation, the biological outcomes are different, further highlighting the importance of





1 Cell culture and treatments (I-III)
Human K562 erythroleukemia cells, Jurkat T lymphocytes and WM35 melanoma cells were
cultured in a humidified 5% CO2 atmosphere at 37°C in RPMI 1640 medium supplemented
with 10% fetal calf serum (FCS), antibiotics (penicillin and streptomycin), and 2 mM L-
glutamine. For WM35 cells, the medium was supplemented with 5 µg/ml insulin. K562 cells
stably overexpressing FLAG-tagged c-FLIPS, c-FLIPR and c-FLIPL wild type isoforms (1E5
and 2E11, 3A6 and 2E10, respectively) or c-FLIP mutants (c-FLIPS S193A 2G7, S193D
2G10; c-FLIPL S193A 1G7, S193D 1F8; c-FLIPS 203-221/1-202 5F4) were maintained in
RPMI 1640 medium containing G418 (500 µg/ml, Calbiochem). Jurkat T cell pools stably
overexpressing FLAG-tagged c-FLIPS (c-FLIPS wild type and 1-202 deletion mutant) were
maintained in RPMI 1640 medium containing G418 (1.5 mg/ml, Calbiochem).
Primary human peripheral T lymphocytes were collected from several healthy volunteers by
venipuncture. The blood samples were diluted 1/2 in PBS, overlaid onto Ficoll-Paque PLUS
(Amersham Biosciences), and centrifuged at 1500 rpm for 30 min. Mononuclear cells from
the Ficoll-Paque separation were depleted by plastic adherence for 2 h. Nonadhering cells
were further separated in a nylon wool column to exclude B lymphocytes. Resting T
lymphocytes (day 0) were stimulated with 1 µg/ml phytohemagglutinin (PHA; Sigma-Aldrich)
for 22 h. After 1 day of activation, cells were washed and T lymphocyte proliferation was
supported by addition of 20 U/ml IL-2 (Sigma-Aldrich). The same dose of IL-2 was added at
day 3 of activation. Human Jurkat T lymphoma cells (American Type Culture Collection) and
primary human peripheral T lymphocytes were cultured in a humidified 5% CO2 atmosphere
at 37°C in RPMI 1640 medium supplemented with 10% FCS, 100 U/ml penicillin and 100
µg/ml streptomycin, and 2 mM L-glutamine.
Apoptosis was induced with agonistic anti-CD95 Ab CH-11 (Biosite), 200 ng/ml for 2 h in
Jurkat cells, if not otherwise indicated, and 1 g/ml for 2 or 12 h in primary human T
lymphocytes. To induce hyperthermia, heat shock treatments (HS) were performed in water
bath at 40 or 42°C for 30 min if not otherwise indicated. After exposure to hyperthermia,
cells were either harvested or returned to 37°C for recovery and/or additional treatments.
The CD95L-blocking antibody NOK-1 (BD Pharmingen) was used at 1 µg/ml for 15 min
before apoptosis induction.
The proteasome inhibitor epoxomicin (Calbiochem) was used at 200 nM for 14 h and the
protein synthesis inhibitor cycloheximide (Sigma) was used at 5-50 µMfor the indicated time
periods. For K562 cells, hemin (Sigma) was added to a final concentration of 30 or 40 µM.
For WM35 cells, cisplatin (Sigma) was added to a final concentration of 7 µg/ml. Apoptosis
was induced by adding 100 ng/ml FLAG-tagged TRAIL (Alexis) together with 2 µg/ml cross-
linking M2 anti-FLAG antibody (Sigma).
DISC formation was induced by adding 1 g of human soluble recombinant FLAG-tagged
TRAIL (Alexis, San Diego, California, USA) together with 2 g/ml crosslinking M2 anti-
FLAG antibody (Sigma) (DISC immunoprecipitation), or either human recombinant soluble
SuperKiller TRAIL (Alexis) or isoleucine zipper human recombinant TRAIL (kind gift from
Dr. Henning Walczak, Imperial College, London, UK), neither of which requires a cross-
linking enhancer, in the final concentration of 250 ng/ml for 1 h (detection of c-FLIP
phosphorylation upon death receptor activation) or 90 ng/ml for indicated time points




For detecting S193 phosphorylation, K562 and HeLa cells were treated with 20 nM phorbol
12-myristate 13-acetate (TPA; Sigma) to activate the PKCs for indicated times. To inhibit
type-1 and type-2A phosphatases, K562 and HeLa cells were treated with 20 nM calyculin
A (Sigma) for 30 min before harvesting. To specifically inhibit PKCα and PKCβ, the cells
were treated with 40 M GÖ6976 (Sigma) for 4 h. To activate the TNF receptor, murine
recombinant TNFα (R&D Systems) was added to K562 cells (10 ng/ml) for 1 h before
calyculin A treatment.
2 Plasmid constructs (I-III)
The FLAG-tagged c-FLIPL and c-FLIPS were a kind gift from Dr. Jürg Tschopp (Institute of
Biochemistry, University of Lausanne, Lausanne, Switzerland). c-FLIPS, c-FLIPR and and c-
FLIPL point mutations were made using the QuikChange site-directed mutagenesis kit
(Stratagene) and confirmed by sequencing. The FLAG-tagged c-FLIPS deletion mutant was
constructed by PCR and cloned into the EcoRI and XhoI sites in-frame with the N-terminal
FLAG tag in pCR3-Met-FLAG. FLAG-tagged c-FLIPR was constructed by PCR using FLAG-





The PCR product was subcloned into the EcoRI and XhoI sites in-frame with the N-terminal
FLAG tag in pCR3-Met-FLAG. The HA-tagged ubiquitin was a kind gift from Dr. Dirk
Bohmann (University of Rochester, Rochester, NY, USA). The GFP-tagged kinase-dead
PKCα and PKCβ constructs were kindly provided by Dr. Christer Larsson (University of
Lund, Lund, Sweden).
3 Transient transfections and generation of stable cell lines (I-III)
For transient transfections, 5x106 K562 cells were centrifuged and resuspended in 0.4 ml of
Opti-MEM, and 20 or 30 µg of plasmid DNA was added. The expression levels of the
mutants were titrated to be comparable because expression levels were noticed to affect
ubiquitylation. Cells were subjected to a single electric pulse (220 V, 975 F), in 0.4-cm gap
electroporation cuvettes (BTX) using a Bio-Rad Gene Pulser electroporator followed by
dilution to 5 x 105 cells/ml in RPMI 1640 medium with 10% FCS and antibiotics. Cells were
incubated at 37°C for 24-36 h prior to the experimental treatments.
After transfections, the stable neomycin-resistant K562 cell lines overexpressing c-FLIP
proteins were selected by G418 (500 µg/ml, Calbiochem) for 2 weeks, the resistant pool
was serially diluted on a 96-well plate in the presence of G418, and the single cell clones
were upscaled and screened for c-FLIP expression by Western blotting. The Jurkat T cell
pools stably overexpressing c-FLIP proteins were transfected with the respective constructs
and selected by G418 (1.5 mg/ml) for two weeks.
4 Ubiquitylation assay (I-III)
For immunoprecipitating ubiquitylated c-FLIP in K562 cells, the pellet from transiently
transfected K562 cells was resuspended in 75 µl of boiling 1% SDS in PBS, and the
resulting lysate was heated at 100°C for 5 min. The lysates were suspended 1:10 in 1%
Triton X-100 in PBS. DNA was sheared by sonication, and the particulate material was
centrifuged for 15 min at 15,000 x g. Samples were taken from the cleared lysates for input
control. The lysates were further diluted 1:1 with 1% Triton X-100, 0.5% bovine serum




15 µl of a 50% slurry of protein G-Sepharose under rotation for 2 h. After incubation, the
Sepharose beads were washed four times with 1% Triton X-100 in PBS, and the
immunoprecipitated proteins were separated on an 8 or 10% SDS-polyacrylamide gel and
immunoblotted with anti-FLIP antibody.
For immunoprecipitating c-FLIP in Jurkat cells, the pellet from 3 x 107 c-FLIP stably
overexpressing Jurkat cells was resuspended in 75 µl of boiling 1% SDS in PBS, and the
resulting lysate was heated at 100°C for 5 min. The lysates were then suspended in 1 ml
0.5% Triton X-100 in PBS. DNA was sheared by sonication and the particulate material was
centrifuged at 15,000 x g for 10 min. Samples were taken from the cleared lysates for input
control. The lysates were precleared for 30 min without antibody at room temperature and
then incubated with anti-FLIP antibody 1/10 (NF6 supernatant, a gift from Dr. Peter
Krammer, German Cancer Research Center, Heidelberg, Germany) and 20 µl of a 50%
slurry of protein A-Sepharose beads under rotation for 2 h at 4°C. After incubation, the
Sepharose beads were washed four times with 0.5% Triton X-100 in PBS, and the
immunoprecipitated proteins were run on SDS-PAGE, and immunoblotted with anti-ubiquitin
antibody.
5 FLAG immunoprecipitation (III)
To immunoprecipitate FLAG-tagged c-FLIP, the cell pellets were lysed on ice in co-
immunoprecipitation buffer (25 mM Hepes (pH 7.5), 150 mM sodium chloride, 5 mM EDTA,
0,5% Triton X-100, 20 mM sodium pyrophosphate, 0.5 mM PMSF, 0.1 mM  sodium
orthovanadate, 1 mM DTT, Complete Protease Inhibitor Cocktail Tablets (Roche
Diagnostics GmbH)) and 10% of the lysates were used as input samples. The cleared cell
lysate was immunoprecipitated with 15 l of M2-agarose FLAG-beads (Sigma), at 4°C on a
rotamix for 1-2 h. The beads were collected by mild centrifugation and washed five times
with TEG-buffer (20 mM Tris-HCl, pH 7.5; 1 mM EDTA; 10% glycerol; 150 mM sodium
chloride; 0.5% Triton X-100) and three times with FLAG-buffer (10 mM Tris-HCl, pH 7.5; 50
mM sodium chloride; 30 mM sodium pyrophosphate; 50 mM sodium fluoride; 5 M zinc
chloride; 10% glycerol; 0.5% Triton X-100). FLAG-tagged c-FLIP was eluted from the beads
by adding 250 g/ml of FLAG-peptide (Sigma) in FLAG-buffer and incubating in shaking
overnight at 4°C. The supernatant was collected and mixed with 3xLaemmli sample buffer,
boiled, and run on 12.5% SDS-PAGE, followed by autoradiography with an imaging plate
using Fujifilm BAS-1800 Bioimaging analyzer.
6 CD95 and TRAIL DISC analysis (I-III)
A total of 5 x 107 Jurkat cells were resuspended in 1 ml of prewarmed RPMI 1640 medium.
To ligate CD95 and induce DISC formation, 1 µg of Fc-CD95 ligand fusion protein
(CD95L:Fc), a gift from Dr. Pascal Schneider (Institute of Biochemistry, University of
Lausanne, Lausanne, Switzerland), was added to the cell suspension. The cells were
incubated at 37°C for 12 min, and the reaction was stopped by adding 10 ml of ice-cold
PBS. After washing, the cells  were lysed in  1  ml  of  lysis  buffer  (20 mM Tris-HCl (pH 7.4),
150 mM NaCl, 10% glycerol, 0.2% Nonidet P-40, and complete protease inhibitor mixture
(Roche)) for 20 min on ice. The cell debris was removed by centrifugation at 15,000 x g for
12 min at 4°C. 1 g of CD95L:Fc was added to control samples without CD95 ligation.
Samples were immunoprecipitated with 15 µl of protein G beads (Amersham Biosciences)
for 2.5 h at 4°C. The beads were washed five times with lysis buffer, resuspended in
Laemmli sample buffer, and finally boiled for 5 min. The immunoprecipitates and
corresponding cell lysates were analyzed by Western blotting. A control sample without




To stimulate TRAIL receptors, 4 x 107 K562 cells were pelleted (500 x g for 7 min) and
resuspended in 1 ml of prewarmed RPMI 1640 medium. Thereafter 1 µg of FLAG-tagged
TRAIL (Alexis) and 2 µg of anti-FLAG monoclonal M2 antibody (Sigma) were added to the
cell suspension. The cells were incubated at 37°C for 20 min, and the reaction was stopped
by adding 10 ml of ice-cold PBS. After washing, the cells were lysed in 1 ml of lysis buffer
(20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10% glycerol, 0.2% Nonidet P40, and Complete
protease inhibitor mixture (Roche Applied Science)) for 30 min on ice. The cell debris was
removed by centrifugation at 15,000 x g for 15 min at 4°C. The amount of protein was
determined by the Bradford assay, and an equal amount of protein from each sample was
precleared with 50 µl of Sepharose CL-4B for 2 h at 4 °C. A total of 2.5 µg of monoclonal
anti-DR5 and 2.5 µg of monoclonal anti-DR4 (Alexis) were added to samples and
immunoprecipitated with 15 µl of protein G beads (Amersham Biosciences) for 2.5 h at 4°C.
The beads were washed six times with 1 ml of lysis buffer, resuspended in 3x Laemmli
sample buffer, and finally boiled for 3 min. The immunoprecipitated samples and
corresponding cell lysates were analyzed by 11% SDS-PAGE and Western blotting.
7 SDS-PAGE and Western blotting (I-III)
For Western blot analysis, cells were harvested by centrifugation and washed once with
PBS. Cells were lysed either in the Laemmli SDS sample buffer or  in  lysis  buffer  (30 mM
Tris, pH 7.5, 150 mM NaCl, 1% Triton X-100, 10% glycerol, 1 mM PMSF, Complete
miniprotease inhibitor mixture (Roche Applied Science)). Triton X-100 lysis buffer lysates
were centrifuged to remove insoluble material, and the protein concentrations were
determined by Bradford assay. Each lysate containing 30-50 µg of protein was loaded and
resolved by SDS-PAGE and transferred to nitrocellulose membrane (Protran nitrocellulose,
Schleicher & Schuell) by using a semidry transfer apparatus (Bio-Rad).
Western blotting was performed using antibodies against c-FLIP (NF6 FLIP antibody, kindly
provided by Peter Krammer, German Cancer Research Center, Heidelberg, Germany; or
NF6 and Dave-2, Alexis), Hsc70 (SPA-815; StressGen), DR5 (Alexis), FADD (BD
Transduction Laboratories), GFP (JL-8), caspase-8 (C15, Alexis), CD95L (clone G247-4;
BD Pharmingen), PARP (C-2-10, Sigma), ubiquitin (FK-1; Biomol), and c-FLIP
phosphorylated on S193. HRP-conjugated secondary antibodies were purchased from
Amersham and Southern Biotechnology. The bands were visualized using the enhanced
chemiluminescence method (ECL; Amersham).
8 In vivo 32P labeling, Edman sequencing and mass spectrometry
(III)
K562 cells stably overexpressing FLAG-c-FLIPS or FLAG-c-FLIPL were grown in RPMI 1640
medium supplemented with 10% FCS, L-glutamine, and antibiotics. 2,5x106/ml cells were
preincubated in 6 ml for 2.5 h with 0.3 mCi/ml 32P-orthophosphate (ICN Pharmaceuticals) in
phosphate-free minimum essential medium Eagle (MEME; Sigma-Aldrich) supplemented
with 10% FCS. After treatment for 30 min with 50 nM of the phosphatase inhibitor calyculin
A (Sigma), the cells were collected by centrifugation, washed with ice-cold PBS and
subjected to the FLAG-immunoprecipitation. The resulting immunoprecipitates were
separated by SDS-PAGE followed by autoradiography with Fujifilm BAS-1800 Bioimaging
analyzer.
In-gel tryptic digestion of the 32P-labeled FLAG-c-FLIPS and FLAG-c-FLIPL followed by 2D
phosphopeptide mapping on a thin layer chromatography (TLC) sheet were carried out as
previously described (Kochin et al. 2006). Labeled c-FLIP bands were excised from the




(Promega) in 50 mM ammonium bicarbonate solution (pH 8). The tryptic digest was applied
on a cellulose TLC sheet (20x20 cm, Merck KgaA) and separated by 2D electrophoresis
and TLC. The first dimension, electrophoresis, was performed in a pH 1.9 buffer (formic
acid 2.3 %, acetic acid 2.9% v/v) at 750 V for 1.5 h using the Hunter Thin Layer Peptide
Mapping System, model # HTLE-7000 (C.B.S. Scientific Co.). The sheet was dried and
ascending TLC in the second dimension performed for 14 h in a chromatography tank
saturated with a mobile phase containing 30% water, 37.5% n-butanol, 7.5% acetic acid,
and 25% pyridine. The sheet was air-dried and the 32P phosphopeptides visualized by
autoradiography on a phosphorimager plate. For MALDI mass spectrometry and Edman
sequencing corresponding 32P peptides were extracted from cellulose sheets by scraping
off the powder and then eluted twice with 30% ACN, 0.1% TFA solution. The resulting
extract was vacuum-evaporated and MALDI MS and Edman sequencing were performed as
described by Kochin and coworkers (2006). For Edman degradation, phosphopeptides were
immobilized on arylamine membrane discs (Sequelon-AA membrane; Applied Biosystems)
using water-soluble carboiimide. Individual c-FLIP phosphopeptides are immobilized on the
Sequelon-AA discs via their C-terminal carboxyl groups. Therefore, the N termini of
peptides are free, and amino acids are clipped off during Edman degradation cycles. The
collected fractions were spotted on a Whatman filter paper and visualized by
autoradiography on a phosphor imager plate to reveal the cycle at which the radiolabel is
released, corresponding to the position of the phosphorylated amino acid counting from the
N terminus.
9 Preparation and use of the anti-pS193 phosphopeptide antibody
(III)
To generate an antibody that specifically recognizes phosphorylated human c-FLIP serine
193, the phosphopeptide (Ac-)CLQAAIQK(pS)LKDPSNN(-CONH2) was conjugated to
keyhole lymphet haemocyanine and 150 g of the conjugate was repeatedly injected into
rabbits (NZ white, 5 kg). The antiserum against pS193-c-FLIP was collected on day 7 after
injections and positively and consequently negatively affinity purified using (Ac-
)CLQAAIQK(pS)LKDPSNN(-CONH2) and (Ac-)CLQAAIQKSLKDPSNN(-CONH2)
conjugated to NHS-activated matrix columns (GE Bioscience), respectively. Whole-cell
extracts, as well as lysis buffer lysates, were subjected to 10% SDS-PAGE and tested for
their specificity. Immunoblotting with the anti-pS193-c-FLIP antibody was performed after
SDS-PAGE in reducing conditions and subsequent electric transfer to nitrocellulose
membranes. Membranes were briefly washed in MOPS buffer saline (MOPS 25 mM, NaCl
125 mM, pH=7.4, Tween 20 0.5%) and blocked in 5% BSA in the same buffer overnight.
After three washes, the membranes were exposed to the primary antibodies (1:500)
overnight. After antibody incubation, the membranes were washed three times, incubated
with HRP-conjugated secondary antibody (Pierce), triple washed three times again, after
which the membranes were developed with ACL chemiluminescent substrate (Amersham)
and registered on X-ray films (Fuji).
10 Caspase-3 activity assay (I, II)
After treatments, the cells were washed once with ice-cold PBS, and the caspase-3 activity
was analyzed with phycoerythrin-conjugated monoclonal active caspase-3 antibody
apoptosis kit 1 (BD Pharmingen) according to the manufacturer's protocol.
11 Caspase-8 activity assay (III)
The activity of caspase-8 in the TRAIL DISC overpopulated with wild type or mutant c-FLIP




(Promega) according to manufacturer's protocol. Luminescence was measured by Tecan
Ultra luminometer at MediCity Turku.
12 Detection of apoptosis (II)
Apoptosis in Jurkat cells and primary peripheral blood T lymphocytes was detected by
annexin V analysis. Cells were incubated for 10 min on ice with 4 µl/ml human recombinant
FITC-conjugated annexin V (Sigma-Aldrich) in annexin V binding buffer (2.5 mM HEPES
(pH 7.4), 35 mM NaCl, and 0.6 mM CaCl2) and analyzed on a FACScan flow cytometer (BD
Biosciences).
13 Surface expression analysis of CD95 (II)
Cells were washed twice with PBS and blocked for 30 min with 1% BSA in PBS. Cells were
then incubated with CH-11 anti-CD95 antibody (Biosite), 1/500 in 1% BSA in PBS for 30 min
followed by washing with PBS. Finally, cells were incubated with Alexa 488-conjugated goat
anti-mouse IgG (Molecular Probes) for 30 min. After washes, cells were analyzed by flow
cytometry on a FACScan flow cytometer (BD Biosciences). Samples without primary
antibody were used as negative controls (second antibody control).
14 RNase protection assay (II)
Hyperthermia was induced in Jurkat cells at 42°C for indicated times and RNA was
prepared with the Qiagen kit for RNA isolation according to the manufacturer’s protocol. The
RNase protection assay was done with the RiboQuant MultiProbe RNase Protection Assay
System (BD Pharmingen) according to the manufacturer’s standard RPA protocol using the
hApo-3b probe (cat. no. 45611P). The results were visualized by autoradiography using
BAS Imaging Plates (Fuji Film) and a BAS-1800 Imaging Plate Reader (Fuji Film).
15 Metabolic labeling by 35S (III)
1-5x106 K562 cells stably overexpressing c-FLIP were washed once with methionine and
cysteine-free RPMI 1640 supplemented with 10% dialysed FCS, antibiotics, and L-
glutamine, and pulse labeled at 37°C for 3 h with 200 Ci (0.1mCi/ml) 35S-methionine and
cysteine (MP Biomedicals, Irvine, California, USA). The labeled cells were washed with
supplemented RPMI 1640 containing unlabeled methionine and cysteine 100 times in
excess (Sigma). The cells were chased for indicated times, washed with PBS and treated
according to the FLAG-immunoprecipitation protocol. The relative amounts of 35S-labeled c-
FLIP were quantified by phosphorimager analyses, statistical significance of the differences
between wild type and mutant c-FLIPS from three independent experiments were
statistically analyzed.
16 Quantification, densitometry and statistical analysis of c-FLIP
half-lives and caspase-8 activation (I-III)
The relative amounts of c-FLIP in the K562 CHX chases were analyzed by densitometry
(ScionImage GlePlot 2 and Adobe Photoshop) and normalized against the Hsc70 loading
control. The amounts of 35S-labeled c-FLIP were quantified by phosphorimager analysis.
The relative half-lives and the relative caspase-8 activation were illustrated using GraphPad
Prism and statistical significance analyzed by Student’s unpaired t test (n=3, *P=0.05,
**P=0.005). The graphs show mean values and the standard errors of mean (n=3).




(ScionImage GelPlot 2 and GraphPad Prism software. Student’s unpaired t tests were
performed on data from different individuals, i.e., primary T lymphocytes, whereas paired t
tests were performed on data from Jurkat cells and Jurkat-based cell lines. Statistical
significance is marked with asterisks (*P =0.05, **P=0.005, and ***P=0.001) and ns (P>0.05)
stands for not statistically significant. The bar graphs represent mean values and standard
deviation (n 2). Caspase-8 activity induced in the K562 cells was given the value 1, and the
activity readings from c-FLIP overexpressing cell lines were related against this value.
Relative caspase-8 activation in different cell lines was illustrated using GraphPad Prism
(version 5). The graphs show mean values and the standard errors of mean (n 2).
17 Molecular modeling of c-FLIPS (I)
All models were built using the Modeler computer program. The sequence of c-FLIPS
contains two conservative DEDs between S2 (numbering according to Irmler et al. 1997)
and V79 and between Y93 and Q176. A model structure for the second DED in c-FLIPS
(DED2) was built by using the NMR structural data for phosphoprotein enriched in
astrocytes, 15 kDa (PEA-15; pdb code 1n3k) and the NMR structure of the FADD death
effector domain (F25Y mutant; pdb code1a1w). The secondary structure of the c-FLIPS C-
terminal segment (amino acids 176-221) was predicted using the following computer
programs: PHD: Profile network prediction HeiDelberg (Rost and Sander 1993a, Rost and
Sander 1993b, Rost and Sander 1994), SAM-T99 Secondary Structure Prediction (Karplus
et al. 1997), SCRATCH (Sspro) (Pollastri et al. 2002), PROF-Secondary Structure
Prediction System (Ouali and King 2000), and nnpredict (Kneller et al. 1990). The loop
between the DED2 and the c-FLIPS C-terminal segment has been taken as seen in the
structure of PEA-15, the only currently known representative structure covering this region
(Hill et al. 2002). Surface construction and lipophilic potential calculations were done using
SYBYL (Tripos Inc.). Figure 8 (I) was produced with MolScript v2.1 (Kraulis 1991) and





1 Increased death receptor sensitivity during differentiation and
hyperthermia is due to c-FLIP downregulation (I, II)
1.1 Death receptor sensitivity is adjusted by c-FLIP downregulation during
differentiation and hyperthermia (I, II)
Death receptor sensitivity is dynamically regulated in response to environmental stimuli, and
it may also change during differentiation. The human K562 cell line originates from a patient
suffering from chronic myelogenous leukemia (CML). The CML cells express the Bcr-Abl
fusion protein as a result of a mutation called the Philadelphia translocation (t9:22) (Lozzio
and Lozzio 1975), producing a constitutively active tyrosine kinase that prolongs cell
survival independently of growth factor signaling (Bedi et al. 1994). Hence, K562 cells are
abnormally resistant to programmed cell death induced by a variety of stimuli (McGahon et
al. 1994). The K562 cell line is a valuable research model because of its differentiating
capacity. K562 cells are progenitors, and their non-terminal differentiation towards the
erythroid-like lineage can be induced by hemin, the ferric chloride salt of heme (Andersson
et al. 1979). In addition, the K562 cells can be stimulated to differentiate towards the
megakaryocytic lineage by TPA (Tetteroo et al. 1984). In some cell types, including the
K562 cells, differentiation causes changes in the sensitivity towards apoptotic stimuli.
Earlier work from our group has shown that the induction of erythroid differentiation results
in increased sensitivity to TRAIL in K562 cells (Hietakangas et al. 2003). Interestingly, the
sensitization correlated with hemin-induced downregulation of c-FLIP. From this starting
point, we aimed at determining how c-FLIP levels are decreased during K562 erythroid
differentiation (I).
The ability to adjust death receptor sensitivity in response to environmental cues is a
valuable asset to the cell and the organism. In addition to the K562 cells, also HEL and HL-
60 cells were sensitized to TRAIL upon differentiation (Hietakangas et al. 2003). Therefore,
differentiation-induced sensitivity is not a cell type-specific phenomenon. During
differentiation of the primary erythroblasts, the expression of death receptors is dynamically
regulated, but the expression of CD95L and TRAIL is restricted to mature erythroblasts (De
Maria et al. 1999). This allows receptor-mediated apoptosis of immature erythroblasts to
occur in locations where additional mature erythroblasts are not needed. c-FLIP has been
demonstrated to regulate death receptor sensitivity also in other cell types. For example,
the human CD34+ hematopoietic progenitor cells are protected from CD95-mediated
apoptosis due to high expression levels of c-FLIP (Kim et al. 2002), but erythroid
differentiation in response to Epo and kit ligand induces c-FLIP downregulation and
sensitization to TNF  (Ratajczak et al. 2003).
In addition to differentiation, also cellular stresses, such as hyperthermia, have been shown
to modulate death receptor sensitivity (reviewed by Nadeau and Landry 2007). Heat stress
affects apoptotic sensitivity, but its impact largely depends on the cell type. Although heat
shock protein expression has been shown to promote cell survival, stress may also change
the expression and activity of the proteins that regulate apoptosis (reviewed by Beere
2004). Moreover, previous studies from our laboratory revealed that heat stress sensitizes
Jurkat cells to CD95-mediated apoptosis (Tran et al. 2003). The Jurkat T lymphocyte cell




et al. 1977, Weiss et al. 1984). In Jurkat cells, changes in JNK or MAPK activities or Hsp70
expression did not contribute to the effect, although they have been shown to contribute to
cell survival (reviewed by Jäättelä 1999; Kyriakis and Avruch 1996, Holmström et al. 1999,
Tran et al. 2001). Instead, the sensitization was due to heat stress-induced downregulation
of the c-FLIP proteins, rendering the cells susceptible for receptor-mediated apoptosis. This
led us to examining how c-FLIP is regulated upon heat stress.
The downregulation of c-FLIP in response to heat shock and the following increase in death
receptor sensitivity also apply to more than one cell model, as HeLa cervical
adenocarcinoma cancer cells were sensitized to CD95 by hyperthermia treatment (Tran et
al. 2003). Whereas the unstimulated primary T cells are not sensitive to TRAIL, the Jurkat
cells are, and they are further sensitized by heat shock (Annika Meinander, PhD thesis).  In
addition to the malignant Jurkat leukemia cells, we confirmed our results using primary T
cells. Indeed, there was a dramatic reduction in the levels of c-FLIP in response to
hyperthermia in primary T cells, and the c-FLIP expression returned to normal after a 6-hour
recovery period in normal cell culture conditions (Figure 3A and 3D, II). Furthermore, CD95
sensitivity was reduced to normal in correlation with the recovering c-FLIP levels (Figure
3B-C, II). Moreover, c-FLIP was absent from the CD95 DISC of the hyperthermia-treated
Jurkat T cells (Figure 5, II). These results strongly suggest that c-FLIP acts as a switch
dictating the sensitivity towards death receptor stimulation during hyperthermia in several
cell models, including primary T cells.
Although heat shock proteins act to protect the cell, many reports still describe increased
cell death sensitivity in response to heat stress. Human glioma cells, for instance, are
sensitized to CD95-mediated apoptosis by hyperthermia (Hermisson et al. 2000). In
addition, c-FLIP is not the only anti-apoptotic protein downregulated by hyperthermia. For
example, the Bcl-2 family member Mcl1, another short-lived inhibitor of cell death, is
destabilized by heat shock. The stabilizing interaction between Mcl1 and Noxa is lost upon
hyperthermia, leaving Mcl1 available for a BH3-containing E3 ubiquitin ligase Mule. Mule
catalyses the ubiquitylation and degradation of Mcl1, resulting in increased sensitivity to
apoptosis after heat shock (Stankiewicz et al. 2009). We were interested in determining
how c-FLIP downregulation occurs during hyperthermia, finding out if the ubiquitin-
proteasome pathway is involved, and identifying the potential common denominators
between hyperthermia- and differentiation-induced regulation of c-FLIP.
1.2 c-FLIP proteins are ubiquitylated and degraded in the proteasome
following erythroid differentiation of K562 cells and upon fever-like
hyperthermia of Jurkat T cells (I, II)
The c-FLIP isoforms are produced from one gene by alternative mRNA splicing (Shu et al.
1997). The messenger RNA levels of c-FLIP do not significantly change during hemin
treatment (Hietakangas et al. 2003), suggesting that the downregulation of c-FLIP occurs
primarily at the protein level. In addition, the kinetics of hemin-induced downregulation of
the short and long isoforms are very different. These observations led us to explore the
potential ubiquitylation and proteosomal degradation of the c-FLIP proteins. In addition, we
wanted to assess whether the c-FLIP isoforms are differentially regulated. First, we used
the proteasome inhibitor epoxomicin to investigate whether hemin-induced downregulation
of c-FLIP upon erythroid differentiation was due to induced proteosomal degradation.
Indeed, we observed that the hemin-induced downregulation of c-FLIP could be rescued by
proteasome inhibition (Figure 1A, I). Notably, the effect was most prominent in Laemmli
total cell lysates, as hemin treatment seemed to accumulate c-FLIP into the insoluble




insoluble fraction also in HeLa and Jurkat cell lines (data not shown). Similarly, the
hyperthermia-induced downregulation of c-FLIP was rescued with epoxomicin (Figure 7A,
II), suggesting a role for proteasomal activity in downregulation of c-FLIP.
The contribution of the proteasome in downregulating c-FLIP during differentiation and
hyperthermia encouraged us to study if c-FLIP proteins were inducibly ubiquitylated during
differentiation or heat shock. For this purpose, we transfected K562 cells with plasmids
encoding FLAG-tagged c-FLIP and HA-tagged ubiquitin, and treated cells with hemin. Next,
we prepared whole cell lysates, immunoprecipitated the overexpressed ubiquitin, and
analyzed the ubiquitylation of c-FLIP by SDS-PAGE and Western blotting. We found that
while exogenous wild type c-FLIP proteins were ubiquitylated during control conditions,
hemin treatment clearly increased the ubiquitylation of both c-FLIPS and c-FLIPL (Figure 1C,
I). After hemin and epoxomicin treatments, similar smears indicating polyubiquitylation
could be seen in whole cell lysates prepared from K562 cell lines stably overexpressing c-
FLIPS or c-FLIPL (Figure 1B, I).
To investigate c-FLIP ubiquitylation in response to hyperthermia, we overexpressed c-FLIP
in Jurkat T cells, performed immunoprecipitation with antibodies against c-FLIP and
immunoblotted the samples with antibodies recognizing endogenous ubiquitin. Importantly,
we detected a clear increase in the ubiquitylation of both c-FLIPS and c-FLIPL in response to
heat shock (Figure 7B, II). The high molecular weight ubiquitin smear was present on both
endogenous and overexpressed c-FLIP, indicating that both c-FLIPS and c-FLIPL are
inducibly ubiquitylated upon hyperthermia. As transcription and translation are generally
repressed during hyperthermia, we investigated whether it affected the transcription of c-
FLIP. However, according to the RNase protection assays, c-FLIP mRNA levels were
unaffected by heat shock (Figure 6B, II). In addition, downregulation by the translation
inhibitor cycloheximide was slower than the hyperthermia-induced degradation (Figure 6C,
II), and since c-FLIPS and c-FLIPL declined rapidly upon heat stress (Figure 6A, II), this
downregulation was more likely to occur via degradation of c-FLIP proteins than
transcriptional repression of the CFLAR gene. Together, these results strongly support the
idea of hyperthermia affecting death receptor sensitivity through destabilizing c-FLIP.
Prior to our work, the mechanisms of c-FLIP ubiquitylation had not been widely
investigated. However, some reports indicated that c-FLIP is regulated by the ubiquitin-
proteasome pathway, and these observations were later confirmed in a number of model
systems. For example, Fukazawa and coworkers suggested that the stability of c-FLIP is
under the transcriptional control of p53, as c-FLIP levels are low in p53 expressing cells,
and the levels can be restored by proteasome inhibitors (Fukazawa et al. 2001).
Consistently, cisplatin induces the ubiquitylation of c-FLIP in ovarian cancer cells by a p53-
dependent mechanism (Abedini et al. 2008). In addition, the proteasomal degradation of c-
FLIP can be induced by inhibition of PPAR  (Kim et al. 2002). Interestingly, also adenoviral
E1A infection sensitizes tumor cells to apoptosis by specifically inducing the ubiquitylation
and proteasomal degradation of c-FLIPS, underlining the isoform-specific functions of the c-
FLIP proteins (Perez and White 2003). Another example of isoform-specific regulation was
recently shown in hepatoma cells, in which the flavonoid quercetin induces proteasomal
degradation of c-FLIPS and sensitizes cells to TRAIL (Kim et al. 2008). In addition, nitric
oxide was shown to counteract CD95-mediated apoptosis by inhibiting the proteosomal
degradation of c-FLIP (Chanvorachote et al. 2005). A single report even shows that c-FLIP
may, perhaps unexpectedly, regulate the proteasome, because in lung cancer cells,
exogenous c-FLIPL forms aggregates which impair the proteasome function (Ishioka et al.
2007). However, whether this effect is c-FLIP-specific, or if the overexpression of any DED-




2 Mechanisms of isoform-specific ubiquitylation and degradation of
the c-FLIP splice variants (I, II)
2.1 c-FLIP isoforms display different half lives (I)
Despite the high degree of similarity between the c-FLIP proteins, the isoforms modulate
apoptosis in disparate ways. It is therefore hardly surprising that the c-FLIP proteins are
also regulated in an isoform-specific fashion. Hence, we were especially interested in
examining the isoform-specificity of c-FLIP function and regulation. During this thesis work,
Golks and coworkers (2005) reported the detection of the third c-FLIP isoform, c-FLIPR, in
the human Raji cell line. Prompted by this finding, we explored whether c-FLIPR was
expressed also in other human cell lines. Surprisingly, the endogenous short c-FLIP isoform
in K562 cells migrated faster compared to the short c-FLIP expressed in Jurkat or Hela
cells, which indicates that the short isoform expressed by the K562 cells is more likely to be
c-FLIPR than c-FLIPS (Supplementary Figure 2, III). It is therefore conceivable that we have
determined the half-life of endogenous c-FLIPR and not c-FLIPS as indicated in article I.
However, as most of the analyses of this thesis are based on overexpression experiments,
conclusions on how c-FLIPS is regulated are likely to be correct and apply to c-FLIPR as
well. This hypothesis is supported by our own data as well as the fact the short c-FLIP
isoforms are yet to be assigned any differences as far as biological functions are
concerned. To avoid confusion, I have chosen to refer to the respective isoforms by the
names used in the original articles.
To determine the half-lives of the c-FLIP isoforms, we analyzed the c-FLIP protein levels in
K562 and HeLa cells after a time course treatment with the translation inhibitor
cycloheximide. Although these cell lines express differing amounts of the isoforms, c-FLIPL
being more abundantly expressed than c-FLIPS in K562 cells whereas HeLa cells
expressed similar amounts of both, we were able to see that the half-lives of the c-FLIP
isoforms are different. c-FLIPS declined faster than c-FLIPL in both cell lines (Figure 2A-D,
I), suggesting that although the c-FLIP isoforms are ubiquitylated and degraded in the
proteasome, their stability is determined by distinct mechanisms. We have also determined
the half-lives of c-FLIP proteins in Jurkat cells and found c-FLIPL more stable than c-FLIPS
also in this cell model (data not shown).
Figure 14. Alignment of the splicing tails of c-FLIPS and c-FLIPR proteins in
different species. c-FLIPR appears to be the predominant short c-FLIP isoform and
evolutionarily older (Annika Meinander, PhD thesis; Ueffing et al. 2008, Ueffing et
al. 2009). The predicted protein sequences of the chimpanzee and macaque c-










While c-FLIPL is a product of nine exons, c-FLIPS consists of five exons, exon 7 accounting
for the unique C-terminal tail. The splicing tail of c-FLIPR, however, is a result of run-through
from exon 6 to intron 6 (Djerbi et al. 2001, Golks et al. 2005; Annika Meinander, PhD
thesis). The C-terminal tail of c-FLIPS is 19 amino acids long and the tail of c-FLIPR is 11
amino acids, respectively (Figure 14). Notably, the sequences of the splicing tails are
entirely different (Golks et al. 2005, Ueffing et al. 2008, Ueffing et al. 2009). In contrast to
the short isoforms, c-FLIPL contains a C-terminal caspase-like domain, enabling it to
dimerize with procaspase-8 (Scaffidi et al. 1999, Krueger et al. 2001, Micheau et al. 2002,
Boatright et al. 2004).
The differential regulation of the c-FLIP isoforms can be explained by their differential
functions in the DISC. Surprisingly, when we overexpressed c-FLIPS or c-FLIPL in Jurkat T
cells and studied apoptosis after hyperthermia, we found that the heat stress-induced
sensitivity was only counteracted by overexpression of c-FLIPS, but not c-FLIPL (Figure 4,
II). These results may be partially due to non-physiological expression levels of c-FLIPL,
which in other studies have been reported to induce cell death (Scaffidi et al. 1999). This is,
however, unlikely, as overexpression of c-FLIPL did not significantly increase apoptosis on
its own (Figure 4, II). Because c-FLIP proteins seem to play differential roles during
hyperthermia, and yet both isoforms are downregulated in the process, it can be speculated
that the underlying mechanisms are isoform-specific.
The differential stability of the c-FLIP isoforms has been addressed in a handful of studies.
The overall data suggests that the short c-FLIP proteins are less stable than c-FLIPL, and
that half-lives of the c-FLIP proteins vary in a cell type-specific fashion. Cycloheximide
experiments showed that in BoeR cells, which express all three c-FLIP isoforms, the half-life
of c-FLIPR was approximately similar to that of c-FLIPS (Golks et al. 2005, Ueffing et al.
2008). In contrast to K562 and HeLa cells, c-FLIPL is less stable than c-FLIPS in SHEP
neuroblastoma cells (Fulda et al. 2000). In addition, the half-life of c-FLIPL in keratinocytes
has been reported to be less than 90 minutes (Leverkus et al. 2000), whereas in SV80-
CD40 cells both c-FLIPS and c-FLIPL were entirely degraded after four hours of
cycloheximide treatment (Kreuz et al. 2001). In summary, our data and the studies of others
demonstrate that the half-lives of the c-FLIP isoforms are modified in a cell type-specific
fashion, and that in most cellular systems c-FLIPL displays a longer half-life than the short
isoforms.
The specific regulation of the stability of splice variants provides variability in protein
function and enables the cell to adapt to changing circumstances. In activated T
lymphocytes, c-FLIPS expression was primarily responsible for resistance towards CD95-
mediated apoptosis, while the role of c-FLIPL was slightly obscure. In contrast to c-FLIPS,
the biological functions of c-FLIPL extend beyond being a protector against apoptosis, and
these features are likely to differ in compliance with the cell type and environmental cues.
This is exemplified by an interesting study, according to which the lymphocytes of
transgenic mice overexpressing c-FLIPL are not protected from AICD, but instead proliferate
more than wild type lymphocytes in response to sub-optimal activation (Lens et al. 2002).
Consequently, c-FLIPL could be acting as an amplifier for proliferatory signals. The
divergent roles of the short and long c-FLIP isoforms in death receptor signaling may
explain why the post-translational modification of these proteins is dissimilar.
A number of examples of differential stability of protein splice variants are described in the
literature. For instance, the transcription factor suppressor of cytokine signaling 3 (SOCS3)
is expressed in long and short isoforms, the latter of which is expressed under stress
conditions, and the truncated SOCS3 is more stable than the full-length protein due to the
absence of a major ubiquitylation site in the truncated SOCS3 isoform (Sasaki et al. 2003).
The splice variants of the S. cerevisiae microtubules regulator, chromosome instability and




pheromones. Intriguingly, the short Cik1 protein, which is expressed upon exposure to
mating pheromone  factor, is not a substrate for the APC/cyclosome complex, indicating
that the short and long isoforms regulate different aspects of mitosis (Benanti et al. 2009).
Moreover, the ubiquitin ligase Siah1 is expressed in two isoforms, Siah1 and Siah1 short
(Siah1-S), of which Siah1-S, but not Siah1, is capable of autoubiquitylation and has a short
half-life (Mei et al. 2007). Finally, an important cell cycle regulator, cyclin D1, is expressed
in two isoforms, cyclin D1a and D1b, of which D1b is shorter and more stable, because it
lacks the stabilizing C-terminal region (Leveque et al. 2007). These examples illustrate how
several isoforms of a protein, possibly serving in disparate functions, are often targeted for
degradation by distinct mechanisms.
2.2 K192 and K195 are the primary ubiquitylated lysines in c-FLIPS during K562
erythroid differentiation (I)
We and others have established that c-FLIP proteins are capable of modifying death
receptor responses and that their protein levels are under precise regulation. While in most
conditions all c-FLIP proteins counteract apoptosis, the short and long isoforms also play
differential roles, prompting us to investigate the molecular mechanisms behind the induced
downregulation of c-FLIP, and to examine the structural basis for isoform-specific
modifications. We chose to perform most of these biochemical analyses in the K562 system
for two reasons: firstly, the K562 cells could be easily transfected, allowing overexpression-
based studies; and secondly, according to the current knowledge, c-FLIP operates similarly
in the CD95 and the TRAIL DISCs. The fundamental findings regarding c-FLIPS have been
confirmed in the Jurkat system.
Covalent modification of proteins by ubiquitylation occurs on lysine residues. The choice of
a particular acceptor lysine may be primed by areas such as ubiquitin-interacting domains
or other interaction motifs around the lysine which aid the docking of the ligase. However,
ubiquitylation tends to be rather promiscuous, and it is often difficult to pinpoint one lysine
residue that is entirely responsible for accepting ubiquitin. We were interested in
determining which lysines of c-FLIP are subject to ubiquitylation in order to understand the
mechanisms of isoform-specific regulation. To this end, we performed mutational analyses
focusing on c-FLIPS because of its structural simplicity compared to c-FLIPL. We mutated all
20 lysine residues of c-FLIPS in four clusters conservatively into arginines to preserve native
protein structure. The cluster mutants were transiently transfected into K562 cells and their
ubiquitylation was analyzed by immunoprecipitation. As seen in Figure 5C (I), mutation of
three lysines (K192, K195 and K214) in the C-terminal part led to a marked loss of c-FLIPS
ubiquitylation. To further dissect the role of the three lysines, we generated K214R, K192R,
K195R and K192,195R mutants. Surprisingly, the only lysine present in the C-terminal
splicing tail of c-FLIPS, K214, did not appear to be the main target for ubiquitylation, but
seemed to render c-FLIPS more susceptible for ubiquitylation (Figure 5A, I), probably due to
conformational changes in the splicing tail of the mutant. In contrast, the mutation of K192
and K195 in the linker area between DED2 and the splicing tail significantly decreased c-
FLIPS ubiquitylation, indicating that K192 and K195 are the primary ubiquitylated residues in
c-FLIPS (Figure 5D, I). When K192 and K195 were individually mutated, c-FLIPS
ubiquitylation was decreased, although not as efficiently as with the K192,195R mutant
(Aura Kaunisto, unpublished data), signifying that the lysines are probably targeted by the
same ligase. As K192 and K195 are conserved between species and present in other c-
FLIP splice variants, we wanted to investigate their role in the ubiquitylation of c-FLIPL.
Surprisingly, mutating K192 and K195 did not affect the overall ubiquitylation of c-FLIPL,
underlining the isoform-specificity of the process. In addition, according to our results, K192




not shown), suggesting that in addition to isoform-specific regulation, selection of target
residues is largely a cell type- and context-dependent event.
2.3 C-terminal regions determine the half-lives of c-FLIP proteins (I, II)
A single lysine residue seldom governs the ubiquitylation and stability of a protein. In fact,
proteins often contain restricted motifs or larger domains that facilitate ubiquitylation and
degradation by assisting the interaction with a ubiquitin ligase or a proteasome subunit.
After we found that the c-FLIP isoforms display different half-lives, we sought to determine if
this was due to structural differences, as the c-FLIP proteins share the 202 N-terminal
amino acids, but differ in their C-terminal parts. To see whether the differential C-terminal
regions explained the relative instability of c-FLIPS, we deleted the splicing tail and studied
the ubiquitylation of the remaining part encompassing only the amino acids common to all
isoforms (called c-FLIPS 203-221 in I, c-FLIP1-202 in II and III). Our analysis revealed that
deleting the splicing tail abolished most of c-FLIPS ubiquitylation, demonstrating that the C-
terminal areas, unique to each individual c-FLIP, dictate their particular stability. In addition,
we showed that these areas are not likely to contribute to anti-apoptotic functions and DISC
recruitment, as the c-FLIP1-202 mutant was recruited to the TRAIL-induced DISC in K562
cells similarly to the wild type proteins, and its overexpression effectively protected cells
from TRAIL-mediated apoptosis (Figure 4, I). Importantly, upon cycloheximide treatment, c-
FLIP1-202 was remarkably more stable than wild type c-FLIPS, as its half-life extended to
approximately 12 hours compared to the 4 hours of the exogenous wild type c-FLIPS
(Figure 6, I). These results strongly suggest that the C-terminal splicing tail of c-FLIPS is a
destabilizing element. Although the half-lives of exogenous proteins do not correspond to
those of endogenous protein, they do still provide an approximation on how certain regions
affect protein stability. Our results show that the C-terminal areas of c-FLIP are crucial to
their modification and processing by the ubiquitin-proteasome machinery.
To uncover the structural details of the interaction between the C-terminal part and lysines
192 and 195, we performed computational analysis to model these regions of c-FLIPS. The
analysis revealed that the C-terminal tail of c-FLIPS includes an -helix encompassing
amino acids Y182-D196 (Figure 7, I), but does not adapt a tightly folded state (Figure 8A, I).
The loosely structured parts of the C terminus are likely to contribute to the unstable nature
of c-FLIPS. This idea is supported by the fact that although K192,195R double mutation
clearly reduces the ubiquitylation of c-FLIPS, it does not significantly impair c-FLIPS stability
(data not shown). It is plausible that in the absence of K192 and K195, c-FLIPS would still
be minutely ubiquitylated onto other lysine residues, and this would be enough to target c-
FLIPS for degradation. Alternatively, the loose C terminus may be able to compensate for
the loss of the primary target lysines by attracting the proteasome. Our model provides an
indirect explanation on why K192 and K195 are especially important for the ubiquitylation of
c-FLIPS, but not c-FLIPL. The computational programs did not predict -helical structures for
the corresponding area of c-FLIPL despite sequence similarity. It is possible that K192 and
K195 are very differently positioned in c-FLIPL compared to c-FLIPS, and therefore not
available for ubiquitylation.
In addition to determining the structure adapted by the c-FLIPS C-terminal area, we
analyzed its hydrophobic and hydrophilic properties. Our modeling showed that DED2
contains two lipophilic grooves, whereas the remaining C-terminal region has two lipophilic
surfaces (Figure 8B-C, I). As these areas cannot reside freely or exposed in the cytosol, we
suggested that they interact with each other or with an unknown protein by weak
interactions. To test our hypothesis, we mutated Y182S, L186R and I190N, three residues
of the  helix, to generate a triple point mutant called 3Xmut. In addition, we removed the 




ubiquitylation and stability of these mutants comparing them to wild type c-FLIPS. We found
that both serial point mutations and the deletion of the helix significantly reduced the
ubiquitylation of c-FLIPS (Figure 9A, I) and prolonged the half life of c-FLIPS, supporting our
hypothesis (Figure 9B-C, I). In terms of ubiquitylation, the  helix mutants resembled the
K192,195R mutants, displaying only little ubiquitylation, yet more than the c-FLIP1-202
mutant (Figure 9A, I). However, although the K192,195R mutations did not destabilize c-
FLIPS, both  helix mutants exhibited a longer half-life compared to wild type c-FLIPS
(Figure 9B-C, I). It therefore seems that disruption of the -helical region crucially affects
the conformation of the C terminus of c-FLIPS, possibly rendering the primary target lysines
less likely to be ubiquitylated, but probably also interfering with the overall structure of the C
terminus. In summary, our model where weak interactions regulate the C-terminal structure
of c-FLIPS, thereby affecting stability, is likely to be correct.
To investigate whether the C-terminal region governed the ubiquitylation and stability of c-
FLIP in our other experimental model, the Jurkat T lymphocytes, we compared the
ubiquitylation status of wild type c-FLIPS, the isoform primarily responsible for protecting T
cells from receptor-mediated apoptosis, to the deletion mutant c-FLIP1-202, which only
contains the amino acids common to all c-FLIP isoforms. Indeed, the c-FLIP1-202 mutant
displayed less ubiquitylation than the wild type exogenous c-FLIPS in response to
hyperthermia (Figure 7D, II). The faint remaining signal most likely originated from the
endogenous ubiquitylation. Furthermore, when compared to the wild type c-FLIPS, the c-
FLIP1-202 mutant proved more resistant to heat stress, as it was not downregulated by 2-
hour hyperthermia treatment, in contrast to wild type c-FLIPS (Figure 7C, II). What is more,
the sensitizing effect of hyperthermia could be rescued by stable overexpression of the c-
FLIP1-202 mutant (Figure 7E, II). In summary, these results firmly demonstrate that the
sensitizing effect of hyperthermia in T lymphocytes is due to induced ubiquitylation and
proteasomal degradation of the c-FLIP proteins, in particular c-FLIPS.
Later studies have addressed how c-FLIP stability is affected by the characteristics of the
C-terminal area. In the original article describing c-FLIPR, the half-life of c-FLIPR was
described to be very similar to that of c-FLIPS (Golks et al. 2005). Later, it was found by our
group and recently reported by Ueffing and colleagues that the murine short c-FLIP isoform
actually corresponds to c-FLIPR, and not c-FLIPS as previously thought (Annika Meinander,
PhD thesis; Ueffing et al. 2008). Interestingly, Ueffing and coworkers reported that lysines
K196 and K200 of the murine c-FLIPR, which correspond to K192 and K195 of the human c-
FLIPS, did not affect ubiquitylation, whereas the opposite was later demonstrated by
another group (Kundu et al. 2009). Considering these results, it seems likely that similarly to
human cell models, also murine cell models differ from each other with respect to target
lysine selection.
In our experimental models, deletion of the C-terminal splicing tail or the caspase-like
domain substantially stabilized c-FLIP. A possible explanation for this phenomenon is that
these regions may provide a binding platform for E3 ubiquitin ligases. Although we have not
addressed this question, our hypothesis was supported by the identification of Itch as the
E3 ligase that specifically ubiquitylates c-FLIPL through interaction with the caspase-like
domain (Chang et al. 2006). Recently, c-Cbl was reported to bind and ubiquitylate c-FLIPS
upon mycobacteria infection-induced, TNF -mediated apoptosis (Kundu et al. 2009). These
results are in line with our observations, while other findings have indirectly challenged our
idea. Golks and colleagues previously described c-FLIP-p22, a proteolytic product of
caspase-8-mediated c-FLIP cleavage, which is generated in the absence of death receptor
stimulation and activates NF- B in malignant cells (Golks et al. 2006). The p22 fragment
corresponds to amino acids 1-196 and should therefore be very stable in the light of our
results, but the exogenous p22 was downregulated in BoeR cells by cycloheximide within 4
hours. It is feasible that the malignant T and B cell lines expressing p22 have acquired




conclusion, C-terminal regions are essential for the regulation of c-FLIP stability, and they
have been shown to attract ubiquitin ligases in an isoform-specific manner.
3 Regulation of TRAIL-mediated apoptosis by PKC-mediated c-FLIP
phosphorylation (III)
3.1 Regulation of death receptor signaling by protein kinase C (III)
Post-translational modifications form complex networks. Phosphorylation is involved in
almost every imaginable biological process, and it is perhaps the best characterized of all
PTMs. It has been estimated that 30% of all proteins are targets for phosphorylation, and
individual substrates are often targeted at several sites (reviewed by Pinna and Ruzzene
1996, Cohen 2000). Members of the protein kinase C family have been found to modulate
death receptor-mediated apoptosis on multiple levels (reviewed by Tran et al. 2004). Unlike
the classical family members PKC  and PKC , PKC  and PKC  have not been found to act
at receptor level, although they are often connected to receptor-mediated cell death. In
Jurkat T cells, cPKC interferes with the formation of the CD95 DISC by blocking FADD
recruitment and subsequent caspase-8 activation (Gomez-Angelats et al. 2000, Gomez-
Angelats and Cidlowski 2001). PKC activation has also been observed to inhibit FADD
recruitment to the TRAIL-DISC in HeLa cells (Harper et al. 2003). However, as these effects
were not due to PKC-mediated FADD phosphorylation, their specific mechanism has
remained unclear. The atypical PKC  negatively regulates CD95-induced apoptosis in
Jurkat cells by preventing FADD recruitment to the DISC (de Thonel et al. 2001, Leroy et al.
2005). However, it is not known to which extent these effects rely on the kinase activity of
PKC . In addition, PKC  and PKC  mediate opposing effects on cigarette smoke extract-
induced apoptosis in human lung fibroblasts (Park et al. 2008). Collectively, these reports
suggest that PKC modulates death receptor signaling both positively and negatively, but the
underlying mechanisms of action are still largely unknown.
Recently, flavopiridol, an inhibitor of cyclin-dependent kinases currently undergoing clinical
trials, was shown to sensitize breast tumor cells to TRAIL by inducing proteasome-
dependent degradation of c-FLIP (Palacios et al. 2006). Also casein kinase inhibition has
been shown to downregulate c-FLIP in a proteasome-dependent manner (Llobet et al.
2008). When this thesis was initiated, little was known about the mechanisms and biological
implications of c-FLIP phosphorylation. We were especially interested in deciphering if there
was a link between the modification of c-FLIP with ubiquitin and phosphorylation. Indeed,
we found that the two modes of post-translational regulatory mechanisms cooperate to
accommodate c-FLIP stability. We discovered a PKC-phosphorylated serine that
specifically regulates the stability of the short c-FLIP isoforms, thereby describing a novel
link between death receptor-mediated apoptosis and the classical PKC.
3.2 c-FLIP is phosphorylated on serine 193 (III)
c-FLIP proteins are targeted by several post-translational modifications including
phosphorylation. The reports made hitherto indicate that many signaling pathways are
involved in c-FLIP phosphorylation, and its physiological function varies according to the
stimulus and the cell model. To resolve whether c-FLIP was regulated by phosphorylation in
our model system, we treated K562 cell lines stably overexpressing c-FLIPS or c-FLIPL with




Using electrophoresis and autoradiography, we detected clear signals of both isoforms,
indicating that c-FLIP proteins are phosphorylated in vivo (Figure 1A, III). As no one had
identified phosphorylated residues of c-FLIP when this study was initiated, we performed
tryptic phosphopeptide mapping and mass spectrometric analyses to identify the sites.
Indeed, serine 193 (S193) was revealed a novel phosphorylation site common to both c-
FLIPS and c-FLIPL (Figure 1B-G, III). To continue the biochemical analyses on this site, we
developed a polyclonal antibody against phosphorylated S193. Use of our antibody allowed
the detection of overexpressed, immunoprecipitated c-FLIP in K562 cells treated with
different phosphatase inhibitors (Figure 2A, III, and data not shown), but its titer was not
high enough to detect endogenous phosphorylated proteins.
3.3 Serine 193 phosphorylation is mediated by PKC  and PKC  (III)
S193 is conserved in all c-FLIP proteins and present also in the initiator caspase-10, but not
in caspase-8. The amino acids surrounding S193 correspond to a PKC consensus
sequence, which led us to detect the phosphorylation status of c-FLIP serine 193 after
manipulating the activity of different PKCs. We treated cells with several PKC inhibitors and
an activator, and found that S193 phosphorylation was differentially modulated in response
to some of these agents. Importantly, we found that GÖ6976, an inhibitor of the classical
PKC isoforms PKC  and PKC , considerably decreased S193 phosphorylation (Figure 2B,
III). This effect was somewhat stronger in c-FLIPS, which may either be due to c-FLIPL
phosphorylation by additional kinases that are not inhibited by GÖ6976, or the differential
affinity of the phosphopeptide antibody to the c-FLIP isoforms. In addition to GÖ6976, we
also studied phosphorylation of S193 upon treatment with the pseudosubstrate of PKC
and PKC  (data not shown), and obtained results similar to those with GÖ6976, supporting
our hypothesis on PKC-mediated phosphorylation of c-FLIP S193. Remarkably, the
phosphorylation of S193 was greatly enhanced by treatment with TPA, an activator of the
classical and the novel PKCs (Figure 2C, III). A great increase in S193 phosphorylation was
evident when the cells were treated both with TPA and calyculin A, but TPA also allowed
the detection of S193 phosphorylation without phosphatase inhibition (Figure 2C, III).
Similar results were obtained with c-FLIPR, indicating that S193 phosphorylation of both
short c-FLIP isoforms is regulated in a similar manner (Figure 2E, III). Furthermore, K562
cells stably overexpressing c-FLIP proteins were pretreated with GÖ6976 before treatment
with TPA in order to see to what degree the TPA-mediated enhanced phosphorylation was
due to PKC  and PKC , the kinases primarily inhibited by GÖ6976. Indeed, TPA-mediated
phosphorylation of c-FLIPS was almost completely abolished by GÖ6976 pretreatment,
indicating that the phosphorylation of c-FLIPS S193 is mainly mediated by PKC  and PKC
(Figure 2D, III). The phosphorylation of c-FLIPL S193, in turn, was decreased by GÖ6976
pretreatment, but to a lesser degree than the phosphorylation of c-FLIPS, implying that c-
FLIPL is likely to be subject to phosphorylation by a wider array of kinases than c-FLIPS
(Figure 2D, III).
We utilized genetic tools to ensure the specificity of our results obtained by the
pharmacological PKC inhibitors. We transfected c-FLIP-expressing K562 cells with kinase-
dead, GFP-tagged PKC  and PKC , treated cells with TPA and calyculin A, and monitored
S193 phosphorylation. We expected the kinase-dead PKCs to act as dominant negative
inhibitors of the endogenous PKCs upon TPA-induced activation and to thereby interfere
with the induction of c-FLIP phosphorylation. Indeed, in line with our hypothesis, we
detected a decrease in S193 phosphorylation levels in both c-FLIPS and c-FLIPL (Figure 2F,
III), supporting our previous data. As the co-expression with PKC-GFP sometimes reduced
the expression level of FLAG-c-FLIP, we normalized the signal from phospho-S193 to c-




as the co-expression of c-FLIP and PKC-GFP constructs was challenging, we were unable
to express both PKC  and PKC  together with c-FLIP in order to see how dual PKC
inhibition would affect S193 phosphorylation.
Previous reports have suggested that c-FLIP is a substrate for CaMKII (Yang et al. 2003)
and Akt/PI3K (Shi et al. 2009). However, we did not detect changes in S193
phosphorylation after treating cells with the CaMKII inhibitors KN-63 and KN-92 or the PI3K
inhibitor LY29400, suggesting these pathways do not target S193. In addition,
acknowledging that TPA is an activator of the novel PKCs and the MAP kinase family, the
phosphorylation of S193 was monitored after treatment with Rottlerin, an inhibitor of PKC
and PKC  (Gschwendt et al. 1994) which is known to have some unspecific effects on
MAPK and PKA (Davies et al. 2000), or with more specific MAPK inhibitors (data not
shown). We could not observe any changes in S193 phosphorylation in response to
Rottlerin or the MAPK inhibitors, indicating that the effect of TPA is likely to be mediated via
the classical PKCs, possibly even by direct phosphorylation.
3.4 Serine 193 mutations have isoform-specific implications on c-FLIP
ubiquitylation and stability (III)
In article I, we showed that the C-terminal regions are pivotal in regulating ubiquitylation and
stability of the c-FLIP proteins. Specifically, we found that the primary ubiquitin acceptors in
c-FLIPS during erythroid differentiation are K192 and K195, surrounding S193. We were
therefore prompted to investigate whether S193 phosphorylation influenced c-FLIP
ubiquitylation. We performed site-directed mutagenesis to mutate S193 into a non-
phosphorylatable alanine or into aspartate to mimic constitutive phosphorylation, and
assayed c-FLIP ubiquitylation by immunoprecipitation and Western blotting. Interestingly,
the S193A mutation increased the ubiquitylation of all c-FLIP isoforms (Figure 3A-C, III). In
contrast, the phospho-mimetic S193D mutation efficiently decreased the ubiquitylation of
the short c-FLIP proteins (Figure 3A-B, III), while c-FLIPL S193D was ubiquitylated similarly
to wild type c-FLIPL (Figure 3C, III).
Mutations of S193 may have an impact on the in the -helical region of c-FLIPS. It is
possible that while S193A mutation probably does not significantly alter the properties of the
 helix, S193D mutation creates a negative charge, and could thereby interfere with the
potential interactions mediated by the  helix. While according to our modeling, K192 and
K195 are susceptible for ubiquitylation in the native helix, they could be less favorably
positioned in the S193D mutant, thereby inhibiting ubiquitylation. Therefore, it was important
to detect c-FLIP ubiquitylation after GÖ6976 treatment to see if inhibition of S193
phosphorylation led to increased ubiquitylation. We found that c-FLIPL and c-FLIPR were,
indeed, more ubiquitylated in response to GÖ6976 treatment. Moreover, the ubiquitylation
of c-FLIPR S193D mutant was not affected by GÖ6976 treatment (Figure 2E, III), confirming
that the change in ubiquitylation truly was due to changes in the phosphorylation state of
S193. As c-FLIPL does not contain an  helix similar to c-FLIPS, and the ubiquitylation of all
isoforms was affected by S193 mutations as well as treatment with GÖ6976, it seems likely
that changes in ubiquitylation are not mutation artifacts, but regulated by the
phosphorylation status of S193. In addition, GÖ6976-induced ubiquitylation was more
pronounced in c-FLIPL than in c-FLIPR, indicating that phosphorylation is likely to diminish
the ubiquitylation of all c-FLIP proteins, although its effects may differ among the short and
the long isoforms. Given our previous results and the model on the C-terminal structure of
c-FLIPS, S193 phosphorylation probably modulates ubiquitylation sterically by inhibiting the
exposure of K192 and K195. Nevertheless, how S193 affects the ubiquitylation of c-FLIPL is




phosphorylation on S193 affects the folding of the caspase-like domain and thereby inhibits
ligase binding, correct positioning of the target lysine(s), or both. The physical proximity of
these binding sites or sites of modification is not necessarily required, since post-
translational modifications have been described to affect interactions and other
modifications also outside its instant vicinity.
After establishing that S193 phosphorylation indeed regulates c-FLIP ubiquitylation, we
wanted to determine whether the C-terminal areas were required for S193-mediated effects.
For this purpose, we performed site-directed mutagenesis using the deletion mutant c-
FLIP1-202 as a template, producing the c-FLIP1-202 S193A mutant, which is prone to
ubiquitylation, but lacks the crucial C-terminal structures. Our ubiquitylation assays showed
that in the absence of the C-terminal part, c-FLIP cannot be ubiquitylated (Figure 2D, III).
The C-terminal tail was not important for S193 phosphorylation, because c-FLIP1-202 was
efficiently phosphorylated in vivo (data not shown). This indicates that while the C-terminal
parts of c-FLIP are not needed for kinase recruitment, they are required for ubiquitylation. In
addition, we wanted to examine the effect of S193 phosphorylation on ubiquitylation of c-
FLIPS in the absence of the primary target K192 and K195. Surprisingly, when S193A
mutation was introduced into the c-FLIPS K192,195R mutant, c-FLIPS was  still  more
ubiquitylated than wild type (data not shown). This indicates that dephosphorylation is able
to impose strong destabilizing effects on both c-FLIP proteins, even when the principal
target lysines are unavailable. These data further underline the importance of S193
phosphorylation in determining c-FLIP ubiquitylation.
Targeting proteins to degradation is the most thoroughly described function of
ubiquitylation. However, ubiquitin conjugation may also serve signaling purposes. To
decipher if c-FLIP was a subject for K48-linked or other kind of ubiquitin conjugation, we
determined the effect of S193 phosphorylation on the half-lives of c-FLIP isoforms. We
therefore transfected K562 cells with low amounts of wild type and phosphomutant c-FLIPS,
c-FLIPR and c-FLIPL to mimic endogenous expression levels. This aim was met with c-
FLIPL, whose endogenous levels are higher, but we were unable to achieve such levels
with c-FLIPS and c-FLIPR, as their endogenous expression is very low. Nevertheless, we
downregulated the translation of the c-FLIP constructs by cycloheximide to compare their
half-lives (Figure 4A-C, III). Remarkably, mutations of S193 did not affect the half-live of c-
FLIPL at all, suggesting that the function of S193 phosphorylation of c-FLIPL is unrelated to
protein degradation (Figure 4C, III). In contrast, S193A mutation decreased the half-lives of
both c-FLIPS and c-FLIPR, whereas S193D mutation extended their half-life (Figure 4A-B,
III). These results indicate that phosphorylation on S193 specifically affects the stability of
the short c-FLIP proteins, while regulating the ubiquitylation of c-FLIPL in an unrelated
fashion. To further solidify these findings, we performed 35S metabolic labeling in K562 cell
lines stably overexpressing c-FLIPS or c-FLIPL. Again, due to the high levels of
overexpression in the cell lines in question, the half-lives were longer than the endogenous
ones, and we therefore detected c-FLIP levels at relatively long time points. Metabolic
labelings yielded similar results as the cycloheximide chases: c-FLIPS S193A mutant was
destabilized compared to wild type c-FLIPS, whereas S193D displayed a longer half-life
(Figure 4D, III). Furthermore, the stability of c-FLIPL was unaffected by S193 mutations also
in this experimental setting (Figure 4E, III). Together, our results show that while
phosphorylation on S193 affects the ubiquitylation of all c-FLIP isoforms, it specifically
regulates the stability of the short c-FLIP proteins.
In addition to establishing a role for S193 phosphorylation in c-FLIP stability, we wanted to
characterize its function in death receptor responses. We determined S193 phosphorylation
upon TRAIL and TNF receptors stimulation, and found, intriguingly, that both TRAIL (Figure
5A, III) and TNF  (Figure 5B, III) increased S193 phosphorylation when combined with
phosphatase inhibition, presumably leading to the stabilization of c-FLIP. The effect was




the cPKCs upon TNF receptor stimulation compared to TRAIL receptor stimulation. Death
receptor stimulation may affect c-FLIP phosphorylation secondarily via signals transmitted
from the receptor signaling complexes, resulting in increased PKC activity. These survival
pathways are primarily mediated via the TNF receptor system, although low-level
stimulation of the CD95 and the TRAIL receptor systems have also been reported to convey
survival signals (reviewed by Siegel et al. 2000, Falschlehner et al. 2007). Alternatively, it is
conceivable that the recruitment of c-FLIP to death receptor complexes augments direct
physical interaction with active cPKCs, especially since cPKCs are recruited to cellular
membranes during their activation process (reviewed by Greiner and Kazanietz 2007). The
latter explanation is perhaps more likely in the case of TRAIL-mediated phosphorylation,
because upon TNF receptor stimulation, c-FLIP is not recruited to the complex 1 at the
membrane, but to the cytosolic complex 2 (Micheau and Tschopp 2003).
Since c-FLIP is a potent inhibitor of caspase-8 activation and a critical regulator of cell
death, a crucial question is whether S193 phosphorylation affects these functions. Ueffing
and coworkers reported that the C-terminal part (aa186-215) of murine c-FLIPR facilitated
DISC binding, thereby raising the possibility that S193 was involved in regulating DISC
assembly (Ueffing et al. 2008). To study this hypothesis, we analyzed the recruitment of
wild type and phosphomutant c-FLIP proteins to the TRAIL DISC. According to our results,
however, S193 phosphorylation does not affect DISC binding properties, as the c-FLIP
mutants were recruited to the DISC at even efficiency, correlating with the relative
expression levels of the stably overexpressing K562 cell lines (Figure 5C, III). This finding is
logical, since S193 resides outside the DEDs responsible for DISC binding (Scaffidi et al.
1999). To ascertain whether S193 phosphorylation affects caspase-8 activation in the
DISC, we analyzed the caspase-8 activity in the TRAIL DISC induced in cell lines stable
overexpressing wild type, S193A or S193D c-FLIPS or c-FLIPL. In accordance with our
previous results and data published by others, we found that c-FLIPS is a potent inhibitor of
caspase-8, whereas c-FLIPL allows or may even accentuate the activation of caspase-8 in
the DISC (Figure 5D, III). S193 mutations did not, however, alter these features of the c-
FLIP proteins. Statistically insignificant changes were detected among individual
overexpressing clones, again correlating with their relative overexpression levels. These
data suggest that S193 phosphorylation does not directly affect the ability of c-FLIP proteins
to bind to the DISC or to regulate caspase-8 activation within the DISC.
Although S193 phosphorylation does not qualitatively affect the potential of c-FLIP to inhibit
apoptosis, its isoform-specific stabilizing effects are likely to have profound implications on
cell death sensitivity. To demonstrate that the prolonged half-life of c-FLIPS following S193
phosphorylation eventually results in delayed progression of apoptosis, we monitored
apoptosis markers during cycloheximide-induced downregulation of wild type and S193A c-
FLIPS (Figure 5E, III). Indeed, during the rapid degradation of S193A c-FLIPS, we saw the
cleavage of caspase-8 and PARP1 occurring earlier than in wild type c-FLIPS
overexpressing cells. This result suggests that since S193 phosphorylation regulates the
stability of the short c-FLIP isoforms, it is a pro-survival modification with physiologically
relevant consequences. A simplified model of S193 phosporylation-directed events is
depicted in Figure 15.
Our studies on S193 phosphorylation and c-FLIP stability add to understanding how
malfunction in c-FLIP regulation may contribute to the pathogenesis of cancer. Abnormally
high levels of c-FLIP have been reported to promote carcinogenesis and protect cancer
cells from death receptor-mediated apoptosis (Djerbi et al. 1999, Medema et al. 1999). It
can therefore be speculated that accumulating mutations that stabilize c-FLIP, either
directly or indirectly, would offer malignant cells a selection advantage over cells that




An interesting question, largely left unanswered by our studies, is the biological function of
c-FLIPL S193 phosphorylation. Our investigations revealed that c-FLIPL is ubiquitylated in
the absence of S193 phosphorylation, but the biological function of this modification is yet
to be established. It is worth emphasizing that the ubiquitylation assay used in these studies
does not disclose the type of ubiquitin chain c-FLIP is modified with. As the enhanced
ubiquitylation of c-FLIPL S193A mutant did not affect the stability of the protein, it can be
speculated that the mutation exposes c-FLIPL to regulatory ubiquitylation, conjugation of
K63-linked ubiquitin chains for instance, instead of K48 chains favored by the proteasome.
In this case, K63-linked chains could mediate binding to other proteins, perhaps even non-
covalently via ubiquitin-interacting domains. Recent body of evidence has shown that the
ubiquitin interacting motifs display an astounding specificity against ubiquitin chain linkage
types, and that many players of the NF- B pathway, for example, are modified by non-
degradative ubiquitylation. Some of these proteins, RIP for instance, are established
interaction partners of c-FLIP and might therefore be especially interesting in this respect. In
our future studies, we will utilize mass spectrometric approaches to define the potential
binding partners that specifically interact with non-S193-phosphorylated c-FLIPL, and to
elucidate which interactions are brought on or disrupted by physiological cues that affect
S193 phosphorylation. Furthermore, antibodies that specifically recognize K48- or K63-
linked ubiquitin chains have recently been developed (Newton et al. 2008), hopefully
opening up new opportunities to study the ubiquitylation of c-FLIP.
While examining the protein sequences of c-FLIP, we found that the c-FLIP proteins contain
a potential UIM (Figure 16). A functional UIM usually contains an acidic patch (..EDE..) N-
terminal to sequence L-X3-A-X3-S-X2-D. c-FLIP proteins contain a sequence that conforms
to the UIM core, but lacks the acidic patch, raising the question  whether the motif is
functional. However, because S193 is one of the potential UIM residues, we wanted to find
out whether the UIM was functional and if so, would phosphorylation of S193 regulate it. In
preliminary pulldown analyses utilizing GST, single moieties of GST-ubiquitin, or ubiquitin
agarose as bait, the putative UIM of c-FLIPS/L did not appear to bind ubiquitin noncovalently
(Aura Kaunisto, unpublished data). In the light of our preliminary results and the fact that the
acidic patch is missing from the c-FLIP sequence, it seems unlikely that the putative UIM of
c-FLIP would be functional in vivo. Nevertheless, ubiquitin binding domains and motifs have
preferences towards certain forms of ubiquitin, such as monoubiquitin, linear diubiquitin,
K48-linked or K63-linked chains (reviewed by Ikeda and Dikic 2008). Therefore, further
experiments could be conducted to determine whether c-FLIP is able to specifically bind




but only prolongs the half-life of
the short c-FLIP isoforms.
Stabilization of c-FLIPS prevents
caspase-8 activation and
apoptosis. Although the
phosphorylation of S193 also
seems to protect c-FLIPL from
ubiquitylation, it does not
regulate the stability of c-FLIPL.
The biological function of c-FLIPL





As evidenced by the differential biological outcome of c-FLIP phosphorylation on S193,
isoform-specific functions of c-FLIP can be adjusted by post-translational modifications. An
open question is whether also other phosphorylation events contribute to isoform-specific
functions of c-FLIP. While investigating the phosphorylation sites of c-FLIP proteins, we
found one phosphorylated serine specific to c-FLIPL (Vitaly Kochin, PhD thesis). S227,
located in the caspase-like domain (Figure 16), was found to be phosphorylated in our in
vivo labeling experiments in K562 cells. According to computer-based prediction programs,
the sequence surrounding S227 could potentially be recognized by PKC, CKII or GSK3.
Intriguingly, the sequence S-I-Q-E also fills the minimal requirements for a TRAF2-binding
domain. Interestingly, c-FLIPL has been reported to interact with TRAF2 to promote NF- B
(Kataoka et al. 2000). Similarly, the KSHV v-FLIP reportedly contains an interaction motif
that is absent from c-FLIPs, but mediates the binding of v-FLIP to TRAF2 and TRAF3 to
promote NF- B and JNK signaling (Guasparri et al. 2006). It is therefore tempting to
speculate that S227 phosphorylation may be involved in regulating c-FLIPL-TRAF2
interaction. We are currently characterizing the role of S227 phosphorylation in the
interaction between c-FLIPL and TRAF2, as well as its potential implications in NF- B and
JNK signalling. In addition, identifying the signaling pathways governing S227
phosphorylation warrants further studies.
Phosphorylation is known to regulate ubiquitylation and protein stability. In many cases,
phosphorylation promotes ubiquitylation by providing a binding site for E3 ubiquitin ligases
targeting phosphorylated substrates. For example, the tumor suppressor and transcription
factor p53 is phosphorylated on S362 and S366 by IKK , which leads to ubiquitylation by
the E3 ligase SCF -TrCP and subsequent proteasomal degradation. Another example of a
substrate that is recognized by an E3 ligase due to phosphorylation is cyclin E, whose multi-
site phosphorylation promotes the binding of the SCFFbw7 ubiquitin ligase (Ye et al. 2004,
Xia et al. 2009).
Recent studies have begun to elucidate how the concerted phosphorylation and
ubiquitylation jointly regulate the stability of c-FLIP. The c-FLIPL-specific E3 ubiquitin ligase
Itch is under the control of the JNK pathway, and the ligase is active upon mild JNK activity
(Chang et al. 2006). The JNK pathway is also activated during hemin-induced differentiation
of the K562 cells, although JNK activity is not required for TRAIL sensitization (Minna
Figure 16. The c-FLIP isoforms are
post-translationally modified by
ubiquitylation and phosphorylation. The
primary target lysines of the short
isoforms are K192 and K195. S193 is a
common phosphorylation site for all c-
FLIP proteins, operated by the PKC. All
c-FLIP proteins contain a putative UIM,
and S193 is one of the potential UIM
residues. In addition, we have identified
another phosphorylation site, S227, in c-
FLIPL. S227 is a part of a putative
TRAF2-binding domain. The figure is




Poukkula and Ville Hietakangas, unpublished results). Considering the specificity of Itch, it
can be speculated that Itch would contribute to c-FLIPL downregulation during erythroid
differentiation. It is also conceivable that c-FLIPL stability is adjusted by other
phosphorylation events. During macrophage activation, the Akt1-mediated phosphorylation
of c-FLIP on S273 has been reported to mediate proteasomal degradation of c-FLIPL (Shi et
al. 2009). This is perhaps surprising considering that the PI3K/Akt pathway positively
regulates the transcription of c-FLIP, but the destabilizing modification of c-FLIP by
PI3K/Akt could also be viewed as a negative feedback loop. Finally, shortly after our study,
two additional phosphorylation sites were identified in murine c-FLIPS/c-FLIPR. In this report,
Kundu and coworkers (2009) described S4 and Y211 of murine c-FLIPS to be
phosphorylated by p38 and c-Abl, respectively. Intriguingly, both of these phosphorylation
events were required to facilitate the interaction between murine c-FLIPS and the E3 ligase
c-Cbl. Y211 is located in the C-terminal splicing tail, and could therefore in part explain its
importance for the rapid degradation of the human short c-FLIP isoforms, as the tyrosine
residue is present in both. Whether S4 is phosphorylated in c-FLIPL,  or if  it  plays a role in
regulating the stability of c-FLIPL, requires further studies. In summary, these recent
developments highlight the importance of correct regulation of c-FLIP levels and
demonstrate that the stability of c-FLIP is, indeed, determined isoform-specifically by a
complex interplay of post-translational modifications, especially phosphorylation and
ubiquitylation.
The ability to resist apoptotic stimuli is a characteristic feature of a cancer cell, and the
dynamic adjustment of death receptor signaling is essential for maintaining homeostasis in
the immune system. Our results provide insights into how targeting of c-FLIP by
phosphorylation and ubiquitylation affects c-FLIP levels and thereby determines death
receptor sensitivity. These findings may have implications on the development of cancer
therapies, as c-FLIP levels are upregulated in various malignancies that are resistant
towards conventional treatments. In addition, our data may help understand the
pathogenesis of various autoimmune diseases, since they are often characterized by
abnormally low levels of c-FLIP. Furthermore, new aspects are presented how cPKC might






Cells sense their environment by their surface receptors. The family of death receptors
includes the TRAIL and CD95 receptors, which transmit signals engaging cellular suicide. c-
FLIP proteins antagonize receptor-mediated cell death by regulating the activation of
caspase-8. Since abnormal levels of c-FLIP are indicated in various autoimmune diseases
and cancer, it is a potential therapeutic target. In this thesis, I have investigated how c-FLIP
levels are adjusted through post-translational modifications, with a strong emphasis on
phosphorylation and ubiquitylation.
Post-translational modifications provide means for rapid and exact modulation of crucial
regulatory proteins and play an important role also in the molding of death receptor
responses. When this thesis project was initiated, little was known about the regulation of c-
FLIP via ubiquitylation or phosphorylation. During the work for this thesis, we established
that while all c-FLIP proteins are ubiquitylated, the stability of the isoforms is governed by
their unique C termini. These mechanisms are not restricted to only one cell model, since
we were able to show that the differential regulation of c-FLIP isoforms determines death
receptor sensitivity both in differentiating K562 erythroid leukemia cells as well as activated
Jurkat and primary T lymphocytes. We were the first to identify phosphorylation sites of c-
FLIP and develop an antibody that specifically recognizes S193-phosphorylated c-FLIP.
Furthermore, we showed that the phosphorylation of S193 was mediated by classical PKC,
and demonstrated that PKC-mediated S193 phosphorylation negatively regulates the
ubiquitylation of all c-FLIP proteins, although it only affects the half-lives of the short c-FLIP
isoforms. In the future, the post-translational modifications of c-FLIP and their effective
biological significance should be studied in primary cells. These prospective endeavors
would greatly benefit from the development of antibodies against individual post-
translational modifications of c-FLIP, especially if they allowed the monitoring of
endogenous c-FLIP. Our results underline the importance of c-FLIP stability in modifying
death receptor sensitivity and especially in determining immune cell homeostasis.
During the course of these studies, other groups have discovered three additional
phosphorylation sites, and two E3 ubiquitin ligases have been demonstrated to regulate c-
FLIP turnover in an isoform-specific fashion, supporting our findings and hypotheses. In
addition, independent studies have concluded that the stability of c-FLIP is adjusted by a
cross-talk between phosphorylation and ubiquitylation. When the pathways and enzymes
governing these events are characterized in more detail, c-FLIP will probably be even more
closely linked to the key signaling complexes regulating cellular death and survival.
Due to its important role in determining sensitivity to apoptotic signals, c-FLIP has been
considered a potential therapeutic target for treating cancer and diseases of the immune
system. While TRAIL is perhaps one of the most promising candidates for inducing
apoptosis in cancer cells, some tumors are resistant to TRAIL because of c-FLIP
overexpression. The first steps in conferring this resistance by specific c-FLIP
downregulation by RNAi, or by more general means such as protein synthesis inhibitors or
existing chemotherapeutic drugs, have been successful and validated c-FLIP as a potential
therapeutic target. Therefore, forthcoming studies addressing the regulation of c-FLIP
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